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ABSTRACT 
 
 The objective of this study was to develop a clear, aqueous drug loaded 
nanomicellar formulation (NMF) for the back-of-the-eye delivery. Hydrophobic 
drugs such as cyclosporine, resolvin analog (RX-10045), dexamethasone, 
rapamycin were entrapped in the core of polymeric micelles and solubilized. 
Polymeric amphiphilic molecules (e.g., hydrogenated castor oil – 40 (HCO-40) and 
Vit. E TPGS) are known to generate nanomicellar constructs with hydrophobic core 
and hydrophilic corona. However, constructs prepared from a single polymer are 
unstable and easily fall apart at high temperature. Inclusion of a second polymer 
such as Oc-40 improves stability and prevents nanomicellar destabilization. Such 
stable nanomicellar constructs can encapsulate hydrophobic drugs in their 
lipophilic core while the hydrophilic corona helps solubility in aqueous solution. 
We screened resolvin for efflux pumps and prepared resolvin analog nanomicelles. 
Studies showed that NMFs were tolerable and delivered high drug concentrations 
to back-of-the-eye tissues with topical eye drop application to rabbits. Negligible 
drug levels were quantified in systemic circulation. These nanomicellar constructs 
efficiently utilize their hydrophilic corona and evade the wash-out into the systemic 
circulation from both the conjunctival and choroidal blood vessels and lymphatics, 
iv 
 
thus overcoming the dynamic barrier. Moreover, this pathway might overcome the 
major drawback associated with steroid therapy (glaucoma and cataract), since a 
trans-scleral route of absorption is accessed.  
In summary, for the first time we identified that resolvin analog was 
substrate/inhibitor for BCRP and MRP but not P-gp. Moreover, resolvin analog was 
identified as a strong inhibitor of influx transporter (OCT-1). Clear, aqueous NMF 
encapsulating hydrophobic drugs were successfully developed. Ocular 
bioavailability and pharmacokinetic studies demonstrated a very high drug levels 
in retina-choroid (place of drug action) with a negligible drug partitioning into lens 
and vitreous humor. These results suggest that drug and/or NMFs cannot reach 
back-of-the-eye tissues following corneal pathway. Alternatively, ~12 nm - 20 nm 
nanomicelles efficiently permeate through 20 nm to 80 nm scleral pores and reach 
back-of-the-eye tissues (retina-choroid) following conjunctival-scleral pathway. In 
the lipoidal posterior ocular tissues, these nano-constructs may release the cargo 
into Bruch’s membrane/retina-choroid generating high drug levels. 
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Chapter 1 
INTRODUCTION 
Overview 
The eyes are one of the most important and complex sensory organs that act 
as a gateway to collect external images and transmit them to brain as signals 
through the optic nerve.  By this process they maintain a connection with body and 
our surroundings.  Dry eye, ocular inflammation, surface injuries and diseases rank 
among the most painful eye conditions and are the leading cause of visit to 
ophthalmologists in United States. Anterior ocular tissues are exposed to external 
environment and, consequently, are subjected to inflammations (anterior uveitis) 
due to disease, dust, microbes such as but not limited to bacteria, virus, fungus and 
parasites(1, 2).  In healthy eye, such ocular insults are normally prevented by blood 
aqueous barrier, while regulatory molecules and immune cells in the eye actively 
suppress immune response.  Ocular inflammation and surgical trauma induce 
changes in blood aqueous barrier (3-5).  This process causes entry and accumulation 
of immune cells and inflammatory mediators in ocular tissues and develops 
redness, pain, swelling and itching(6).  Similarly, dry eye (keratoconjunctivitis 
sicca) is another commonly observed anterior ocular disease in United States 
population. Dry eye is a chronic disease condition that affects millions of people. 
Prevalence of this ocular disease in US increases with age, hypertension and benign 
prostatic hyperplasia. (7, 8). Traditionally, dry eye has been broadly classified 
depending on the recognized cause as aqueous-deficient or tear evaporative (9, 10).  
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Age-related macular degeneration (AMD), macular edema (ME), 
glaucoma, diabetic macular edema (DME), proliferative vitreoretinopathy (PVR), 
cytomegalo virus retinitis (CMV), non-infectious uveitis, endophthalmitis and 
diabetic vitreoretinopathies are some of the common posterior eye diseases which 
may lead to vision loss if not treated.   
NIU affects patients of different age groups and it may be chronic and 
recurrent (11). However, management of NIU is far more challenging than anterior 
uveitis which leads to irreversible vision loss/impairment. Immediate and vigorous 
response (immunological and inflammatory) against ocular antigens is still unclear. 
Lymphocytes can stimulate ocular autoimmune activity in response to Th1 or Th17 
(12). A major aim of NIU management includes suppression of inflammation and 
diminution of NIU intensity (13). Back-of-the-eye neovascularization diseases 
develop new leaky and fragile blood vessels which branches out from the choroid 
and then grows through the Bruch's membrane into sub-retinal pigment epithelia. 
Further, this new vasculature causes capillaries to leak causing blood and fluid 
accumulation in the retinal layers. During neovascularization, vascular endothelial 
growth factor (VEGF) is upregulated (14). Increased production of VEGF is 
induced by multiple cellular pathways: (i) hypoxia and (ii) pro-inflammatory 
cytokines such as TNF-α and β2 (15, 16).  
DEX is a FDA approved drug as a first line of treatment for dry eye, uveitis 
and macular edema. Immunosuppressants (eg. cyclosporine (CsA) and rapamycin) 
are recommended as second line of treatment in steroid responders. Moreover, CsA 
is approved by FDA for the treatment of dry eye (keratoconjunctivitis sicca). 
3 
 
Rapamycin is in clinical trials for the treatment of posterior ocular 
neovascularization following sub-conjunctival and/or intravitreal injection. 
Resolvin analog is another novel investigational molecule which is currently in 
clinical trials for the treatment of dry eye syndrome and ocular inflammations. 
Statement of the Problem 
Oral and intravenous drug administrations have achieved limited success in 
treating ocular diseases due to sub-therapeutic levels of drug reaching ocular 
tissues. Moreover, conventional routes of drug administration are associated with 
development of systemic toxicities. To treat anterior ocular conditions topical 
applications of medications, preferably as eye drops, are usually indicated. 
Topically administered drugs have low probability of reaching anterior and 
posterior ocular tissues in therapeutic concentrations. Drug delivery to the anterior 
segment is important since 90% of the administered dose is lost due to excessive 
tear production, reflex blinking and drainage into the naso-lacrimal ducts. In order 
for a drug to reach therapeutic concentrations in the anterior segment, it has to pass 
through the anterior segment barriers. The precorneal pocket can accommodate a 
maximal fluid volume of 30 L while draining 40% of drug solution (17). In order 
to achieve therapeutic levels in anterior ocular tissues highly concentrated drug 
solutions (~2 - 3% wt/v) is usually required. High rate of tear turnover also reduces 
drug residence in the pre-corneal and pre-conjunctival areas. Therefore, the tear 
film also acts as a barrier to topical drug absorption (17). On the other hand, the 
advent of diseases affecting posterior tissues of the eye, it is difficult to reach and 
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treat. Therefore, local invasive routes of drug administration (subconjunctival, 
intravitreal or periocular routes) have been developed for back-of-the-eye diseases. 
Though high drug concentrations may be achieved in posterior ocular tissues with 
intravitreal injection several route of administration based concerns limit its usage. 
However, intravitreal injection suffers from drawbacks such as development of 
toxicity due to dose dumping, interference with vision due to floating drug 
molecules, requires multiple intraocular injections, treatment is expensive, requires 
medical specialist to inject drug and is highly patient non-acceptable.  
The first line of treatment for ocular diseases is with corticosteroids (eg. 
dexamethasone, DEX). Short-term treatment with topical corticosteroids may 
provide symptomatic improvement (18). However, chronic topical or intravitreal 
use of corticosteroids is often associated with side effects such as cataract, increased 
intraocular pressure (IOP), and other steroid related adverse effects(19-21). In such 
cases, a second line treatment of choice is immunosuppressants like CsA and 
rapamycin, which are not associated with steroid related ocular side effects. 
Another class of drugs (resolvin analog (RX-10045)) is under investigation for 
ocular disease treatment such as dry eye syndrome and inflammations.   
Drug molecules (CsA, resolvin analog, DEX and rapamycin) suffer from 
two major barriers (i) sub-optimal physicochemical properties such as low aqueous 
solubility and (ii) ocular static and dynamic barriers. Ocular static barriers include 
corneal epithelium, corneal stroma, blood aqueous barrier sclera, and retinal 
pigment epithelium (RPE). The dynamic barriers include tear drainage, 
conjunctival and choroidal blood and lymph vessels that wash drug out of ocular 
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tissues into systemic circulation and metabolic barriers (22). Moreover, efflux 
pumps such as MDR1 (P-glycoprotein (P-gp)), multidrug resistance protein (MRP) 
and breast cancer resistance protein (BCRP) expressed on the cell membrane 
constitute another significant barrier to drug delivery. DEX, CsA and rapamycin 
are substrates of efflux transporter (23-25) that prevent drug accumulation into the 
target cells. Similarly, drug delivery to back-of-the-eye tissues (retina-choroid) is a 
challenging task. Various formulation strategies, including oil solutions, emulsions, 
nanoemulsions, ointments, and gels have been developed. These is still an unmet 
need for development of an aqueous, clear, topical formulation that could 
encapsulate drug and deliver the cargo to anterior and back-of-the-eye tissues with 
topical drop instillation. An aqueous clear nanomicellar formulation appears to be 
better candidate to improve aqueous solubility for drug and aid in drug delivery. 
Therefore, the following objectives were developed.  
 
Objectives 
Objectives of the project were: 
To develop and optimize CsA, resolvin analog (RX-10045), DEX and rapamycin 
loaded nanomicellar formulations with blend of FDA approved amphiphilic 
polymers (hydrogenated castor oil-40 (HCO-40), vitamin E tocopherol 
polyethylene glycol succinate-1000 (Vit. E TPGS) and octoxynol-40 (Oc-40)). To 
characterize the above formulations with respect to their appearance, encapsulation 
efficiency, loading efficiency, dissociation temperature, regeneration time, 
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viscosity, size, polydispersity index, surface potential, surface morphology, proton 
NMR, critical micellar concentration, in vitro release and stability studies. To (i) 
evaluate in vitro cytotoxicity on corneal cell line (rabbit primary corneal epithelial 
(rPCEC) and human corneal epithelial cells (HCEC)) and retinal pigment epithelial 
cells (D407 and ARPE) with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay (ii) to evaluate membrane integrity of 
rPCEC/HCEC cells with lactate dehydrogenase (LDH) assays. To (i) study in vivo 
biocompatibility and ocular toxicity in rabbits post topical drop instillation with 
Hackett-McDonald ocular scoring (Microscopic Ocular Grading System) of 
inflammation (ii) study intraocular pressure development (iii) study retinal health 
with electroretinography (ERG) (iv) study histopathology of anterior and posterior 
ocular tissues after multiple topical dose treatment. To study drug (CsA, resolvin 
analog, DEX and rapamycin) ocular bio-distribution or tissue distribution 
pharmacokinetics post single topical drop administration to rabbit eye. 
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Chapter 2 
LITERATURE REVIEW 
Ocular Drug Delivery 
Drug delivery to the eye is a challenging task for ocular pharmacologists. 
The eye can be broadly divided into two segments; the anterior segment and the 
posterior segment (Figure 1).  The anterior segment consists of cornea, 
conjunctiva, aqueous humor, iris, ciliary body and crystalline lens. They occupy 
approximately one-third portion of front of the eye. The remaining portion i.e., 
posterior segment, comprises sclera, choroid, Bruch’s membrane, RPE, neural 
retina and vitreous humor (VH).   
Anterior Segment 
Cornea 
 
The cornea is a thin, transparent, smooth, avascular, highly innervated and 
the most sensitive tissue in the body.  It is convex, aspheric shaped, and directly 
exposed to external environment (Figure 1).  The cornea is continuous with white 
part of the eye called sclera and the semi-transparent tissue called conjunctiva.  
Border of the cornea, where it continues with sclera, is called limbus (Figure 1).  
Limbus is highly vascularized and contains a reservoir of pluripotential stem cells 
(26). Corneal surface exposed to external environment is suffused by tear film and 
its inner surface is directly in contact with fluid called aqueous humor. Thickness 
of cornea gradually increases from center to periphery and vice versa (27). This is  
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Figure 1. The structure of human eye 
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observed with corneal curvature which is greatest at the center and smallest at the 
limbus. 
Corneal contour, surface smoothness, transparency and refractive index 
determine the optical properties of the cornea. The corneal stroma is embedded with 
relatively homogenous and uniform arrangement of collagen fibers (diameter 25 – 
35 nm) (28). Such arrangement is thought to be responsible for preventing and 
cancelling scattered light interference from the incident ray of light on collagen.  
The precise arrangement and function of fibers allow the light rays to pass through 
cornea without any interference.  Corneal smoothness is maintained by the corneal 
epithelium and tear film.  Any deviation from normal architecture of corneal 
collagen fibers and the absence of tear film coverage causes dry eye, scattering of 
incident light ray and leads to loss of corneal contours, transparency and 
smoothness. 
Corneal nerve fibers travel deeper into stroma radially and anteriorly to 
form subepithelial plexus (29).  Any damage or loss of corneal epithelium exposes 
nerve endings to external environment causing severe ocular pain (30). Normal 
cornea does not have supply of blood vessels.  So this tissue is considered as one 
of the avascular tissues in the body along with cartilage and lens. Despite being 
avascular, the epithelial and endothelial cells of cornea are metabolically active and 
actively involved in wound healing.  Both cell layers get blood components and 
other requirements from the blood vessels of internal and external carotid arteries 
that form an arcade around the cornea in limbal region (27). The aqueous humor 
supplies glucose and small portion of oxygen required by cornea.  Most oxygen 
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supply to the cornea comes from exposure to air, where oxygen absorbed into tear 
layer diffuses to corneal epithelial cells.  This exposure of suffused tear layer on 
corneal surface is necessary for oxygen supply, maintenance of smoothness and 
integrity.   
A histological section shows that the cornea is composed of six different 
layers namely, the corneal epithelium, Bowman’s layer, the stroma, Dua’s layer, 
Descemet’s membrane and the endothelium (Figure 2).  Corneal epithelium is 
made of 5 to 6 layers of stratified and squamous nonkeratinized epithelial cells.  
The different epithelial layers of cornea include two to three layers of superficial 
and wing cells and a single layer of basal cells.   Epithelial cells are anchored to a 
0.05µm thick basal lamina, made of columnar epithelium, approximately 20 µm 
tall.  The presence of tight cell junctions between the cells and scaffolding make 
them highly impermeable (31).  Basal cells are only corneal epithelial cells which 
are capable of undergoing mitosis (32).  
Bowman’s layer is an 8 to 15 µm thick, amorphous band of fibrillar material 
present just below basal corneal epithelial cells.  This layer is non-regenerative, 
forms a boundary between corneal stroma and epithelial cells, and maintains 
corneal shape. It is thought to be involved in re-epithelialization (33).  Bowman’s 
layer contains short type I collagen fibrils implanted in the proteoglycan matrix.   
Corneal stroma is sandwiched between Bowman’s layer and Descemet’s membrane 
and accounts for 95% of corneal thickness.  Stroma consists of Keratocytes, 
fibroblastic cells, neural tissue and Schwann cells (27).  Most of the stroma is 
occupied and made by collagen fibrils, mainly type I collagen (34).   
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Figure 2. Corneal layers of the eye.  
(1) corneal epithelium, (2) Bowman’s layer, (3) Stroma, (4) Descemet’s membrane 
and (5) endothelium.  Figure A represents the corneal histological image.  Figure B 
and C represent the expanded diagrammatic representation of corneal layers of the 
eye. Figure A represents the corneal histological image.  Figure B and C represent 
the expanded diagrammatic representation of cornea. Reproduced and modified 
with permission from Journal of Ophthalmic Vision Research and Progress in 
Retinal and Eye Research (35, 36).   
  
Dua’s layer 
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These fibrils extend from one end of the limbus to other end, angled at 90° in the 
anterior and orthogonally at posterior stroma.  The collagen fibril provides 
mechanical strength to cornea.  The fibrils at posterior stroma are more strictly 
organized than anterior, probably to contribute to mechanical strength and dioptric 
stability in cornea (37).    
Descemet’s membrane is 10 µm thick with an amorphous texture and is 
unbanded.  During developing stage, this layer is discontinuous and homogenous 
acellular which gradually becomes Descemet’s membrane (38, 39). This membrane 
is thrown into several folds, which appear as striae, due to asymmetric swelling of 
the posterior stroma, and structural restrictions imposed by limbus.  
Corneal endothelium is the innermost monolayer of cells, which is non-
mitotic and in direct contact with aqueous humor. While endothelium maintains 
itself, stroma remains in deturgescence state to provide corneal transparency (40).  
This monolayer has limitedly permeable to ion flux, which is necessary in 
establishing osmotic gradient.  Generally endothelial cell numbers decrease with 
age. During diseased conditions, cells increase in their size (polymegathism) and 
show shape variation (polymorphism) to compensate the spaces formed from 
degenerated cells. 
 
 
Conjunctiva 
 
The conjunctiva is a thin, highly vascularized, semi-transparent, and mucous 
secreting tissue, which forms the inner lining of upper and lower eye lids (41). It is 
reflected onto the eye as a thin transparent tissue on sclera (Figure 1) and extending 
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up to the corneal limbus.  This tissue is highly innervated with efferent, afferent 
and sensory nerves and is also supplied with lymphoid tissue.  The total surface 
area of conjunctiva is approximately 17 times larger relative to cornea (42, 43).  
Due to its elastic nature, conjunctiva facilitates motion of the eye ball and eye lids. 
Mucous layer of tears in conjunction with small portion of aqueous humor protect 
the inner ocular tissues from external environment. Depending on location, 
thickness and vascularization, this tissue can be further divided into three types as 
palpebral, fornic and bulbar conjunctiva.  Upper and lower eyelids are internally 
lined by palpebral conjunctiva.  A relatively a small fraction of the conjunctiva, 
called bulbar conjunctiva, is present near to sclera. The Bulbar conjunctiva is very 
thin, continuous with cornea, and exposed to external environment with an air 
interface during the intervals of open-eye.  The Palpebral and bulbar portions are 
connected with a small portion of tissue called fornicial conjunctiva.  Fornicial and 
palpebral conjunctiva are richly supplied with blood vessels and composed of 
heterogenous tissue (41). Histologically, conjunctiva is mainly composed of 
superficial multilayered epithelium and an underlying stroma (44).  Conjunctival 
stroma is sandwiched between the anterior epithelium and posterior sclera.  This 
layer is supplied with blood and lymph vessels and innervated with nerve endings.  
This is intertwined with mature lymphocytes, predominantly with T-cells relative 
to B-cells. Mucous associated lymphoid tissue (MALT) plays an important role in 
immune response (45).  MALT is composed of lymphatic cells present below the 
epithelium which induces immune response against the antigens by secreting 
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soluble antibodies.  Lymphocytes are circulated through a specialized vascular 
system termed high endothelial venules (46-48).   
 
Aqueous Humor 
 
Aqueous humor is an optically clear, slightly alkaline ocular fluid that is 
continuously formed (~ 2.5 µL/min in humans) from plasma by epithelial cells of 
ciliary body (49).  Three different processes namely, diffusion, ultrafiltration and 
active secretion contribute for its chemical composition and formation of aqueous 
humor.  It is estimated that the entire aqueous humor is replaced within an 
approximate time of 100 mins (50).  This fluid contains relatively fewer amounts 
of proteins, albumin and γ-globulins, than plasma.  Additionally, glucose, lactic 
acid, ascorbic acid and immunoglobulin-G (Ig-G) are also present (51, 52). 
Aqueous humor supplies nutrients and some amount of oxygen to the ocular 
avascular tissue, namely cornea and lens. It removes waste products, macrophages, 
blood and other debris from the posterior of cornea and anterior of the lens.  Also, 
it plays an important role in maintaining the shape and internal ailments of eye ball 
along with production of intraocular pressure.  Aqueous humor is produced and 
secreted into the posterior eye segment and passes through the pupil into the 
anterior chamber.  It is drained into venous blood circulation via trabecular 
meshwork and the canal of Schlemm.   Approximately 5% to 10% of aqueous 
humor is drained following the uveo-scleral pathway (53, 54).  
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Iris-Ciliary Body 
 
Iris and ciliary body (ICB) are two different tissues with different 
anatomical locations and physiological functions.  For easy understanding and 
close anatomical localizations, their anatomy and physiology are described 
together. The iris is located at the posterior region of cornea and appears as a root 
of the ciliary body.  Histologically, the iris is composed of three different layers, 
namely endothelium, stroma and epithelium. Iris makes a small circular opening or 
aperture in front of the lens called pupil that helps to regulate the amount of light 
passing through to the retina.  Each ciliary body contains a ciliary process which in 
turn possesses fibrovascular core that appears to be continuous with the stroma of 
ciliary body.  The blood flows from anterior to posterior choroidal veins.  All the 
blood from the ciliary body of the eye is drained out via vortex vein. Ciliary body 
is anatomically located anterior to the iris and is involved in regulating three major 
functions in the eye:  (i) it secretes aqueous humor, which passes in front of the lens 
and drains out of the eye via tubules called trabecular meshwork and canal of 
Schlemm near to the junction of cornea and the iris; (ii) this tissue also contains 
smooth muscles that act via zonular fibers on the crystalline lens to adjust focusing 
objects and; (iii) it can help in draining of aqueous humor from the eye into the 
adjacent trabecular meshwork by extending smooth muscle fibers and tendons.           
 
Lens 
 
The lens is a transparent, avascular, non-innervated and biconvex in 
structure.  It is positioned behind the pupil and iris with the support of ciliary body’s 
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zonular fibers (55).  The anterior lens is covered with aqueous humor and the 
posterior with VH.  The lens-membrane (also known as capsule) regulates passive 
exchange of metabolic substrates and waste through simple diffusion (56) regulated 
by their size and charge (57-60). The lens consists of four distinct parts: the capsule, 
epithelium, cortex (fiber cell mass) and the nucleus.  Also, it controls the light entry 
into the eye and its refraction. The lens nucleus is highly protected by its location. 
It contains 63.4% water (61) and is formed by deposition of old fiber cells that 
translocate to the center from periphery.  Due to accumulation of old cells in this 
region, it becomes very thick and denser.  
 
Posterior Segment 
Sclera 
The sclera, commonly called the “white of the eye”, is a tough, avascular, 
sieve-like elastic tissue present below the conjunctiva and continuous with cornea 
(Figure 1). The optic nerve exits posteriorly through this densely interwoven 
fibrous tissue network called lamina cribosa. The episclera (topmost layer of sclera) 
supplies required nutrients to the sclera.  The sclera makes almost 80% of the eye’s 
tunic and remainder is made by cornea anteriorly.  Thickness of sclera depends on 
its anatomical location. Anterior sclera, near the limbus, is thick and as one moves 
towards the equator, thickness decreases (62).  Further moving to posterior of the 
eye, near and around the optic nerve, it doubles in thickness. The sclera is composed 
of a disorderly arranged network of collagen fibers derived from dura matter of the 
central nervous system.  This type of arrangement causes scattering of all visible 
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light wavelengths and appears brilliant white in color. At the junction of sclera and 
cornea this irregular arrangement abruptly changes to a regular and systematic 
arrangement. Such change brings opaque white sclera to transparent cornea. Same 
collagen fibers are present in cornea but are arranged in a regular pattern which 
provides transparency to the tissue.  Being hydrated scleral fibers remain opaque 
while corneal fibers do not retain water, become transparent. The corneal 
endothelium helps to maintain its transparency by draining out water. Sclera being 
the outer coat of the eye ball is subjected to frequent changes of external 
environment as well as intra ocular pressure. Diameter of the scleral fibers in the 
equatorial region ranges from 25 to 230 nm and the aqueous pore diameter of the 
sclera ranges from 20-80 nm (28, 63). 
 
Choroid 
 
The choroid is present between peripheral sclera and inner retinal 
pigmented epithelium. It is a highly vascularized and innervated tissue containing 
melanocytes along with mucous like extracellular fluid. The choroid consists of 
three distinct parts: from outer to inner (i) suprachoroid (sc), (ii) vascular layer, and 
(iii) Bruch’s membrane.   
The suprachoroid is made of 6 to 10 layers, approximately 30µm in 
thickness, which form the interface between outer sclera and inner choroid (29).  
The suprachoroid continues anteriorly with supraciliary space and extends 
posteriorly up to the optic nerve.  This region is highly innervated with nerve fibers 
and ganglion but no vasculature. Thin lamellar fibers, in apposition to each other 
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interconnect choroid (CH) and sclera.  This arrangement causes development of 
small space between these tissues called suprachoroidal or perichoroidal space.  
This space is generally absent as one move posteriorly towards the macula.      
The vascular layer underneath suprachoroid consists of three distinct vessel 
layers with gradually decreasing capillary and luminal diameters. These vessels are 
surrounded by pigmented melanocytes and non-pigmented fibrocytes and occupy 
the largest choroid volume.  The vessels, fibrocytes and melanocytes are embedded 
in small amounts of choroidal stroma.  The density of melanocytes increases from 
center to periphery.  Choroidal vessels are named according to luminal diameter 
and location as: (i) Haller’s layer with outer larger size vessels, (ii) intermediately 
located Sattler’s layer with medium sized vessel, and (iii) deeply located 
choriocapillaries with vessel of small diameter.  The blood circulation in choroid is 
relatively high compared to other ocular tissues and brain (64-66).  Increased 
choroidal blood circulation allows nutrient supply and diffusion of high gradient 
oxygen into the inner neural retina. Retinal metabolic wastes are removed along 
with changing intraocular temperature generated by visual process. Also, this 
accelerated blood flow is appeared to play a role in regulating intraocular pressure 
(67-69).   
 Bruch’s membrane is the last and innermost layer of choroid that lies above 
the RPE/PE (70). It is also called lamina vitrea. This is a thin, pentalamillar, elastic, 
and acellular membrane-like structure which is produced in collaboration of 
choriocapillaries and RPE.  Bruch’s membrane extends from the posterior segment 
of the eye, i.e. optic nerve, to ora serrata of iris where its thickness gradually 
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decreases from back-of-the-eye to periphery.  This membrane separates RPE and 
choriocapillaries.  The retinal cellular organization contains seven different types 
of cells, including RPE cells. They are photoreceptor cells (rods and cones), 
horizontal cells, amacrine cells, interplexiform cells, bipolar cells, ganglion and 
glial cells (Figure 3).   
 
Retinal Pigment Epithelium 
 
Each eye of an individual contains approximately 3.5 million RPE cells (71) which 
adhere together to form tight junctions (zonulae occludentes).  The RPE is 
composed of non-dividing cells which forms a monolayered lining above the neural 
retina.  Though these cells are non-dividing, under pathological conditions they 
may proliferate.  It provides protection to inner ocular tissues and secretes large 
number of growth factors (vascular endothelial growth factor, ciliary neurotrophic 
factor and platelet derived growth factor).  This monolayer maintains ocular 
immunity and protects from oxidative damage (72) with secretion of 
immunomodulatory cytokines (73). The RPE cells produce several enzymes such 
as superoxide dismutase, catalase, glutathione, and melanin pigment. RPE plays a 
vital role in providing support and survival of choriocapillaries and functioning of 
photoreceptors.  Therefore, its presence is essential for maintaining the visual 
endothelial growth factor, ciliary neurotrophic factor and platelet derived growth 
factor).  This monolayer maintains ocular immunity and protects from oxidative 
damage (72) with secretion of immunomodulatory cytokines (73). The RPE cells 
function (74).  Its functions involve disposition of photoreceptor to outer segments, 
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Figure 3. Layers and histology of normal adult human retina.  
Adult human retina 2 mm nasal from the fovea center. The layers and their 
abbreviations used in this paper and in subsequent figures are choroid (CH); retinal 
pigment epithelium (PE); outer nuclear layer (ONL), which is subdivided into the 
photoreceptor outer segment (OS) and inner segment (IS) layers distal to the 
external limiting membrane (ELM); and the nuclear layer containing a single row 
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of cone (C) cell bodies near the ELM and multiple rows of deeper rod (R) cell 
bodies. The thin rod IS are indicated (R-IS). The rod OS are about half the thickness 
of the rod IS, are longer and reach the PE. The larger tapered cone IS have a shorter 
OS (arrow). The ELM marks the distal edge of the retina. IS myeloid (M) and 
ellipsoid (E) are indicated. The outer plexiform layer (OPL) contains a distal layer 
made up of the fibers of Henle or photoreceptor axons (Ax) and a proximal synaptic 
contact layer (S) containing cone pedicles and rod spherules. The inner nuclear 
layer (INL) contains the cell bodies of horizontal cells (HZ) lying most distal, 
bipolar cells (BP) in the middle, Müller glia (MG), and amacrine cells (AM) lying 
most proximal. The inner plexiform (IPL), ganglion cell (GCL), and nerve fiber 
(NFL) layers complete the inner retina (Reproduced with permission from 
American Journal of Ophthalmology (75)). 
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retinoid metabolism, maintaining visual cycle and regulation  of subretinal 
chemical milieu (76-78). 
 
Neural Retina 
 
Topographically, the retina is organized into macula, optic disc, fovea and 
peripheral retina.  The macula or area centralis is about 1.5mm in thickness and 
located approx. 3mm away from optic disc.  The macula derives its name from the 
yellow carotenoid pigment, xanthophyll, as macula lutea. The center of the macula 
represents an important region of visual acuity (79) and is named fovea.  The fovea 
has the highest density of narrow and elongated cone receptors to maximize light 
detection (80). The center of fovea is avascular up to 500 µm and the blood supply 
to this region comes from choriocapillaries.  Retinal temporal blood vessels 
surround/enclose fovea. The outer layer of the fovea is thick and contains nuclei of 
photoreceptor cells.   The remaining peripheral retina, anatomically one layer of 
ganglionic cells, is present outside the temporal retinal arteries.  Most of the outer 
retina gets its blood supply from choroidal circulation whereas general retinal 
circulation fulfills inner retinal blood supply (81, 82).  The inner lining of the eye 
ball is composed of light sensitive neural cells, called the neural retina, which 
transmits sensory information to the brain and interacts with external environment.  
These sensory nerves are originated from central nervous system (83, 84).  Neural 
retina is made up of approximately 7.7 million rods and 5 million cones (85-87).   
The photoreceptor cells consist of rods and cones.  These cells mainly 
function to capture and convert the photons into a nerve signal (85). Retinal rod 
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cells are responsible for differentiating colors in bright light whereas cone cells take 
care in distinguishing black and white color in dim light.  The highest amount of 
cones is found in fovea whereas the rods are distributed through the retina except 
the central fovea.  The cones and rods are interconnected with inter-neurons called 
bipolar cells.  The visual information is transmitted to ganglion cells through the 
bipolar cells, which act as a bridge. Ganglionic cells transmit information as electric 
signals to central nervous system, i.e. brain. During this process Müller’s cells help 
in regulating local microenvironment for proper visual functioning.  
 
Vitreous Humor (VH) 
 
The posterior segment of the eye is mostly avascular and transparent thick 
gel-like fluid that covers the space between lens and retina.  It is called vitreous 
humor or vitreous body.  It aids in maintaining the structure of globe. This fluid is 
composed of 99.9% water and 0.01% collagen fibrils, hyaluronic acid and ions (76, 
88, 89).  The vitreous body and neural retina are separated from each other by an 
inner limiting membrane.  The vitreous is firmly attached to anterior retinal layers 
at ora serrata which is present at the posterior segment of the iris ciliary body. It is 
loosely attached at optic nerve and posterior macula.  In this way the anterior and 
posterior chamber fluids are separated.   These connections around the optic nerve 
and macula help to hold the vitreous body against the retina.   
 Thickness of the fluid decreases with growing age.  During this condition, 
anterior aqueous humor may permeate into posterior vitreous resulting in a tugging 
effect at the attachment point of retina and vitreous fluid.  Additionally, this may 
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cause release of cells into the fluid, which appear as floaters and if significant 
tugging effect is developed it may pull away or detach retina. 
Barriers to Ocular Drug Delivery 
 
Ophthalmic drugs are available as solutions, suspensions, and ointments 
and are primarily administered topically.  Other routes of drug delivery to the eye 
are oral, intravenous, intravitreal, subconjunctival and periocular injections or via 
implants (90). A challenging task in drug delivery is to overcome ocular barriers 
and deliver drugs efficiently to the targeted ocular tissue. Drugs are prevented from 
reaching targeted ocular tissues due to static and dynamic biological ocular barriers.  
These barriers can be classified depending on their anatomical location and their 
functional properties.  In general, these barriers can be classified as anterior and 
posterior segment barriers.   
 
Anterior Segment Barriers   
There are two types of barriers i.e. static or dynamic barriers.  Static barriers 
include cornea, conjunctiva, iris ciliary body, lens, blood aqueous barrier, and 
efflux pumps expressed on cell surface such as multidrug resistant (MDR) proteins: 
P-gp.  Conjunctival lymph, blood flow, opposite directional flow of aqueous humor 
and tear production together make up the dynamic barriers.  These barriers are 
described in detail below. 
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Anterior Segment Static Barriers 
 
Cornea 
 
The anatomy and physiology of the cornea has been described earlier in this 
chapter.  Cornea behaves as a multilayered mechanical barrier to prevent exogenous 
substances, including topically applied drugs, from penetrating deeper into ocular 
tissues.  In order to demonstrate corneal permeability, a comparative study was 
conducted with different molecular weights of hydrophilic polymer, polyethylene 
glycol (PEG) (average molecular wt. 200 to 1000) across the rabbit cornea, 
conjunctiva and sclera (91).  Corneal tissue appears 15 and 25 times more resistant 
to PEG permeation in comparison to conjunctiva and sclera.  Increasing molecular 
size affects the conjunctival permeability.  Bulbar and palpebral conjunctiva does 
not show significant difference. Permeability comparison indicates that the 
conjunctiva is two times more permeable than the sclera, whereas the sclera is 
approximately ten times more permeable than cornea. The conjunctival epithelial 
pore size and density are two and sixteen times higher than sclera respectively. An 
estimated total paracellular space in conjunctiva is 230 times higher than that of 
cornea. 
The outer corneal layer, with 90% epithelium cells, renders this membrane 
to be highly lipophilic. Mature corneal epithelial cells act as a barrier to drug 
absorption as they are tightly bound by cell adhesion proteins such as occludins, 
ZO-1 and ZO-2 (92).  These proteins provide a continuous seal around the cells and 
form tight junctions to prevent paracellular drug transport across cornea.  Drugs 
traverse the membrane by different mechanisms, namely (i) paracellular, (ii) 
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transcellular, (iii) active, (iv) carrier mediated and (v) receptor mediated transport.  
Paracellular diffusion of ionic (polar) molecules is prevented by the corneal tight 
junctions whereas lipophilic drugs may easily diffuse across lipophilic cornea by 
transcellular mechanism. Bowman’s layer has no significant role in preventing 
drugs from deeper ocular diffusion.  The hydrophilic stroma behaves as a rate 
limiting barrier for lipid soluble molecules and hinders their deeper ocular 
permeation.  For highly lipophilic and relatively hydrophilic compounds, corneal 
epithelium and stroma act as depot. Descemet’s membrane does not significantly 
participate in hindering drug absorption. The corneal monolayered endothelium 
forms a cellular barrier between stroma and aqueous humor. This barrier possesses 
leaky tight junctions which allow free movement of macromolecules between 
stroma and the aqueous humor (93). Mostly, transcorneal diffusion of drug 
absorption takes place into aqueous humor.  Molecular size has no significant role 
in permeation across corneal epithelium but the ionization of compounds decreases 
transcellular diffusion. Therefore, the physicochemical properties of molecule, 
ionization constant and their pH of the ocular drug product play important roles in 
regulating and determining ocular drug permeability across corneal epithelium.   
Vernal keratoconjunctivitis (VKC) is an allergic conjunctivitis that causes 
corneal epithelium to lose its integrity and barrier properties. During this condition 
eosinophils are activated to release cytotoxic proteins such as Myc promoter 
binding protein (MBP-1), eosinophil peroxidase, eosinophil-derived neurotoxin 
and eosinophil cationic protein in the tear fluid, which degrade the corneal 
epithelium (94-98).  
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Corneal ulceration develops due to corneal fibroblasts stimulation by 
neutrophils.  These fibroblasts along with other factors such as TNF-α, IL-4, and 
IL-13 participate in corneal collagen breakdown (99-101).  Thereby, cornea loses 
its precise collagen arrangement which may have an effect on corneal barrier 
properties to topically administered drugs. Corneal fibroblasts can participate in 
collagen degradation by altering components of the basement membrane to develop 
corneal ulcers. Tear fluid of VKC patients degrade type IV collagen and laminin, 
chief components of the basement membrane, and consequently allow to develop 
corneal ulcers (94, 102-105).  
 
Conjunctiva 
 
Conjunctival tissue acts as a permeability barrier to topically applied drugs. 
One of the barrier properties can be attributed to its trans-epithelial electric 
resistance (TEER) (106-108). Different routes of drug absorption such as 
paracellular, transcellular, active and endocytic routes play a key role in ocular drug 
delivery through conjunctiva for topically applied drug products.  The paracellular 
route of drug permeation is highly restricted due to the presence of tight junctions 
at the epithelial surface, which is the rate limiting step for drug absorption (109). 
Presence of secretory glands embedded within the conjunctiva may have an impact 
on drug absorption (110, 111).  Tear production is a protective response of the eye 
in response to topically applied xenobiotics. It is a barrier that reduces the drug 
concentration and bioavailability at the conjunctival apical surface.  
Physicochemical properties of the drugs such as hydrophilicity and molecular 
28 
 
weight were found to play a major role in drug permeation across conjunctiva.   
Experimental results demonstrate that hydrophilic drugs with molecular weights 
less than 20 kD are permeable (109, 112), but higher molecular weight drug 
molecules are restricted. Relatively conjunctiva has higher paracellular 
permeability than the cornea for proteins (insulin, molecular weight 5.8 kD) and 
peptides (p-aminoclonidine (molecular weight 245.1 D) because of its larger 
surface area and leaky vasculature. (113, 114). On the other hand, lipophilic drug 
absorption via transcellular route has significantly higher contribution relative to 
hydrophilic drugs. For example, propranolol (a lipophilic drug with logP of 3.21) 
has ten-fold higher absorption than sotalol (hydrophilic drug with log P of -0.62).   
Since, conjunctiva possesses esterase activity (115) it may act as an another barrier 
to drug delivery.  During the diseased conditions the conjunctiva may grow larger 
and develop fibrosis, due to high amounts of collagen production (94). 
 
Blood Aqueous Barrier  
 
Endothelial cells of iris/ciliary blood vessels and the non-pigmented ciliary 
epithelium together form the blood aqueous barrier (BAB) in the anterior part of 
eye.  This barrier forms tight junctions at the cellular level and regulates the 
exchange of solutes between the anterior and posterior ocular segments.  Thereby, 
impedes some non-specific drug entry into deeper ocular tissues by functioning as 
a barrier.  Cellular tight junctions impede non-specific drug entry into inner ocular 
tissues and act as barrier.  BAB helps to maintain ocular transparency and regulate 
chemical composition (116, 117).  An intact BAB possesses incomplete barrier 
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functionality; for example, 40 kD horse radish peroxide (HRP) reaches aqueous 
humor through fenestrated ciliary capillaries, which are engaged in regulating 
permeation of plasma proteins, into the aqueous humor. Most of the drugs reaching 
aqueous humor are eliminated into the systemic circulation through the iris blood 
capillaries. Hence, drugs in aqueous humor are absorbed by the iris pigments and 
eliminated into the iris blood circulation (118, 119). On the other hand, small 
lipophilic drug molecules that escape tight junctions and traverse BAB can be 
eliminated more rapidly than the larger hydrophilic molecules. As a result, drug 
penetration to deeper ocular tissues is prevented. 
 
Efflux Pumps 
 
Multidrug resistance in cells may be partially developed due to cell 
membrane anchored efflux transporter proteins. These efflux pumps belong to 
adenosine triphosphate (ATP) binding cassette (ABC) superfamily and are actively 
engaged in effluxing out exogenous xenobiotics and provide protection to the cell.  
Permeability glycoprotein (P-gp) and multidrug resistance associated protein 
(MRP) are two efflux proteins that majorly participate in drug efflux at cellular 
level, causing reduced intracellular drug concentration.  
 
Anterior Segment Dynamic Barriers 
 
Tear Drainage 
 
Ophthalmic drug products are primarily administered by topical route into 
the cul-de-sac.  A large fraction (~ 90%) of administered drug is lost due to pre-
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corneal barrier - tear drainage into nasolacrimal ducts (Figure 4). Also, other 
factors that contribute to reduce drug concentrations in cul-de-sac include tear 
dilution, drug binding to tear proteins and accelerated clearance. Usually, 
commercially marketed droppers are adjusted to deliver a volume of topical drop 
from 20-50 µL. From the applied dose, the precorneal pocket holds only 7-10 µL 
by replacing tear which is already present in the precorneal pocket (120). Such 
excess administered dose may be lost due to spillage from the precorneal pocket or 
drainage through the nasolacrimal duct (120, 121).  Precorneal tear drainage washes 
the topically instilled drops/solutions within the first 15-30 seconds, causing a 
significant reduction in drug contact time and ultimately reducing ocular 
bioavailability (< 5%) (122-124).  
 
Conjunctival Lymph and Blood Flow  
 
The conjunctiva is highly vascularized and supplied with lymph vessels.  
Topically applied drugs into the precorneal pocket may be primarily carried away 
into the systemic and lymph circulation while traversing the conjunctiva (125), 
resulting in lower drug permeation to deeper ocular tissues. Conjunctival blood and 
lymph considerably limit the transport of sodium fluorescein from reaching the 
inner retinal tissues (126, 127), indicating the dynamic role in drug elimination. 
 
Aqueous Humor 
 
Aqueous humor secreted by the ciliary body flows toward the cornea, i.e. in 
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Figure 4. Picture showing the pathway for tear drainage. 
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opposite direction to the drug entry applied topically.  Topically applied drugs, 
which traverse across the anterior corneal epithelial barrier, may be further limited 
by aqueous humor flow.  Drugs may be drained out through trabecular meshwork 
into the canal of Schlemm.  Larger hydrophilic drugs are found to be eliminated by 
aqueous humor causing sub-therapeutic levels in the inner ocular tissues (128).   
Ocular BAB function may be compromised due to immunologically 
induced ocular inflammation and may prevent effective permeability of several 
agents.  Intravitreally administered fluorescein labeled serum albumin (F-RSA) 
diffused into the anterior chamber after five mins in the inflamed eye but not in the  
control/non-inflamed eye (129).  It is well known that only fluorescein sodium 
molecules easily traverse BAB but F-RSA does not.  The F-RSA diffusion into the 
anterior chamber followed a biphasic pattern until it reached concentration maxima 
(Cmax) by 2 to 3 hours in the anterior chamber.  Then there was a gradual decrease 
in the fluorescence.  These experimental results indicate loss of BAB barrier 
function, and loss of drug into the anterior chamber through pupil (129).  In another 
study, Xiangyun K, et al. showed that primary angle closure glaucoma damaged the 
BAB and developed inflammation in the anterior segment of the eye (130).  A 
comparative study between the patients suffering from acute primary angle closure 
glaucoma (APACG) and chronic primary angle closure glaucoma (CPACG) 
revealed that patients suffering from APACG had highest BAB damage than 
CPACG (130).  It was hypothesized that a dramatic increase in IOP may be the 
causative factor for the change of BAB in the eye of PACG patients.     
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Posterior Segment Barriers 
Posterior Segment Static Barriers 
Sclera 
 
The sclera is one of the outermost layers of the eye which provides 
protection and prevents entry of exogenous substances to the posterior ocular 
tissues.  Permeability across sclera mainly depends on certain parameters of the 
permeating molecule, such as molecular radius, physicochemical properties and 
surface charge. Drug permeability across sclera gradually recedes with increasing 
lipophilicity and molecular radius ( 
 
 
 
 
 
 
 
Figure 5).  Thus, molecules with higher lipophilicity and larger molecular 
radius may be prevented from permeation through aqueous scleral pores. The 
opposite surface charge of the molecule also limits its permeation across sclera.  
Drug molecules gets trapped in pores of sclera causing low permeability possibly 
due to interactions with negatively charged pores and proteoglycan matrix (131).  
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Scleral thickness varies with anatomical location. It is very thick at the 
posterior segment, near the optic nerve. Due to its thickness, here the posterior 
sclera has very low permeability for drug molecules.  
 
Bruch’s Membrane 
 
The Bruch’s membrane is partly involved in regulating the exchange of 
nutrients, fluids, metabolic waste, oxygen and biomolecules between choroidal 
blood circulation and retina (132).  Thickness of Bruch’s membrane increases with 
age, resulting in calcification, high collagen fiber crosslinking and 
glycosaminoglycan turnover (133-135).  Changes in the thickness of this membrane 
may also affect permeability of molecules from the sclera into retinal tissues.  
Moreover, most of the drugs may be lost in the choroid before reaching Bruch’s 
membrane. During diseased conditions such as age related macular degeneration, 
increased accumulation of extracellular debris causes oxidative stress and chronic 
inflammation to Bruch’s membrane.  Higher accumulation of extracellular debris 
reduces the transport of nutrients as well as drug molecules.  This may contribute 
to the development of secondary metabolic stress (Figure 6) (136).  
 
Blood Retinal Barrier 
 
Blood retinal barrier (BRB) is composed of both inner and outer BRB. Outer 
BRB is composed of tight junctions of RPE cells whereas inner BRB by retinal 
capillary endothelial cells. Zonulae occludentes of outer BRB separates the retinal 
photoreceptors from RPE (137, 138). Both astrocytes and Müller cells provide 
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necessary functional support to these tight junctions. These two cells together 
regulate the exchange of substances between outer choroid and inner retina.  
Astrocytes help to maintain the integrity, enhance the barrier property of retinal 
endothelial capillaries (139, 140) and provide protection to inner retinal cells from 
circulating molecules in retinal circulation.   
Similar to blood brain barrier, the lack of fenestrations in the RPE and 
retinal endothelial cells prevents passive drug diffusion.  RPE allows diffusion of 
very small molecules such as CO2, O2 and lipophilic molecules to inner retinal 
tissues 
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Figure 5. A comparative relationships between 14C labeled permeants: tetraethyl 
ammonium bromide (130 Da), salicylic acid (138 Da), bovine serum albumin (~67 
kDa), poly-(styrene sulfonic acid) (7 kDa), bevacizumab (149 kDa) molecular 
weight and passive permeability coefficients for human sclera (63).  
Symbols: closed diamonds, experimental passive permeability with human sclera 
(mean and standard deviation, n ≥ 4); open squares, previous published human 
passive permeability data (141), open triangles, rabbit passive permeability data 
(142), open circles, porcine passive permeability data (143). Reproduced with 
permission from International Journal of Pharmaceutics (63).  
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Figure 6. Extracellular accumulation of debris in Bruch’s membrane (top) normal 
eye versus (bottom) diseased eye.  
(Source - http://www.decleeneoptometry.com/pages/diseases.htm)  
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from the choroid. Thus, the transport of molecules may be mediated by receptor or 
energy/ATP dependent fluid phase pinocytosis. Therefore, drug entry is highly 
restricted due to the presence of tight junctions.  Also, RPE works as a pump by 
dehydrating the subretinal space.  This helps to maintain the normal neuroretinal 
apposition with RPE (144, 145).  The pump function is necessary because there is 
no strong adhesion between the segments of external neural retina and RPE.  The 
interphotoreceptor matrix, a gel-like viscous solution present between retinal cells, 
forms very weak bonds.  During the ischemic conditions, retinal adhesive forces 
diminish within minutes (145).  
 
Efflux Pumps 
Trans-membrane efflux pumps such as P-gp or MRP expressed on apical 
and basal side of human RPE have been reported (146, 147).  Expression of P-gp 
on rat retinal endothelial cells was also reported (148).  Similarly the presence of 
P-gp, MRP4 and BCRP in retinal vasculature of postnatal mouse has been reported. 
The expression of P-gp in retinal astrocytes has also been reported (149). Recently, 
different expression levels of MRP1, MRP4 and MRP5 efflux proteins in human 
retinal pigment epithelial cells have also been indicated (150).  At cellular level, 
these efflux pumps are actively involved in reducing the intracellular drug 
concentrations and act as a major barrier to drug delivery.  
 
 
 
39 
 
Posterior Segment Dynamic Barriers 
 
Choroidal Blood and Lymph Circulation 
 
The choroid is a highly vascularized tissue (see above) and supplied with 
lymph vessels.  This tissue has the highest blood vasculature (~80%) of the total 
ocular blood supply relative to iris-ciliary body and retina (151).  Drug molecules, 
lipophilic, may be actively drained in the choroidal and systemic circulation, 
preventing further entry into the inner ocular tissues.  This restricted drug entry may 
lead to sub-therapeutic drug concentration in retinal tissues.  Studies with 
hydrophilic drugs such as sodium fluorescein indicate very low elimination through 
choroid (127, 152). 
Approaches to Ocular Drug Delivery 
 
Topical instillation is the most widely preferred non-invasive route of drug 
administration to treat diseases affecting the anterior segment. Conventional dosage 
forms such as eye drops account for 90% of the marketed ophthalmic formulations. 
The reason may be attributed to ease of administration and patient compliance (153, 
154). Nonetheless, the ocular bioavailability is very low with topical drop 
administration. Numerous anatomical and physiological constraints such as tear 
turnover, nasolachrymal drainage, reflex blinking, and ocular static and dynamic 
barriers pose a challenge and impede deeper ocular drug permeation (155). Hence, 
less than 5% of topically applied dose reaches to deeper ocular tissues (156). Also, 
it is difficult to achieve therapeutic drug concentration into posterior segment ocular 
tissues following topical eye drops instillation because of the above mentioned 
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barriers. The drug can be delivered to the posterior segment ocular tissues by 
different mode of administration such as intravitreal injections, periocular 
injections, and systemic administration. However, the small volume of eye 
compared to whole body and presence of blood retinal barriers; makes systemic 
administration an impractical approach. Intravitreal injection is the most common 
and widely recommended route of drug administration to treat posterior ocular 
diseases. Though, the need of repeated eye puncture with intravitreal injections 
causes several side effects such as endophthalmitis, hemorrhage, retinal detachment 
and poor patient tolerance (157). The transscleral drug delivery with periocular 
administration route is evolved as an alternative mode of drug delivery to the 
posterior ocular tissues. Although transscleral delivery is comparatively easy, less 
invasive and patient compliant, drug permeation is compromised by ocular static 
and dynamic barriers. Ocular barriers to transscleral drug delivery include: static 
barriers, i.e. sclera, choroid, RPE, and dynamic barriers, i.e., lymphatic flow in the 
conjunctiva and episclera, and the blood flow in conjunctiva and choroid (126, 
158).   
            To overcome the ocular drug delivery barriers and improve ocular 
bioavailability, various conventional and novel drug delivery systems have been 
developed such as emulsion, ointments, suspension, aqueous gels, nanomicelles, 
nanoparticles, liposomes, dendrimers, implants, contact lenses, nanosuspensions, 
microneedles, and in situ thermosensitive gels for the earlier mention ocular 
diseases. This review will provide an overview on various conventional and novel 
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ophthalmic drug delivery systems developed to deliver drug to diseased ocular 
tissues for the treatment of ocular diseases.  
Conventional Ocular Drug Delivery Systems 
 
Topical drop instillation into the lower precorneal pocket is a patient 
compliant and widely recommended route of drug administration. However, most 
of the topically administered dose is lost due to reflux blinking and only 20% (~7 
µL) of instilled dose is retained in the pre-corneal pocket (120). Concentration of 
drug available in the precorneal area acts as a driving force for its passive diffusion 
across cornea.  However, for efficient ocular drug delivery with eye drops, high 
corneal permeation with longer drug cornea contact time is required. Several efforts 
have been made toward improving precorneal residence time and corneal 
penetration. To improve corneal permeation iontophoresis, prodrugs, ion-pair 
forming agents and cyclodextrins are employed (113, 159-162). There is a wide 
range of ophthalmic products available in the market of which about 70% of 
prescription include conventional eye drops. The reasons may be due to ease of 
bulk scale manufacturing, high patient acceptability, drug product efficacy, stability 
and cost effectiveness.  
 
Topical liquid/solution eye drops 
 
Topical drops are the most convenient, safe, immediately active, patient compliant 
and non-invasive mode of ocular drug administration. An eye drop solution 
provides a pulse drug permeation post topical drop instillation, after which its 
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concentration rapidly declines.  The kinetics of drug concentration decline may 
follow an approximate first order.  Therefore, to improve drug contact time, 
permeation and ocular bioavailability; various additives may be added to topical 
eye drops such as viscosity enhancers, permeation enhancers and cyclodextrins. 
Viscosity enhancers improve precorneal residence time and bioavailability upon 
topical drop administration by enhancing formulation viscosity. Examples of 
viscosity enhancers include hydroxy methyl cellulose, hydroxy ethyl cellulose, 
sodium carboxy methyl cellulose, hydroxypropyl methyl cellulose and polyalcohol 
(163-165). 
 Permeation enhancers improve corneal uptake by modifying the corneal 
integrity. Other additives such as chelating agents, preservatives, surface active 
agents and bile salts were studied as possible permeation enhancers. Benzalkonium 
chloride, polyoxyethylene glycol ethers (lauryl, stearyl and oleyl), 
ethylenediaminetetra acetic acid sodium salt, sodium taurocholate, saponins and 
cremophor EL are the examples of permeation enhancers investigated for 
improving ocular delivery (166-168). Addition of permeation enhancers to ocular 
solutions improves ocular drug bioavailability, but a few studies revealed a local 
toxicity with permeation enhancers (169). Hence, research is still being conducted 
to modify the effect of permeation enhancers and evaluate their safety on corneal 
tissues.  Hornoff, et al. evidenced that polycarbophil-cysteine as an excipient did 
not damage the corneal tissue integrity and suggested that it could  be  safe for 
ocular formulations (170).  Cyclodextrins act as carriers for hydrophobic drug 
molecules in aqueous solution.  This helps to deliver drugs to the surface of 
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biological membrane.  Highly lipophilic biological membrane has much lower 
affinity towards hydrophilic cyclodextrins. Therefore, cyclodextrins remain in 
aqueous solution and the hydrophobic drug is absorbed by the biological 
membrane. Optimal bioavailability was achieved for eye drops with cyclodextrins 
concentration of <15% (171). Other applications of cyclodextrins in eye drop 
formulation were recently reviewed elsewhere by Cholkar et al.(172).  
Among these approaches, viscosity enhancers and cyclodextrins suffer from 
the disadvantage of precorneal loss. In the case of penetration enhancers, care 
should be taken in the selection due to high sensitivity of ocular tissues. Hence, it 
leads to development of other conventional formulations approaches with inert 
carrier systems for ocular delivery of therapeutics. Conventional ocular 
formulations such as emulsions, suspensions, and ointments have been developed 
to improve solubility, precorneal residence time and ocular bioavailability of drugs. 
In the current era of nanotechnology, these conventional formulations still retain 
their place, importance and capture the market at large. However, these 
formulations are associated with various side effects such as ocular irritation, 
redness, inflammation, vision interference and stability issues (119). Currently, 
research is being conducted to improve the in vivo performance of these carrier 
systems and to minimize their side effects (173). Several attempts are also being 
made to deliver the drugs to posterior ocular tissues with the conventional 
formulations. In the following sections, attempts have been made to describe the 
recent efforts made to improve in vivo performance of conventional ocular 
formulation and reduce their side effects.  
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Emulsions 
 
An emulsion based formulation approach offers an advantage to improve 
both solubility and bioavailability of drugs. There are two types of emulsions which 
are commercially exploited as vehicles for active pharmaceuticals: oil in water 
(o/w) and water in oil (w/o) emulsion systems (174). For ophthalmic drug delivery, 
o/w emulsion is common and widely preferred over w/o system. The reasons 
include less irritation and better ocular tolerance of o/w emulsion.  Restasis™, 
Refresh Endura® (a non-medicated emulsion for eye lubrication) and AzaSite® are 
the examples of currently marketed ocular emulsions in the USA. Several studies 
have demonstrated applicability of emulsions in improving pre-corneal residence 
time, drug corneal permeation, providing sustain drug release and thereby 
enhancing ocular bioavailability (175).  
In a recent study, Tajika, et al. demonstrated improved anti-inflammatory 
activity with a prednisolone derivative, 0.05%  [3H] difluprednate, with an emulsion 
as vehicle (176).  Results confirmed that in the rabbit eye, emulsion could deliver 
drug to the anterior ocular tissues with small amount of drug reaching posterior 
tissues following single and multiple topical drop instillation. Single and multiple 
topical drop instillation studies revealed highest radioactivity in cornea followed by 
iris-ciliary body > retina-choroid > conjunctiva > sclera > aqueous humor > lens > 
and vitreous humor.  Post single drop administration, Tmax for cornea, conjunctiva, 
lens, iris-ciliary body, aqueous and vitreous humor was 0.5 h while Tmax for retina-
choroid was 1 h. Negligible amount of drug was quantified in systemic circulation. 
With repeated dose instillation, Tmax for lens and retina-choroid was 8 h and 0.5 h, 
45 
 
respectively. After 168 h, a total dose of approximately 99.5% of radioactivity was 
excreted in urine and feces. This study suggests difluprednate emulsion as a 
potential candidate for treating anterior ocular inflammations.   
 Emulsions with lipid additives such as soyabean lecithin, stearylamine 
were evaluated as carrier systems for azithromycin to demonstrate better ocular 
performance and bioavailability (177). A comparative study for azithromycin 
solution vs emulsion at different doses (3, 5 and 10 mg/mL azithromycin) was 
studied for tear elimination characteristics.  In vivo studies were conducted in 
rabbits with topical drop administration. Emulsion, not only observed to behave as 
a vehicle for azithromycin but also slowed drug release, improved its chemical 
stability and precorneal residence time. Additionally, emulsion formulation 
improved the chemical stability (t1/2) of azithromycin at pH 5.0 and 7.0 relative to 
aqueous solutions.  Altogether, results suggest that lipid emulsion could be a 
promising vehicle for ocular drug delivery.  
 Similarly, another novel approach is to derivatize active pharmaceutical 
ingredients (API), and improve its ocular bioavailability with an emulsion as carrier 
system. This strategy may help to reduce ocular irritancy and improve the effect of 
API. To test this hypothesis Shen, et al. made attempts to improve emulsion 
biocompatibility for the flurbiprofen. In this study, a derivative of flurbiprofen, 
flurbiprofen axetil, with castor oil and Tween-80 was used to prepare emulsion 
(173, 178).  Four different emulsions with varying ratios of castor oil (0.1 to 2.5 
wt%) and Tween 80 (0.08 to 4 wt%) were prepared and labeled as F1, F2, F3 and 
F4) respectively.   
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Figure 7. Concentration–time profiles of flurbiprofen (FB) in the aqueous humor 
after instillation of flurbiprofen axetil (FBA-EM) emulsion F2–F4, FB-Na eye 
drops and FBA-oil solution in rabbits. (F1 = 0.1 wt% of castor oil, 0.08 wt% of 
Tween-80; F2 = 0.5 wt% of castor oil, 0.4 wt% of tween-80; F3 = 1.0 wt% of castor 
oil, 0.8 wt% of tween-80 and F4 = 2.5 wt% of castor oil, 4.0 wt% of tween-80 with 
2.2 and 0.1 wt% of glycerol and flurbiprofen respectively.  Reproduced with 
permission from reference (173). 
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In vivo studies were conducted in male New Zealand albino rabbits with a topical 
drop instillation. Aqueous humor pharmacokinetic studies showed F2 emulsion 
(castor oil to tween 80 wt% ratio of 0.5:0.4) to be better relative to other emulsion 
formulations and solution.  The F2 emulsion translocated high drug concentrations 
into aqueous humor post topical drop administration relative to 0.03% flurbiprofen 
sodium eye drops (Figure 7).  Similarly, ocular irritation studies with F2 emulsion 
demonstrated better biocompatibility relative to other emulsions. 
Several researchers have introduced mucoadhesive polymers such as chitosan and 
hydroxypropyl methyl cellulose ether (HPMCE) for emulsion coating. Studies 
concluded that chitosan surface coating improves pre-corneal residence time of API 
and thereby ocular bioavailability. Indomethacin loaded oil-in-water emulsion was 
prepared employing castor oil and polysorbate-80 and the resultant emulsion was 
surface coated by chitosan (179). 
A comparative in vivo study for chitosan coated vs non-coated indomethacin 
emulsions were conducted in male albino rabbits with topical drop instillation. Tear 
fluid pharmacokinetic study showed  that emulsion surface coating with chitosan 
improves  emulsion mean residence time and also half-life by 1.5 and 1.8 times, 
respectively relative to non-coated emulsion. Indomethacin concentrations were 
quantified in cornea, conjunctiva and aqueous humor, post 1 h of emulsion 
instillation.  Indomethacin concentrations with emulsion system were found to be~ 
5.3 and 8.2 times higher in cornea relative to conjunctiva and aqueous humor.   
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Suspensions 
 
Suspensions are another class of non-invasive ocular topical drop drug 
carrier system. Suspension may be defined as dispersion of finely divided insoluble 
API in an aqueous solvent consisting of a suitable suspending and dispersing agent. 
In other words, the carrier solvent system is a saturated solution of API.  Suspension 
particles retain in pre-corneal pocket and thereby improve drug contact time and 
duration of action relative to drug solution. Duration of drug action for suspension 
is particle size dependent. Smaller size particle replenishes the drug absorbed into 
ocular tissues from pre-corneal pocket. While on the other hand, larger particle size 
helps retain particles for longer time and slow drug dissolution (156). Thus, an 
optimal particle size is expected to result in optimum drug activity. Several 
suspension formulations are marketed worldwide to treat ocular bacterial 
infections. TobraDex® suspension is one of the widely recommended commercial 
products for subjects responding to steroid therapy. TobraDex® is a combination 
product of antibiotic, tobramycin (0.3%), and steroid, dexamethasone (0.1%). The 
major drawback of this commercial product is high viscosity. Recently Scoper, et 
al. made attempts to reduce the viscosity of TobraDex® and to improve its in vivo 
pharmacokinetics along with bactericidal activity (180). The rationale behind 
developing this formulation was to improve the suspension formulation 
characteristics such as quality, tear film kinetics and tissue permeation. The new 
suspension consists of tobramycin (0.3%), and steroid, dexamethasone (0.05%) and 
called TobraDex ST®.  Suspension settling studies showed that new formulation 
had very low settling over 24 h (~3%) relative to marketed TobraDex® (~ 66%). 
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Ocular distribution studies showed higher tissues concentrations of dexamethasone 
and tobramycin in rabbits treated with TobraDex ST® relative to TobraDex®. New 
suspension formulation was found to be more effective than TobraDex® against 
Staphylococcus aureus and Pseudomonas aeruginosa. Clinical studies in human 
subjects showed high dexamethasone concentrations in aqueous humor than 
TobraDex®. These results suggest that new suspension formulation to be an 
alternative to marketed suspension. This is because the new suspension possesses 
better formulation characteristics, pharmacokinetics, bactericidal characteristic and 
patient compliance than marketed TobraDex® suspension. 
In another study to treat dry eye, 4 week, randomized, double masked, 
multicenter phase II clinical trials were conducted with rebamipide (OPC-12759) 
suspension (181). Two suspension formulations 1% and 2% rebamipide were 
employed for this study, where placebo served as control. The efficacy and safety 
of suspension formulation were determined in human subjects following topical 
instillation. A dose dependent response was observed for placebo, 1% and 2% 
rebamipide suspension for both FCS (fluorescein corneal staining) and Lissamine 
green conjunctival staining (LCGS) studies at 2 and 4 week. Tear production 
showed no significant difference from baseline from day 1 to week 4. But, the tear 
film break up time showed significant change in 1% and 2% rebamipide relative to 
placebo.  All the subjects receiving treatment with suspension rebamipide 
formulation reported improvement of 64.1% and 54.9% respectively than subjects 
receiving placebo. Dysgeusia, ocular irritation and nasopharyngitis adverse events 
were frequently observed in 27.2%, 29.1% and 30.4% patients receiving placebo, 
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1% and 2% suspension, respectively. Drug induced adverse effects such as eye 
irritation was observed in 3.9%, 2.9% and 2.0% subjects receiving placebo, 1% 
rebamipide and 2% rebamipide respectively.  All these adverse effects were found 
to recover without any additional treatment.  This 4 week studies revealed that 
suspension formulations were well tolerated and both formulations were effective 
in treating dry eye.  In some measures, of the two formulations, 2% rebamipide 
suspension was found to be more effective relative to 1% suspension. 
 
Ointments 
 
Ophthalmic ointments are another class of carrier systems developed for 
topical application. Ocular ointment comprises of mixture of semisolid and a solid 
hydrocarbon (paraffin) that has a melting point at physiological ocular temperature 
(34 ºC). The choice of hydrocarbon is dependent on biocompatibility.  Ointments 
help to improve ocular bioavailability and sustain the drug release (182).   
Vancomycin HCl (VCM) is a glycopeptides antibiotic with an excellent 
activity against aerobic and anaerobic gram positive bacteria and methicillin and 
cephem resistant Staphylococcus aureus (MRSA). Inspite of better activity of 
VCM, no appropriate topical formulation was available in the market.  Better ocular 
tissue permeability of VCM was not expected in a normal eye but few clinical 
effects of VCM solution were reported in ocular disease treatment. The reason for 
the observed effects was hypothesized due to broken ocular barrier system, which 
might have improved drug permeation. Fukuda, et al. studied the intraocular 
dynamics of vancomycin hydrochloride ophthalmic ointments in rabbits (183). 
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Thus, authors made attempts to demonstrate ocular dynamics of VCM ophthalmic 
ointment (TN-011) with indications limited to extraocular MRSA infections.  The 
minimum growth inhibitory concentration to treat MRSA bacterial infections was 
found to be 1.56 µg/g.  In vivo studies were conducted in rabbits (normal vs Bacillus 
subtilis (BS) group). The BS group was developed in cornea by injecting BS 
solution into the central portion of parenchyma. Treatment was by topical ocular 
ointment (1% VCM) administration to normal and BS group rabbit eye.  In normal 
group, after 15 mins, VCM concentration in cornea of 12.04 ± 4.73 µg/g was 
attained at 30 mins which was decreased to 0.49 ± 0.97 µg/g at 120 mins. On the 
other hand, VCM concentrations in BS group cornea was 25.60 ± 11.01 µg/g after 
15 min and 3.68 ± 1.38 µg/g after 240 mins of administration. The concentrations 
of VCM were maintained above MIC levels, in MRSA infection induced BS group, 
a considerable benefit to the patients from TN-011 is expected.  
In another study by Eguchi, et al. four different ointment formulation of 
vancomycin with varying concentrations (0.03%, 0.1%, 0.3% and 1.0%) were 
prepared in 1:4 mixtures of liquid paraffin and vaseline (184). The efficacy of 
formulations was evaluated in rabbit model of MRSA keratitis infection after 
topical application. It was observed that at low drug concentrations i.e., 0.03% and 
0.1%, numerous infiltrates were found in corneas with abscesses. On the other 
hand, animals treated with 0.3% formulation showed no recurrence of keratitis in 
any eye over 14 day study period. Therefore, 0.3% vancomycin ointment was 
suggested to be adequate and effective to resolve corneal MRSA keratitis. 
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Though considerable effort is being put into research to improve efficacy, 
still there is a need to overcome certain drawbacks associated with conventional 
formulations. The above mentioned formulations: emulsion, suspension, and 
ointment are known to cause ocular adverse effects such as irritation, redness of 
eye and interference with vision. Also, chronic administration may increase 
systemic API availability which may lead to severe systemic complications (185-
187). Formulations with preservatives also induce adverse reactions upon systemic 
absorption (188, 189). Therefore, to overcome formulation based adverse effects 
and to deliver therapeutic amounts of drug in ocular tissues, research is now being 
focused on exploring and developing other novel strategies of ocular drug delivery. 
In the following sections, we will discuss about the recent developments made in 
nanotechnology and controlled release devices in past decade for improving ocular 
drug delivery. 
Novel Ocular Drug Delivery Systems 
 
Nanotechnology based ocular drug delivery 
 
In a last few decades, many approaches have been utilized for the treatment 
of ocular diseases. Nanotechnology based ophthalmic formulations are one of the 
approaches which is currently being pursued for both anterior, as well as posterior 
segment drug delivery. Nanotechnology based systems with an appropriate particle 
size can be designed to ensure low irritation, adequate bioavailability, and ocular 
tissue compatibility. Several nanocarriers, such as nanoparticles, nanosuspensions, 
liposomes, nanomicelles and dendrimers have been developed for ocular drug 
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delivery (Figure 8). Some of them have shown promising results for improving 
ocular bioavailability.  
 
Nanomicelles  
 
Nanomicelles are the most commonly used carrier systems to formulate 
therapeutic agents in to clear aqueous solutions. In general, these nanomicelles are 
made with amphiphilic molecules. These molecules may be surfactant or polymeric 
in nature. Recently, Cholkar et al. have reviewed in detail about ocular barriers and 
application of nanomicelles based technology in ocular drug delivery (190). 
Currently, tremendous interest is being shown towards development of 
nanomicellar formulation based technology for ocular drug delivery. The reasons 
may be attributed due to their high drug encapsulation capability, ease of 
preparation, small size, and hydrophilic nanomicellar corona generating aqueous 
solution. In addition, micellar formulation can enhance the bioavailability of the 
therapeutic drugs in ocular tissues, suggesting better therapeutic outcomes. So far, 
several proofs of concept studies have been conducted to investigate the 
applicability of nanomicelles in ocular drug delivery. For instance, Civiale et al. 
developed dexamethasone loaded nanomicelles by employing copolymers of 
polyhydroxyethylaspartamide (PHEAC(16)) and pegylated PHEAC(16) for 
anterior segment delivery (191). In vivo dexamethasone concentration time profiles 
were studied and determined in rabbits with aqueous humor sampling. Results 
showed that dexamethasone loaded PHEA micelles have higher ocular bioavailabi- 
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Figure 8. Nanocarriers for ocular drug delivery. 
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lity relative to dexamethasone suspension. The area under the curve for 
dexamethasone micellar formulation was 40% higher than that of control 
suspension.  Results suggest that nanomicellar formulations are a viable option for 
topical ocular delivery of small molecules. Researchers have also utilized 
nanomicelles for ocular gene delivery.  In a study, Liaw et al. made attempts to 
deliver genes by topical drop administration to cornea (192). Copolymer, 
poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-
PEO) was used to develop micelles as a vehicle for gene delivery. This polymeric 
system efficiently transferred plasmid DNA with LacZ gene in rabbit and mice 
ocular tissues. Results were promising and indicated the potential application of 
copolymers in DNA transfer. Further studies were conducted with the copolymer 
to deliver two cornea specific promoters i.e. keratin 12 (K12) and keratocan. 
Transgene expression was quantified with β-Gal activity.  Significant elevated 
levels of keratin 12 (K12) and keratocan were quantified following six doses of eye 
drop of pK12-Lac Z-PM three times a day in both mouse and rabbit corneas. The 
probable mechanism of transfection was endocytosis and particle size dependent 
paracellular transport of polymeric micelles (193).  
Several attempts are also being made to utilize nanomicelles for the 
posterior ocular drug delivery. Recently, Mitra and co-workers have made a 
significant stride to deliver therapeutic drugs to the posterior ocular tissues with the 
aid of topical drops of nanomicellar formulations (194). To bolster the hypothesis 
that the nanomicelles can deliver the drug to the posterior ocular tissues, in vivo 
studies were carried out in rabbits using voclosporin loaded nanomicelles.  
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Interestingly, the nanomicelle formulations were able to efficiently traverse ocular 
tissues and deliver drug to back-of-the-eye tissues. Ocular tolerability of 
nanomicelles was evaluated against Restasis® as control in New Zealand White 
(NZW) rabbits.  A detailed 72 h study with Hackett-McDonald scoring with 
microscopic ocular examination was included for two voclosporin (0.02 and 0.2%) 
micellar and Restasis® formulations.  Post 1 hour topical drop administration of 
Restasis® highest ocular irritation was observed relative to two micellar voclosporin 
formulations.  It was demonstrated that the novel nanomicellar formulations were 
well tolerated and induced markedly low irritation than Restasis®. Further, authors 
also prepared dexamethasone and rapamycin nanomicellar formulations at a 
concentration of 0.1 and 0.2 wt%, respectively. Ocular tissue distribution studies 
with single drop instillation showed that nanomicellar formulation encapsulating 
voclosporin, dexamethasone and rapamycin was able to deliver therapeutic 
concentrations of drug to back-of-the-eye tissues post topical drop instillation.  
These studies suggest that small size, hydrophilic nanomicellar corona help to 
evade ocular barriers and deliver drug cargo to posterior ocular tissues. A non-
corneal pathway of drug delivery has been hypothesized for back-of-the-eye drug 
delivery. Ryuichi and co-workers made attempts to deliver FITC-P(Lys) to back-
of-the-eye tissues via intravenous drug administration to treat back-of-the-eye 
tissue neovascularization (195).  In vivo studies with unformulated FITC-P(Lys) 
resulted in death of animals post 1 h of administration.  In contrast encapsulating 
the FITC-P(Lys) in polyehthylene glycol-block-poly-α,β-aspartic acid micelles 
resulted in no death. This indicates no free drug was available in nanomicellar 
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formulation.  Micellar formulation showed a Cmax at 4 h in retina-choroid and drug 
was detected up to 7 days following single intravenous administration. Prolonged 
micellar circulation was achieved by controlling polymer to drug charge ratios. 
Authors speculated that longer systemic micellar circulation may aid in enhanced 
permeation and retention (EPR) effect at neovascularization site. Micellar 
constructs were observed to selectively accumulate at the pathologic neovascular 
site to a greater extent than in normal tissues.   
  In another study, Ususi et al. made attempts to encapsulate dendritic 
photosensitizer (DP) in PEG-b-P(Lys) micellar construct for the treatment of 
exudative AMD with photodynamic therapy (196). In vitro cytotoxicity studies 
were performed under dark and light irradiation for DP alone and DP loaded 
polyionic complex (PIC) micelles to be more cytotoxic in light irradiated 
conditions. This higher cytotoxic effect of polymeric ion complex micelles under 
light irradiation was utilized for the treatment of exudative AMD. 
Photocoagulation was induced in rat eye. DP loaded PIC micelles were 
administered by intravenous injection and DP accumulation in choroidal 
neovascular site was observed. Application of mild laser light treatment 
destroyed/choked the abnormal vasculature.  This new technology prevents 
further drug leakage.  Histological studies revealed accumulation of PIC micelles 
at ocular lesion site.  Reason may be attributed due to EPR effect.  Administered 
free DP was eliminated within 24 h.  On the other hand,  PIC micelles 
encapsulated DP were detected after 24 h indicating micellar construct 
accumulation at lesion site with slow cell uptake. A reduction in fluorescence was 
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observed post 25 mins intravenous administration of DP loaded PIC micelles, due 
to chocking of abnormal vasculature. Hypofluorescence of DP micelles was 
increasing with time indicating increased vascular chocking.  Normal endothelial 
cell destruction was not observed, possibly due to lower DP accumulation. 
Results suggest that small size and hydrophilic negatively charged micellar 
corona resulted in considerable EPR effect.  This resulted in selective drug 
accumulation in the choroidal neovascular tissues with minimal/no drug induced 
adverse effects on normal cells.  
Ocular research is currently focused to non-invasively deliver therapeutic 
levels of drugs to both anterior and posterior ocular segments.  The advent of 
nanomicellar technology to delivery drugs in a non-invasive route i.e. topical drop 
is novel and patient acceptable.  Due to their extremely small size and hydrophilic 
corona, nanomicelles may be retained in systemic circulation for longer time and 
accumulate at the diseased tissue via EPR effect. Thereby, non-specific drug 
accumulation in to normal tissues may be minimized. Proper selection of 
surfactant/polymer and engineering technique may aid in delivery of drugs to both 
anterior and posterior eye segments.   
 
Nanoparticles 
 
Nanoparticles are colloidal carriers with a size range of 10 to 1000 nm. For 
ophthalmic delivery, nanoparticles are generally composed of lipids, proteins, 
natural or synthetic polymers such as albumin, sodium alginate, chitosan, poly 
(lactide-co-glycolide) (PLGA), polylactic acid (PLA) and polycaprolactone. Drug 
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loaded nanoparticles can be nanocapsules or nanospheres (Figure 8). In 
nanocapsules, drug is enclosed inside the polymeric shell while in nanospheres; 
drug is uniformly distributed throughout polymeric matrix.  From past few decades, 
nanoparticles have gained attention for ocular drug delivery and several researchers 
have made attempts to develop drug loaded nanoparticles for delivery to both 
anterior and posterior ocular tissues (Table 1). 
Nanoparticles represents a promising candidate for ocular drug delivery 
because of small size leading to low irritation and sustained release property 
avoiding frequent administration. However, like aqueous solutions, nanoparticles 
could be eliminated rapidly from pre-corneal pocket.  Hence, for topical 
administration nanoparticles with mucoadhesive properties have been developed to 
improve pre-corneal residence time (197). Polyethylene glycol (PEG), chitosan and 
hyaluronic acid are commonly employed to improve precorneal residence time of 
nanoparticles.  
         Chitosan coating is the most widely explored way of improving precorneal 
residence of nanoparticles.  The chitosan is positively charged and hence it binds 
to negatively charged corneal surface and thereby improves precorneal residence 
and decreases clearance. For instance, natamycin loaded chitosan/lecithin 
nanoparticles exhibited high ocular bioavailability at reduced dose and dosing 
frequency in rabbit eye compared to marketed suspension. Following topical 
administration, the AUC (0-∞) was increased up to 1.47-fold and clearance was 
decreased up to 7.4-fold in case of chitosan/lecithin nanoparticles compared to 
marketed suspension (198). In another study, Teresa, et al. reported that melatonin 
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loaded PLGA-PEG nanoparticles were most effective and demonstrated significant 
intraocular pressure (IOP) lowering effect compared with melatonin loaded PLGA 
nanoparticles and aqueous solution of equivalent concentration in the rabbit eye 
(Figure 9) (199). It was speculated that the reduced zeta potential of nanoparticles 
fabricated from PLGA-PEG than the PLGA allowed better and longer interaction 
between the nanoparticles and eye surface leading to higher hypotensive effect for 
prolonged period.  
Nanoparticles have also been successfully employed as an alternative 
strategy for long term drug delivery to the posterior segment ocular tissues. For 
posterior segment delivery, disposition of nanoparticles depends on the size and 
surface property. Following, periocular administration in to Sprague-Dawley rats, 
20 nm particles were cleared rapidly from periocular tissues. The rapid clearance 
can be due to removal by conjunctival, episcleral or other periocular circulatory 
systems. On the other hand, particles in the range of 200–2000 nm were retained at 
the site of administration for at least two months. Moreover, due to the rapid 
clearance and fast drug release, small size nanoparticles could not sustain retinal 
drug level. Therefore, it can be concluded that for prolonged transscleral drug 
delivery to the back-of-the-eye, nanoparticles with slow drug release and low 
clearance by blood and lymphatic circulations are suitable drug delivery candidates 
(200, 201). Following intravitreal injection, nanoparticles migrate through the 
retinal layers and tend to accumulate in the RPE cells. The PLA nanoparticles were   
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Figure 9. Intraocular pressure in normotensive rabbit eyes after topical instillation 
of melatonin (MEL) aqueous solution (■) or NPs: RG (Ο), RGP (∆), RG-MEL1 
(MEL loaded PLGA NPs) (▲), or RGP-MEL1(MEL loaded PLGA-PEG NPs) 
(♦). *p < 0.01, **p < 0.001 vs. melatonin; ***p < 0.001 vs. RGP-MEL1.  
Reproduced with permission from reference (199). 
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present in rat RPE tissues up to 4 months following single intravitreal injection 
which suggest that nanoparticles have great potential for achieving steady and 
continuous delivery to the back-of-the-eye.  Zhang, et al. investigated the 
pharmacokinetics and tolerance of dexamethasone (DEX) loaded PLGA 
nanoparticles in rabbits following intravitreal injection (202). Authors concluded 
that DEX when encapsulated in nanoparticles exhibited sustained release for ~50 
days. The constant DEX levels were maintained in vitreous over 30 days with a 
mean concentration of 3.85 mg/L. Contrary, only trace amounts of DEX being 
detected on the seventh day after injection of DEX solution. These results imply 
that intravitreal injection of dexamethasone nanoparticles may be employed for 
sustained delivery of drugs for the treatment of posterior segment eye diseases. The 
surface property of nanoparticles is a key factor affecting their distribution from 
vitreous humor to retinal layers (203). Heebeom et al. studied correlation between 
surface properties of the nanoparticles and their distribution in the vitreous and 
retina after intravitreal injection (204). Heterogeneous PEI (polyethyleneimine)/GC 
(glycol chitosan), HSA (human serum albumin)/GC, and HSA/HA (hyaluronic 
acid) nanoparticles were prepared by blending two polymers. The value of zeta 
potential of these nanoparticles were 20.7 ± 3.2, −1.9 ± 4.1 and −23.3± 4.4 for 
PEI/GC, HSA/GC, and HSA/HA nanoparticles, respectively. The nanoparticles 
were injected into vitreous cavity of Long Evans rats and vitreous/retinal 
distribution was evaluated by confocal microscopy. Fig 10 shows vitreal and retinal 
distribution of intravitreally administered heterogeneous nanoparticles. It can be 
depicted from the Fig 10 that PEI/GC nanoparticles easily penetrated the vitreal 
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barrier and reached at the inner limiting membrane. However, PEI/GC 
nanoparticles did not penetrate through the physical pores of inner limiting 
membrane into the deeper retinal layers and also some aggregates were observed 
in vitreous. Similar to PEI/GC nanoparticles, HSA/GC nanoparticles reached to 
inner limiting membrane but could not penetrate to the deeper retinal layers which 
might be due to inhibition of the interaction between HSA and the Müller cells in 
retina by GC. On the other hand, negatively charged HSA/HA nanoparticles, could 
penetrate the whole retina structures and reach the outer retinal layers such as the 
photoreceptor layer and RPE which was attributed to interaction between anionic 
surface and Müller cells. In another study, HSA-NPs penetrated the whole retina 
and localized inside the RPE of the normal retina after intravitreal injection in rat 
eyes. Furthermore, in the laser photocoagulated retina, HSA-NPs were observed to 
reach the choroid through the disruption site of the RPE and Bruch’s membrane. 
Therefore, the anionic HSA-NP could be promising drug delivery carrier for the 
treatment of AMD which required drug distribution to the choroid region in order 
to inhibit choroidal neovascularization (205). 
 
Nanosuspensions 
 
Nanosuspensions are colloidal dispersion of submicron drug particles 
stabilized by polymer(s) or surfactant(s). It is emerged as promising strategy for 
delivery of hydrophobic drugs. For ocular delivery, it provides several advantages 
such as sterilization, ease of eye drop formulation, less irritation, increase 
precorneal residence time and enhancement in ocular bioavailability of drugs which  
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Figure 10. The vitreal and retinal distribution of intravitreally administered (A) 
PEI/GC heterogeneous nanoparticles, (B) HSA/GC heterogeneous nanoparticles, 
and (C) HSA/HA heterogeneous nanoparticles 6 h post-injection. (Red color = 
FPR-552 conjugated nanoparticles, blue color = DAPI staining of retinal cell 
nuclei). VH, RE, ILM, INL, and ONL represent the vitreous, retina, inner limiting 
membrane, inner nuclear layer, and outer nuclear layer, respectively. All images 
were captured at 10x magnification. Reproduced with permission from reference 
(204). 
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Table 1. Summary of recent developments with nanoparticles as ocular drug delivery vehicles 
Drug Polymer Features Ref. 
Carboplatin Chitosan, Sodium alginate Carboplatin loaded NPs demonstrated elevated and sustained 
anti-proliferative activity in a retinoblastoma cell line (Y-79), 
with IC50 of 0.56 µg/ml and 0.004 µg/ml for free carboplatin and 
carboplatin loaded NPs, respectively.  
(206) 
5-Fluorouracil Chitosan (CH), Sodium 
alginate (SA) 
Chitosan (CH) coated sodium alginate (SA)-chitosan (CH) 
nanoparticles (CH-SA-CH NPs) loaded with 5-Fluorouracil (5-
FU) showed significantly higher concentration of 5-FU in 
aqueous humor as compared to SA-CH 5-FU loaded NPs and 5-
FU solution. The higher Cmax was achieved in case of CH-SA-CH 
NPs (24.67 μg/ml) compared to 5-FU solution (6.14 μg/ml).  
(207) 
Sparfloxacin PLGA After topical application, sparfloxacin-loaded nanoparticles were 
retained for a longer duration on the corneal surface as compared 
to an aqueous solution, which was drained rapidly from the 
corneal surface. Also, in vitro release studies revealed an 
extended release of sparfloxacin.  
 
 
(208) 
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Drug Polymer Features Ref. 
Brimonidine 
Tartrate (BT) 
Sodium alginate BT-loaded nanoparticles provided prolong drug release over a 
period of 8 h after topical instillation to albino rabbits. 
(209) 
 
Levofloxacin PLGA The nanosuspensions was retained for the longer time on rabbit 
eye surface and drained out slowly compared to marketed 
formulation. Results of ex-vivo transcorneal permeation study 
across excised goat cornea revealed that levofloxacin from the 
marketed formulation was permeated 36.9% in 4 h whereas 
levofloxacin from PLGA nanoparticles was permeated 47.43% 
in 4 h across cornea. 
(210) 
Diclofenac 
Sodium (DS) 
PLGA An extended DS release was observed from the nanoparticles 
under in vitro conditions.  The developed polymer nanoparticles 
formulation was non-irritant to cornea, iris, and conjunctiva for 
as long as 24 h after application. 
(211) 
Pilocarpine PLGA The in vivo miosis studies showed that the duration of miotic 
response increased by 40% for the nanoparticles compared to the 
eye drops. 
(212) 
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Drug Polymer Features Ref. 
Gatifloxacin/Pr
ednisolone 
Eudragit RS 100 and  
RL 100, coating  
with hyaluronic acid 
In vitro release studies revealed prolonged drug release 
compared to the free drugs with no burst effect. Nanoparticles 
formulation showed better bioavailability of gatifloxacin in 
rabbit eye with 1.76 fold increase in Cmax of gatifloxacin in the 
aqueous humor in comparison to the eye drops. 
(213) 
Cloricromene 
(AD6) 
Eudragit Nanosuspension enhanced stability of the ester drug for several 
months as compared to an AD6 aqueous solution. 
(214) 
Brimonidine 
Tartrate (BT) 
Eudragit RS 100,  
Eudragit RL 100 
The AUC (ΔIOP vs. time) for the selected nanoparticles 
formulations were about seven times higher than that of eye drop 
formulations in rabbit eye. 
(215) 
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are insoluble in tear fluid (216). Efficacy of nanosuspensions in improving ocular 
bioavailability of glucocorticoids has been demonstrated in several studies. 
Glucocorticoids such as prednisolone, dexamethasone and hydrocortisone 
are widely recommended for the treatment of inflammatory conditions affecting 
anterior segment ocular tissues. The current therapy with these drugs requires 
frequent administration at higher doses which induce cataract formation, glaucoma, 
and damage optic nerve.  Efforts have been made toward improving ocular 
bioavailability of glucocorticoids by formulating as nanosuspensions.  For instance, 
Kassem et al. compared ocular bioavailability of various glucocorticoids 
(prednisolone, dexamethasone and hydrocortisone) from nanosuspensions, 
solutions and microcrystalline suspensions. The formulations were instilled into the 
lower cul-de-sac of the rabbit eye and intraocular pressure (IOP) was measured at 
frequent time intervals up to 12 h.   The area under percentage increase in IOP 
versus time curve (AUC) values for all the suspensions were higher than that for 
the respective drug solutions. In addition, higher extent of drug absorption and more 
intense drug effects were observed for all steroids form nanosuspensions compared 
with solutions (217). In another study, Ali et al. compared ocular bioavailability of 
hydrocortisone (HC) nanosuspensions prepared by precipitation and milling 
method with HC solution in rabbits post topical instillation (218). Nanosuspensions 
prepared by both the precipitation and milling method achieved significantly higher 
AUC (0-9 h) values of 28.06 ± 4.08 and 30.95 ± 2.2 than that of HC solution (15.86 
± 2.7). A sustained drug action which was represented in terms of changes in 
intraocular pressure was maintained up to 9 h for the nanosuspensions compared to 
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5 h for the drug solution (Figure 11).  From the results of above research studies, 
it can be concluded that nanosuspensions could be an efficient ophthalmic drug 
delivery system for delivery of poorly soluble drugs. In addition, nanosuspension 
can also be incorporated into hydrogels or ocular inserts for achieving sustained 
drug release for stipulated time period.  
 
Liposomes 
 
Liposomes are lipid vesicles with one or more phospholipid bilayers enclosing an 
aqueous core (Figure 8). The size of liposomes usually range from 0.08 to 10 µm 
and based on the size and phospholipid bilayers, liposomes can be classified as 
small unilamellar vesicles (SUV) (10-100 nm), large unilamellar vesicles (LUV) 
(100-300 nm) and multilamellar vesicles (contains more than one bilayer) (219).  
For ophthalmic applications, liposomes represent ideal delivery systems due to 
excellent biocompatibility, cell membrane like structure and ability to encapsulate 
both hydrophilic and hydrophobic drugs. Liposomes have demonstrated good 
effectiveness for both anterior and posterior segment ocular delivery in several 
research studies. Recent advancements in liposomal ocular drug delivery are 
summarized in Table 2. In a recent study, for delivery of latanoprost to anterior 
segment ocular tissues, a liposomal formulation was developed by Natarajan et al. 
(220). The single subconjunctival injection of latanoprost/liposomal formulation in 
rabbit eye produced sustained IOP lowering effect over a period of 50 days with 
IOP reduction comparable to daily eye drop administration.   For drug delivery to 
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Figure 11. Changes in intraocular pressure (IOP) of rabbits eyes following administration of hydrocortisone solution and 
nanosuspensions produced by milling and precipitation. Reproduced with permission from reference (218).  
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Figure 12. ACV concentrations in aqueous humor after topical administration of ACV solution and ACV-containing liposomes: 
ACV solution (circles), positively charged liposomes (squares), negatively charged liposomes (triangles). * represents significant 
difference; p < 0.05 (n = 6). Reproduced with permission from reference [73]. 
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anterior segment of the eye, efforts are mainly put toward improving precorneal 
residence time by incorporating positively charged lipids or mucoadhesive polymer 
in liposomes. The positively charged liposomes, i.e. cationic liposomes have 
exhibited better efficacy in ocular delivery than negatively charged and neutral 
liposomes due to binding with negatively charges of corneal surface.  
Didodecyldimethylammonium bromide, stearylamine, and N-(1-(2,3-
dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP) are commonly 
employed for fabricating cationic liposomes. 
 Acyclovir loaded cationic and anionic liposomes were prepared by 
incorporating stearylamine and dicetylphosphate (DP), as cationic and anionic 
charge-inducing agents, respectively. In rabbit eyes, the acyclovir concentration in 
the cornea at 2.5 h after topical administration of positively charged liposomes was 
greater than those of negatively charged liposomes and free acyclovir. ACV 
concentrations in cornea were 253.3 ± 72.0 ng/g, 1093 ± 279 ng/g and 571 ± 105 
ng/g for ACV solution, ACV loaded positively and negatively charged liposomes, 
respectively. Also, the extent of ACV absorption through cornea was higher from 
positively charged liposomes which can be observed from ACV concentrations in 
aqueous humor at 2.5 h after instillation (Figure 12). The suggested reason was the 
higher binding of positively charged liposomes with negatively charged corneal 
surface via electrostatic interaction which ultimately lead to an increase of 
residence time and increase in acyclovir absorption (221). In another study, when 
Coenzyme Q10 (CoQ10) loaded liposomes was coated with mucoadhesive trimethyl 
 73 
 
chitosan, there was a 4.8-fold increase in the precorneal residence time in the rabbit 
eye was observed (222). 
For posterior segment delivery, liposomes development is more focused 
toward improving half-life of drug by lessening clearance from vitreous humor, 
protecting labile molecules such as peptides and oligonucleotides from degradation 
and providing sustained drug release (157, 223, 224).  For instance, the vitreal half-
life of fluconazole in rabbit eye was increased from 3.08 h to 23.40 h after 
formulating into liposomes (224). In another study, tacrolimus loaded liposomes 
were developed for the treatment of uveoretinitis. Following single intravitreous 
administration, tacrolimus vitreous level above 50 ng/mL was sustained for 14 
days. The tacrolimus liposomal formulation demonstrated more effectiveness in 
suppressing uveoretinitis relative to drug alone and there was also reduced toxicity 
to inner retinal cells (225).  Several liposomal formulations for ocular drug delivery 
are being exploited, few are in pre-clinical and clinical study stage and few are 
commercially available.  Visudyne® and Tears Again® are the examples of 
commercially available liposomal formulations for the treatment of ocular diseases. 
Visudyne® (QLT Ophthalmics, Inc., Menlo Park, CA, U.S.) is a liposomal 
formulation containing photosensitizer, verteporfin. It is used in photodynamic 
therapy for subfoveal choroidal neovascularization in age related macular 
degeneration, presumed ocular histoplasmosis and pathological myopia (226). 
Tears again® (Optima Pharmaceutical GmbH, Germany) is a phospholipid 
liposomes spray approved for the treatment of the dry eye syndrome. In clinical 
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studies, this liposomal spray demonstrated significant advantages when compared 
with triglyceride-containing eye gel and a balanced salt solution (227, 228). 
 
Dendrimers 
 
Dendrimers are characterized as nanosized, highly branched, star shaped polymeric 
systems. These branched polymeric systems are available in different molecular 
weights with terminal end amine, hydroxyl or carboxyl functional group. The 
terminal functional group may be utilized to conjugate targeting moieties (229). 
Dendrimers are being employed as carrier systems in drug delivery. Selection of 
molecular weight, size, surface charge, molecular geometry and functional group 
are critical to deliver drugs. The highly branched structure of dendrimers allows 
incorporation of wide range of drugs, hydrophobic as well as hydrophilic. In ocular 
drug delivery, few promising results were reported with these branched polymeric 
systems (156, 230, 231). Poly (amidoamine) (PAMAM) dendrimers are  widely 
employed in ocular drug delivery (230). Vandamme et al. demonstrated application 
of PAMAM dendrimers as ophthalmic vehicles for delivery of pilocarpine nitrate 
and tropicamide, for miotic and mydriatic activity (232). In this study, mean ocular 
residence time for fluorescein in saline and in PAMAM solutions was studied in 
rabbit eye. Fluorescein in 0.2% w/v Carbopol solution was used as reference 
bioadhesive polymer. The mean ocular residence time was significantly higher in 
case of PAMAM solutions and 0.2% w/v Carbopo1 solution compared to saline. 
Therefore, the use of dendrimers could be another option for increasing ocular  
. 
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Table 2. Recent advancements in liposomal ocular drug delivery. 
Drug Type of Liposomes Result Ref. 
Acetazolamide Multilamellar, 
Unilamellar 
Multilamellar liposomes produced a more significant 
lowering in IOP in comparison with REVs liposomes. 
(233) 
Ciprofloxacin 
(CPX) 
Multilamellar The mean residence time of ciprofloxacin was three fold 
higher for the CS-coated liposomes (3.85 h) compared to 
commercially available eye drops Ciprocin® (1.39 h). 
(234) 
Cytochrome C  The cytochrome C loaded freeze-dried liposomes exhibited 
significant efficacy in retarding the onset and progression of 
cataract formation in rat eye.  
(235) 
Vasoactive 
intestinal 
peptide (VIP) 
Pegylated 
liposomes 
After intravitreal injection, VIP concentration in ocular 
fluids was 15 times higher for liposomal formulation (155 ± 
65 ng/ml) than the solution (10 ± 1 ng/mL),  at 24 h.  
(236) 
Coumarin-6 Multilamellar After topical administration in mice, the intensity of 
coumarin-6 in the retina was much higher with PLL (poly-
L-lysine) modified liposomes. 
(237) 
Bevacizumab 
(Avastin) 
 
 
Vitreous concentration of bevacizumab after 42 days of 
administration was 16 and 3.3 µg/mL in the eyes for 
(238) 
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Drug Type of Liposomes Result Ref. 
Bevacizumab 
(Avastin) 
 liposomal and non-liposomal bevacizumab, respectively. 
The AUC (conc. Vs time) for liposomal bevacizumab was 
1.5 fold higher compared with non-liposomal bevacizumab. 
(238) 
Fluorescence 
probe 
(Coumarin-6) 
Submicron-sized 
liposomes(ssLips)  
and multilamellar 
After topical instillation of submicron-sized liposomes 
(ssLips), drug was delivered to the posterior segment ocular 
tissues including retina. 
(239) 
Fluconazole   Antifungal activity of fluconazole in liposomal formulation 
was better than that of fluconazole solution. 
(240) 
Edaravone Submicron-sized 
liposomes 
Topical administration of edaravone-loaded ssLips 
protected retina against light-induced dysfunction in mice 
eye while there was no marked protection found in the group 
treated with free edaravone. 
(241) 
Diclofenac Multilamellar Topical administration of diclofenac loaded PVA-R 
modified liposomes lead to improved retinal delivery in 
rabbit eye. Concentration of diclofenac in the retina–choroid 
was enhanced by 1.8-fold in case of drug loaded PVA-R 
modified liposome compared to that of the diclofenac 
solution. 
(242) 
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residence time and therapy enhancing ocular bioavailability and achieving better 
therapeutic outcomes. For instance, PAMAM dendrimers when co-administrated 
with pilocarpine nitrate and tropicamide showed higher miotic and mydriatic 
activity in albino rabbits (232). 
In order to avoid scar tissue formation after glaucoma filtration surgery, 
conjugates of modified PAMAM dendrimers with glucosamine (DG) and 
glucosamine 6-sulfate (DGS) were synthesized to exert immunomodulatory and 
anti-angiogenic activities, respectively. The subconjunctival administration of 
these modified conjugates in rabbit model of glaucoma filtration surgery have 
shown significant inhibition of pro-inflammatory and pro-angiogenic responses and 
consequently reduced scar tissue formation. The results obtained from the 
experiment indicated that the ocular administration of DG and DGS might be 
effective and safe in clinical practice in avoiding scar tissue formation post 
glaucoma filtration surgery (243).  
 
In-Situ Gelling Systems 
 
In-situ hydrogels refer to the polymeric solutions which undergo sol-gel phase 
transition to form viscoelastic gel in response to environmental stimuli.  Gelation 
can be elicited by changes in temperature, pH and ions or can also be induced by 
UV irradiation. For ocular delivery, research studies have been more focused 
toward development of thermosensitive gels which respond to changes in 
temperature (244). Several thermogelling polymers have been reported for ocular 
delivery which includes poloxamers, multiblock copolymers made of 
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polycaprolactone, polyethylene glycol, polylactide, polyglycolide, poly N-
isopropylacrylamide, and chitosan. These thermosensitive polymers form 
temperature dependent micellar aggregates which gellify after a further temperature 
increment due to aggregation or packing (245, 246). For drug delivery, these 
polymers are mixed with drugs in the solution state and solution can be 
administered which forms an in situ gel depot at physiological temperature. These 
thermosensitive gels demonstrated promising results for enhancing ocular 
bioavailability for both anterior and posterior segment. Gao et al. have evaluated 
suitability of thermosensitive gel made of triblock polymer PLGA-PEG-PLGA 
(poly-(DL-lactic acid co-glycolic acid)–polyethylene glycol–poly-(DL-lactic acid 
co-glycolic acid) as a ocular delivery carrier for dexamethasone acetate (DXA) 
(247). It was formulated as either 0.1% w/v DXA solution or 0.1%, w/v DXA in 
20% PLGA–PEG–PLGA in situ gel forming solution and administered topically in 
rabbit eye. Following topical administration, the Cmax of DXA in the anterior 
chamber was significantly higher for the PLGA–PEG–PLGA solution (125.2 
μg/mL) relative to the eye drop (17.6 ± 2.18 ng/mL) along with higher AUC values.  
The increment in both Cmax and AUC was approximately 7- and 7.98-fold for 
PLGA–PEG–PLGA in situ gel compared to the solution eye drops. These results 
suggest potentiality of PLGA–PEG–PLGA thermosensitive gel forming solution in 
enhancing ocular bioavailability.   
Rieke, et al. have reported applicability of ReGel™ (biodegradable and 
thermosensitive triblock copolymer consisting of poly(lactic-co-glycolic acid) 
(PLGA) and polyethylene glycol (PEG), in providing sustained release of a large 
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molecule ovalbumin to the choroid and retina following subconjunctival 
administration in the rat eye (248). The ovalbumin concentrations were maintained 
at measurable levels in the sclera, choroid, and retina of rats over a period of 14 
days. These results suggest feasibility of thermosetting gel system in providing 
sustained delivery of macromolecules to the posterior segment ocular tissues such 
as choroid and retina.  Cross linked polyN-isopropylacrylamide (PNIPAAm)-
polyethylene glycol diacrylate hydrogels were also synthesized for sustained 
release of macromolecules such as bovine serum albumin (BSA) and 
immunoglobulin G (IgG) (249). The gel system has provided nearly 3 week of 
sustained BSA release under in vitro condition. The results of research studies 
clearly signify the advantages of thermosensitive gels in providing sustained drug 
release; prolong contact time of drugs with the cornea, less frequency of 
applications, reduced side effects and higher ocular bioavailability over aqueous 
drops.  In conclusion, the thermosensitive gels may be a viable option for the 
delivery of drugs for treating chronic ocular diseases. 
 
Contact lens 
 
Contact lenses are thin, and curved shape plastic disks which are designed to cover 
the cornea (250). After application, contact lens adheres to the film of tears over 
the cornea due to the surface tension. Drug loaded contact lens have been developed 
for ocular delivery of numerous drugs such as β-blockers, antihistamines and 
antimicrobials. It is postulated that in presence of contact lens, drug molecules have 
longer residence time in the post-lens tear film which ultimately led to higher drug 
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flux through cornea with less drug inflow into the nasolacrimal duct. Usually, drug 
is loaded into contact lens by soaking them in drug solutions. These soaked contact 
lenses demonstrated higher efficiency in delivering drug compared to conventional 
eye drops. Jinah et al. observed much higher bioavailability of dexamethasone (DX) 
from poly hydroxyethyl methacrylate (PHEMA) contact lenses in comparison to 
eye drops (251). Indeed, efficient than topical drops, these soaked contact lenses 
suffers from disadvantages of inadequate drug loading and short term drug release. 
To overcome these obstacles, particle-laden contact lenses and molecularly 
imprinted contact lenses have been developed.  In particle-laden contact lenses, 
drug is first entrapped in vesicles such as liposomes, nanoparticles or 
microemulsion and then these vesicles are dispersed in the contact lens material. 
Chauhan et al. developed particle-laden contact lenses for ocular delivery of 
lidocaine. In two different studies, they have prepared particle-laden contact lenses 
by dispersing lidocaine loaded microemulsion drops or liposome in poly-2-
hydroxyethylmethacrylate (p-HEMA) hydrogels. Results of both the studies 
demonstrated the extended release of lidocaine over a period of eight days (252, 
253). Indeed, particles-laden contact lenses look promising for extended ocular 
drug delivery; it needs to be stored in drug saturated solutions to avoid drug loss 
during storage. The designing of stimuli responsive such as pH or temperature 
sensitive ‘smart’ particles which can release drug only in the eye could eliminate 
this problem. The imprinted contact lenses have also showed benefit in terms of 
both drug loading and drug release (254). It has been demonstrated that soft contact 
lenses fabricated by the molecular imprinting method have 1.6 times higher timolol 
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loading capacity than the contact lenses prepared by a conventional method and 
also provided sustained timolol delivery (255). In another study, ketotifen fumarate 
loaded imprinted lenses have revealed higher tear fluid bioavailability compared to 
drug soaked lenses or ketotifen fumarate marketed eye drops. The relative 
bioavailability for the imprinted lenses was three times greater than that of non-
imprinted lenses. The  AUC value of  ketotifen fumarate for imprinted lenses,  non-
imprinted lenses and eye drops were  4365 ± 1070 μg hr/mL, 493 ± 180 μg hr/mL,  
46.6 ± 24.5 μg hr/mL,  respectively (256). The results clearly demonstrate more 
effectiveness of imprinted lenses over non-imprinted lenses and eye drops.   
 
Implants 
 
Intraocular implants are specifically designed to provide localized controlled drug 
release over an extended period. These devices help in circumventing multiple 
intraocular injections and associated complications (257, 258). Usually for drug 
delivery to posterior ocular tissues, implants are placed intravitreally by making 
incision through minor surgery at pars plana which is located posterior to the lens 
and anterior to the retina. Though implantation is invasive procedure, these devices 
are gaining interest due to their associated advantages such as sustained drug 
release, local drug release to diseased ocular tissues in therapeutic levels, reduced 
side effects and ability to circumvent blood retina barrier (258, 259). Several 
implantable devices have been developed for ocular drug delivery especially for the 
treatment of chronic vitreoretinal diseases.  
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Ocular implants are available as biodegradable and non-biodegradable drug 
releasing devices. Non-biodegradable implants offer long-lasting release by 
achieving near zero order release kinetics (259). Polymers such as polyvinyl 
alcohol (PVA), ethylenevinyl acetate (EVA), and polysulfone capillary fiber (PCF) 
are being employed for fabricating non-biodegradable implants (257). Vitrasert® 
and Retisert® are the examples of marketed non-biodegradable implants. 
Vitrasert® (Bausch & Lomb Inc., Rochester, NY, U.S.)  is a controlled-
release intraocular implant of ganciclovir approved by FDA for the treatment of 
AIDS associated CMV retinitis. It is composed of a ganciclovir tablet of 4.5 mg 
surrounded by PVA/EVA that slowly release the drug over an extended period of 
5-8 months. The device provides long term sustained release without systemic 
toxicity at reduced cost (257, 259, 260).  
Retisert® (Bausch & Lomb Inc., Rochester, NY, U.S.)  is approved by FDA 
for the treatment of chronic uveitis which affects the posterior segment of the eye. 
It is the first marketed silicone laminated PVA implant. The implant provides 
sustained release of fluocinolone acetonide up to three years. The implant had 
effectively controlled inflammation, reduced uveitis recurrences and improved 
vision acuity. The associated side effects are cataracts and elevated IOP (259-262).  
Long term drug release may be achieved with these non-biodegradable implants 
but are associated with certain short comes.  These devices have to be surgery 
implanted and removed after drug depletion, which makes the treatment expensive 
and patient non-compliance. Also, adverse events such as endophthalmitis, 
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pseudoendophthalmitis, vitreous haze and hemorrhage, cataract development and 
retinal detachment limit their applications. 
Another category of ocular implant includes biodegradable implants.  These 
implants are gaining much attention and are being studied at large due to their 
biocompatible property and sustained drug release properties. Because of 
biodegradable nature, these implants are not required to be surgically removed 
which signify a distinctive advantage over the non-biodegradable implants. 
Polylactic acid (PLA), polyglycolic acid (PGA), poly(lactide-co-glycolide) 
(PLGA), and polycaprolactones (PCL) are the most commonly used polymers for 
the fabrication of biodegradable implants (257). Examples of biodegradable 
implants for ocular delivery include SurodexTM and Ozurdex® which are designed 
for the sustained delivery of dexamethasone for the treatment of intraocular 
inflammation and macular edema (ME), respectively (259). SurodexTM (Allergan, 
Inc., Irvine, CA) composes PLGA and hydroxypropyl methylcellulose (HPMC) 
enclosing dexamethasone. The implant is inserted in the anterior chamber of eye to 
control postoperative inflammation in cataract patients. It provides sustained 
dexamethasone release for a period of 7–10 days with improved anti-inflammatory 
effect comparable to topical steroid administration (259).  
Ozurdex® (Allergan Inc., Irvine, CA) is another biocompatible and 
biodegradable intravitreal implant. It was approved by FDA in June 2009 for the 
treatment of macular edema. It employs Allergan’s NOVADUR® technology for 
delivering dexamethasone. The NOVADUR® system contains a PLGA polymer 
matrix which degrades slowly to lactic acid and glycolic acid allowing prolonged 
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release of dexamethasone up to six months. Randomized clinical trials have 
demonstrated its potency in reducing vision loss and improving vision acuity in 
eyes with macular edema associated with branch retinal vein occlusion (BRVO) or 
central retinal vein occlusion (CRVO). Also, clinical studies with Ozurdex® for 
treatment of diabetic retinopathy, and Irvine-Gass syndrome proved it as a  
promising treatment and drug delivery candidate (259).  
 
Microneedles 
 
Microneedle based technique is an emerging and minimally invasive mode of drug 
delivery to posterior ocular tissues.  This technique may provide efficient treatment 
strategy for vision threatening posterior ocular diseases such as age related macular 
degeneration, diabetic retinopathy and posterior uveitis. This new microneedle 
based administration strategy may reduce the risk and complications associated 
with intravitreal injections such as retinal detachment, hemorrhage, cataract, 
endophthalmitis and pseudoendophthalmitis. Moreover, this strategy may help to 
circumvent blood retinal barrier (BRB) and deliver therapeutic drug levels to retina-
choroid. Microneedles are custom designed to penetrate only hundreds of microns 
into sclera, so that damage to deeper ocular tissues may be avoided. These needles 
help to deposit drug or carrier system into sclera or into the narrow space present 
between sclera and choroid called “suprachoroidal space” (SCS). Puncturing of 
sclera and depositing drug solution or carrier systems in sclera or SCS may facilitate 
diffusion of drug into deeper ocular tissues, choroid and neural retina (263). For 
intraocular delivery of drugs, Jason, J et al. investigated the application of 
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microneedles surface coated with drugs. Cadaver eyes were used to evaluate the 
role and scleral penetration of microneedle and intrascleral dissolution of 
microneedle surface coated drug (sulforhodamine).  Results demonstrated that 
surface coated drug was rapidly dissolved in scleral tissue indicating high scleral 
sulforhodamine deposition within microneedle hole. In another study, Jiang et al. 
made attempts to evaluate the performance of microneedles to infuse drug 
solutions, nanoparticles and microparticles into scleral tissues. By use of 
microneedles, authors were able to infuse approximately 10-35 μL of fluid in to 
tissues.  Nanoparticle suspensions and microparticles were also delivered into 
sclera by microneedles however; microparticles were delivered only in the presence 
of collagenase spreading enzymes and hyaluronidase. Study demonstrated that 
hollow microneedles may be employed for scleral infusion of drug or 
micro/nanoparticles with minimal invasive route (264).  
In another study Patel, et al. made attempts to deliver drug solution, 
nanoparticles and microparticles in the SCS of rabbit, pig, and cadaver eyes with 
microneedles.  Authors hypothesized that microneedle based minimally invasive 
strategy may help to deliver high level of both drug and nanocarriers to retinal 
tissues from SCS. Parameters for suprachoroidal delivery with microneedles such 
as microneedle length, pressure, and particle size were studied and optimized. 
Results demonstrated the strategy to be safe, minimally invasive and may sustain 
drug release. But, the study did not provide any evidence of drug reaching the inner 
retinal tissues from SCS (265). Same group made further attempts to study in vivo 
pharmacokinetics of SCS deposited solution/suspension post microneedle infusion. 
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Results demonstrated that microneedle may provide a safe, reliable and targeted 
approach to chorio-retinal tissues (265).  
Conclusion 
 
Human eye is one of the most complex, sensitive and highly protected organs in 
the body after brain and testicles. Being direct contact with external environment 
this organ is highly vulnerable for injury and consequently impervious to 
exogenous chemicals. Moreover, excessive tear production, in response to external 
stimuli or therapeutic agents, increased blinking rate adds to its protection. These 
naturally developed protective functions act as a barrier to externally applied drugs, 
especially when these are targeted to back-of-the-eye tissues. Expression of drug 
efflux pumps at cellular level impedes drug entry into the diseased cell and 
therefore poses severe challenges to ocular drug delivery. The physico-chemical 
properties of the drug and delivery system can be modulated depending on the 
targeted eye tissue. For the back of eye delivery, various routes of drug 
administration such as periocular injections/implants are effectively employed to 
overcome ocular static and dynamic barriers.  Administration of drug solutions as 
topical drop with conventional formulations was associated with certain drawbacks 
which initiated the introduction of different carrier systems for ocular delivery. 
Tremendous efforts are being put into ocular research toward the development of 
safe and patient compliant novel drug delivery strategies. Currently, researchers are 
thriving hard to improve in vivo performance of conventional formulations. On the 
other hand, advent of nanotechnology, new techniques, devices and their 
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applications in drug delivery is developing immense interest to ocular scientists. 
Drug molecules are being encapsulated into nanosized carrier systems or devices 
and are being delivered by invasive/non-invasive or minimally invasive mode of 
drug administration. Several nanotechnology based carrier systems are being 
developed and studied at large such as nanoparticles, liposomes, nanomicelles, 
nanosuspensions and dendrimers. Nanotechnology is benefiting the patient body by 
minimizing the drug induced toxicities and vision loss. Also, these 
nanocarriers/devices sustain drug release; improve specificity, when targeting 
moieties are used, and help to reduce the dosing frequency.  However, there is still 
need of developing a carrier system which could reach targeted ocular tissue, 
including back-of-the-eye tissues, post non-invasive mode of drug administration. 
With the current pace of ocular research and efforts being made and put in, it is 
expected to  result in a topical drop formulation that retains high pre-corneal 
residence time, avoids non-specific drug tissue accumulation and deliver 
therapeutic drug levels into targeted ocular tissue (both anterior and posterior). In 
near future, this delivery system may replace invasive mode of drug administration 
to back-of-the-eye such as periocular and intravitreal injection.  
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Chapter 3 
TOPICAL AQUEOUS CLEAR CYCLOSPORINE NANOMICELLAR 
FORMULATION: OPTIMIZATION, IN VITRO & IN VIVO OCULAR 
TOXICITY EVALUATION AND PHARMACOKINETIC STUDY 
Rationale 
 
CsA is a fungus (Tolypocladium inflatum) derived cyclic decapeptide drug. 
It exerts its mechanism of action by inhibiting T-cell activation and thereby inhibits 
inflammatory cytokine production. Also, CsA blocks the opening of mitochondrial 
permeability transition pore and inhibits apoptosis (266).  Additionally, CsA has 
been found to be important in treating allergic inflammation because of its direct 
inhibitory effects on eosinophil and mast cell activation and release of mediators 
(267). CsA is also shown to increase the conjunctival goblet cell density (268). 
However, CsA is a highly lipophilic drug with poor aqueous solubility of 12 ng/mL 
(269). Two decades ago, the potential of CsA in treating human dry eye 
(keratoconjunctivitis sicca) was evidenced in several small clinical trials (270, 271). 
In a dose ranging, randomized and multicenter efficacy and safety trial with topical 
CsA 0.05% emulsion (Restasis®; Allergan, Irvine, CA) was conducted. CsA 
emulsion has been shown to be an effective therapeutic agent to treat moderate to 
severe dry eye disease in clinical trials and leading to US Food and Drug 
Administration approval of the drug in 2003. The exact mechanism of enhanced 
tear production is not well delineated but, it is hypothesized that it may be related 
to CsA immunomodulatory activity, which reduces local inflammation (272). 
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However, in a recent study it was demonstrated that CsA has no stimulatory effect 
on lacrimal gland but, it increased reflex tear flow (273). 
 CsA 0.05% emulsion (Restasis®) has been studied for various other ocular 
conditions such as uveitis, vernal and atopic keratoconjunctivitis, and posterior 
blepharitis (274). However, Restasis® induces burning sensation and redness 
following topical instillation (275). Cationic, anionic and oily CsA emulsions were 
studied to reduce inflammation, stinging sensation and improve safety and 
tolerability (276). Cationic CsA emulsions were found to be more tolerable relative 
to anionic and CsA oil. But, inflammation was observed with topical application of 
cationic CsA emulsion in rabbits (276). Despite tremendous research in ocular drug 
delivery, only one topical formulation (Restasis®, Irvine, CA) has been 
commercialized in US. Since, the rationale of this chapter was to minimize local 
adverse effects and improve patient's acceptability; an aqueous, clear topical CsA 
nanomicellar formulation was optimized so that it overcomes ocular barriers and 
deliver high drug levels to anterior ocular tissues. 
Materials and Methods 
 
Critical micellar concentration (CMC) of the individual polymers i.e., 
HCO-40 (Barnet Product Corp, USA) and a blend of polymer surfactant selected 
for the preparation of NMF was determined following slight modification of a 
previously described procedure (277). CMC was determined with iodine as a probe 
by varying the ratios (wt%) of HCO-40 to Oc-40.  Iodine solution (1:2 ratio of I2 
and KI) was added to each polymer solution and was incubated overnight. 
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Absorbance of hydrophobic iodine, I2, entrapped in the core of nanomicelle was 
measured at 366 nm with the help of DDX 880, Beckman Coulter, and multimode 
detection software version 2.0.012. 
 
HPLC analysis 
 
In vitro analysis of CsA (Xenos Bioresources, CA) was performed by a 
reversed phase high performance liquid chromatography i.e., (RP-HPLC) method 
with a Shimadzu HPLC pump (Shimadzu, Shimadzu Scientific instruments, 
Columbia, MD). Alcott autosampler (model 718 AL), Shimadzu UV/Visible 
detector (Shimadzu, SPD-20A/20AV, USA), phenyl column (5 μm, 15 x 4.6 mm) 
thermostatted at 50 ± 1 ºC and Hewlett Packard HPLC integrator (Hewlett Packard, 
Palo Alto, CA) were assembled. The mobile phase was prepared with acetonitrile 
(ACN), water and trifluoroacetic acid (TFA) (75:25:0.1% v/v/v), which was set at 
a flow rate of 1.0 mL/min. Detection wavelength was set at 210 nm. The sample 
tray temperature was maintained at 4 °C.  A volume of 50 μL was injected onto the 
HPLC column for analysis.  All the standards and samples prepared were stored at 
4 ºC before and during the analysis.   
 
 
LC-MS/MS analysis 
 
In vivo analysis of CsA was performed with a reversed phase liquid 
chromatography tandem mass spectroscopy (LC-MS/MS) method with CsA-d4 as 
internal standard (IS). LC-MS/MS comprised a triple quadrupole mass 
spectrometer with SCIEX API 4000TM (API 4000; Applied Biosystems/MDI 
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SCIEX) coupled to a liquid chromatography system (Shimadzu LC-10 AD, USA) 
and  reversed phase ACE 5 phenyl column, 50 x 2.1 mm × 5 µm (Advanced 
Chromatography Technologies, LTD) and a guard column (ACE 5 phenyl, 10 X 
2.1 mm, 5 µm (Thermo-Hypersil Keystone). Column temperature was maintained 
at 70 °C (Eppendorf CH-30 column heater, USA). A gradient mobile phase 
comprising 20 mM NH4COOH with 0.1% formic acid as mobile phase A and 
ACN:MeOH:0.4 M NH4COOH (90:7.5:2.5, v/v/v, pH = 3.5) as mobile phase B was 
selected.  The mobile phase was pumped at a flow rate of 0.75 mL/min. A sample 
volume of 25 μL was injected onto HPLC and the analysis run time was 6 min. 
Analyst® version 1.4.2 (Applied Biosystems-MDS Sciex) operated with 
Windows® was utilized for data acquisition and peak integrations.  
 
Nanomicellar Formulation (NMF) 
 
CsA loaded NMF was prepared following solvent evaporation and film 
rehydration method as described previously (278). Briefly, 0.025%, 0.050%, 
0.075%, and 0.10% loaded CsA NMF (100 mL) was prepared in two steps: 
preparation of basic formulation and rehydration. In first step, CsA (0.025%, 
0.050%, 0.075%, and 0.10%), HCO-40 (1.0 wt%) and Oc-40 (0.05 wt%) were 
dissolved separately in ethanol. HCO-40 solution was added with calculated 
volumes of Oc-40 (diluted in ethanol).  This solution was stirred to generate a 
homogenous solution. To this solution, a calculated volume of CsA solution was 
added dropwise. The volumes were made up to 15 mL with ethanol. The solvent 
was removed with high speed vacuum (Genevac, UK); evaporation overnight (~10 
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h) to obtain a solid thin film.  In step two, the resultant thin film was hydrated with 
40 mL of double distilled deionized water (pH= 7.0) and resuspended. The 
rehydrated formulation was added with 10 mL of water and the volume was made 
up with 2X phosphate buffer solution containing 1.2% of povidone K90 (BASF, 
Aktiengesellschaft, Ludwigshafen, Germany). Finally, the formulation was filtered 
with 0.2 μm nylon filter membrane to remove unentrapped drug aggregates and 
other foreign particulates. 
 
Characterization of Nanomicelles 
 
Determination of critical micellar concentration 
 
Critical micellar concentration (CMC) of the individual polymers i.e., 
HCO-40 and Oc-40, and a blend of polymer mixture used in the preparation of 
NMF was determined (N = 3) following a slight modification of previously 
described procedure (279, 280).  CMC was determined with iodine as a probe. 
Earlier studies demonstrated that CMC values determined with iodine as probe 
were similar to other methods such as static surface tension and differential 
refractive index (281). Iodine, I2, is fairly hydrophobic and particularly insoluble in 
water. The aqueous solubility of I2 is improved by adding its salt, potassium iodide, 
which forms KI3 solution. When this solution is added to the polymer solution and 
incubated for sufficient time, pure I2 from KI3 partitions into the hydrophobic core 
of nanomicelles. Iodine partitioning develops a donor-acceptor complex between 
polymer and I2 (in aqueous medium) with electron donation by ether oxygen of 
polyoxyethylene group  (281). The micelle entrapped I2 shows a blue shift from 
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460 nm to 366 nm in the presence of polymeric surfactant medium.  Shift in 
absorbance is due to the donation of electrons to the vacant σ* orbital of iodine by 
the ether oxygen of polyoxyethylene group of the polymer. Partitioning of the 
iodine into the hydrophobic microenvironment/core of nanomicelles causes a rise 
in iodine absorbance indicates increase in micelle concentration. As the 
concentration of monomers in the formulation increases, a sudden rise in 
absorbance will be observed.  The point at which the constant absorbance values 
and the increased absorbance intersect is regarded as CMC. Briefly, thirty different 
concentrations of the polymer solutions ranging from 1 to 4.5x10-5 wt% were 
prepared. Similarly, other blend of polymers were diluted to determine their CMC. 
Iodine solution was prepared by dissolving 0.5:1 ratio of iodine and potassium 
iodide in distilled deionized water.  Iodine solution was protected from light.  The 
resulting solution was diluted to half of its original concentration with distilled 
deionized water for further experiments. Iodine solution (25 µL) was added to each 
polymer solution.  All the solutions were incubated at room temperature for 15 hrs 
in dark. After allowing sufficient incubation time, samples (200 µL) were 
transferred to 96 well plates. Absorbance of hydrophobic iodine, I2, entrapped in 
the core of nanomicelle was measured with the help of DDX 880, Beckman Coulter, 
and multimode detection software version 2.0.012. 
 
Absorbance/Visual appearance 
 
The optical clarity of all sample solutions was assessed by measuring 
absorbance at 400 nm with a UV-visible spectrophotometer, (Model: Biomate-3, 
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Thermo Spectronic, Waltham, MA). One mL of each sample was placed in a 
cuvette and absorbance was recorded. Distilled deionized water served as the 
blank/control. 
 
Osmolality and pH 
 
Osmolality was measured with osmometer (The advanced Osmometer 
Model 3D3, Two technology way, Norwood, Massachusetts, USA). A sample 
volume of 400 μL was used to measure osmolality. The pH of the samples was 
measured with Oakton pH meter (Model: pH 510 series, Oakton Instruments, 
Vernon Hills, IL). 
 
Thermal dissociation temperature 
 
Experiments were carried out to determine the thermal stability of 
nanomicellar formulations. Glass vials containing samples were kept in water bath 
with a thermometer inserted inside the vial. Formulations were observed for 
turbidity and temperature was recorded. A set of 3 samples (N = 3) were used for 
each experiment. 
 
 
Nanomicellar regeneration time 
 
After attaining the turbid temperature, samples were allowed to cool down 
to room temperature. Time taken by the turbid sample to become transparent or to 
original clear solution state, was recorded.  
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Nanomicellar size, polydispersity index and surface potential 
 
Mean particle size, size distribution and polydispersity index of the 
nanomicellar formulations were measured by dynamic light scattering (DLS) 
(Malvern Zetasizer Nano, Westborough, MA, USA) at a wavelength of 630 nm and 
temperature of 25 °C. A sample volume of 1000 μL was used for determining the 
particle size, polydispersity index and surface potential.   
 
Transmission Electron Microscopy 
 
To determine the shapes and surface morphology of CsA loaded 
nanomicellar formulation transmission electron microscopy (TEM) (TEM: JEOL 
JEM 1200 EX II Electron Microscope) was utilized.  Sample preparation included 
the grids (Ted pella Inc): glider grids center marked, 300 mesh copper G300.  A 
layer of nitrocellulose and carbon using the evaporator was applied.  To fix CsA 
nanomicelles on the grids, uranyl formate (UF) stain (Pfaltz and Bauer Inc, U01000 
lot 115080-3) was used.  To prepare a 1% stain, 5 mL of water was boiled and 
added 37.5 mg of UF.  Further the solution was boiled for 5 min and 50 µL of 1 M 
NaOH was added and continued to boil for 5 mins.  The solution was allowed to 
cool to room temperature and then filtered prior to use.  To visualize nanomicelles 
with TEM, negative staining was applied. Preparation of negative staining is 
described below. 
Negative stain 
The grids were etched for 30 sec with SPI supplied Plasma Prep II, then 
added to 5 microliter of CsA nanomicellar sample on to the grid as a drop and 
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allowed 30 sec to adsorb onto the grid.  It was rinsed 3 times with distilled deionized 
water and stain was applied for 30 sec.  The stain was blotted with filter paper and 
dried. 
 
Entrapment and Loading Efficiency 
 
To determine CsA entrapment and loading efficiency of the nanomicellar 
formulation, all the prepared formulations were subjected to entrapment and 
loading efficiency tests.  Briefly, formulations were vortex mixed for homogeneity 
and one mL was transferred to a fresh (15 mL) falcon tube (Midsci, USA).  Each 
formulation was lyophilized to obtain a solid at the bottom of falcon tube.  The 
solid was suspended in 1mL of organic solvent (dichloromethane) to generate 
reverse micelles which release the drug into the external organic phase.  The 
organic solvent was evaporated for ~5 h in speed vacuum.  The resultant reversed 
nanomicelles were resuspended in 1mL of HPLC mobile phase consisting of 
(acetonitrile:water, 1:1 v/v) (dilution factor was taken into account) and further 
diluted to determine the concentration of active pharmaceutical ingredient (CsA) 
entrapped in each nanomicellar preparation with RP-HPLC. The entrapment and 
loading efficiencies of the formulation was calculated with the following equations: 
 
Entrapment efficiency = (amount of CsA quantified in NMF)   X 100                                                       
                                         Amount of CsA added in the NMF                 
 
Loading efficiency =  (amount of CsA quantified in NMF)   X 100   
      (Amount of CsA added+amount of polymers used)              Eq 2. 
 
(NMF= Nanomicellar Formulation) 
Eq 1. 
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Effect of dilution on nanomicellar size 
 
To study the effect of dilution on the size of nanomicellar formulation 
(NMF), all the formulations were subjected to dilution test. NMF’s were diluted 
with phosphate buffer and the effect on the nanomicelle size from no dilution to 
500 times dilutions was studied.  The NMF size and polydispersity indices were 
tested with Malvern Zetasizer and recorded as described earlier.   
 
Proton NMR studies 
 
Nuclear magnetic resonance (NMR) analysis was performed for CsA 
loaded HCO-40/Oc-40 nanomicelles, 1H NMR spectra were recorded on a Varian 
400 MHz spectrometer (Varian, USA) in deuterated water (D2O) or deuterated 
chloroform (CDCl3) at room temperature.  The prepared placebo and 0.10 % CsA 
NMF (600 µL) was subjected to lyophylization to obtain dry pellets.  The obtained 
pellets were resuspended in equal volumes (600 µL) of deuterated aqueous and 
organic solvents as follows: (i) placebo NMFs were resuspended in CDCl3, (ii) 0.10 
% CsA NMFs were resuspended in CDCl3 and D2O, and (iii) CsA drug was 
dissolved in CDCl3. 
 
Formulation viscosity 
 
To determine the viscosity of all the solutions and formulations 
conventional glass Ostwald-Cannon-Fenske viscometer (Fisher Scientific, USA) 
was selected. Briefly, viscometer was filled from one end with sufficient volumes 
of water/buffer/placebo/CsA NMF with extreme care to avoid air bubble formation. 
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The solution was aspirated from the other end. The time taken by the solution to 
flow down under gravity was measured and density of the liquid was also 
determined. The following formula was used to calculate the viscosity. 
vis(liq) = (density(liq) * time(liq) * vis(water)) / (density(water) * time(water))               Eq 3. 
Where vis(liq) represents viscosity of the sample, density(liq) represents density of the 
sample, time(liq) denotes flow time for sample, vis(water) shows viscosity of water, 
0.89 centipoise (25° C), density(water) represents density of water (1 g/mL), time(water) 
denotes flow time for water. 
 
To improve the viscosity of NMF povidone K90 was selected. Earlier studies in our 
laboratory identified that povidone K90 improved NMF properties (small diameter 
of NMF and bio-adhesion) in comparison to other viscosity enhancers such as PVP-
K-30, hydroxypropyl methyl cellulose, hydroxyethyl cellulose or polycarbophil 
(194).  
 
Cell culture  
 
Rabbit primary corneal epithelial cells (rPCEC) and human retinal pigment 
epithelial cells (D407) were cultured according to a previously published protocol 
from our laboratory (282, 283). In brief, rPCEC cells were grown with culture 
medium comprising MEM, 10% FBS, HEPES, sodium bicarbonate, penicillin, 
streptomycin sulfate, and 1% (v/v) nonessential amino acids, adjusted to pH 7.4. 
D407 cells were grown in a culture medium containing DMEM supplemented with 
10% (v/v) FBS (heat inactivated), 29 mM NaHCO3, 15 mM HEPES, 100 mg of 
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penicillin and streptomycin each, and 1% nonessential amino acids at pH 7.4. Cells 
in passage numbers between 75 and 80 were employed. Cells were grown at 37 °C, 
in a humidified atmosphere of 5% CO2 and 90% relative humidity.  Culture medium 
was replaced every alternate day. Both rPCEC and D407 cells were cultured in 
flasks, harvested at 80–90% confluency with TrypLE™ Express (a superior 
replacement for trypsin) (Invitrogen, Carlsbad, CA, USA). Cells were then plated 
in 96-well plates at a density of 10,000 cells/well and utilized for studies. NMFs 
(blank and CsA loaded) were resuspended in half the volume of endotoxin free cell 
culture water (Hyclone Inc, USA) and volume was made up with 2X DMEM 
medium.  
 
Cytotoxicity studies 
 
To evaluate the toxicity of NMFs, lactate dehydrogenase (LDH) release was 
conducted on rPCEC for 2h. Also, the toxicity was evaluated on rPCEC and D407 
with WST-1 cell proliferation reagent assay. CsA loaded and blank NMF's have 
been prepared and evaluated for topical ocular delivery. Following topical drop 
administration, nanomicelles primarily comes in contact with corneal epithelial 
cells. Therefore, we aimed to test the effect of NMF on rPCEC cells.  
 
Cell proliferation assay 
 
Cell viability assay was performed to determine the toxicity of CsA NMF 
on rPCEC and D407 cells. Briefly, 10,000 cells/well were plated into 96-well 
plates. NMFs (blank and CsA loaded) were prepared in serum free cell culture 
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media and filtered with 0.2 µm sterile nylon membrane filters under laminar flow. 
Cells were exposed to 100 µL of placebo (blank/empty) and CsA (0.025%, 0.05%, 
0.075% and 0.1%) loaded NMFs for 1h. In these experiments cell culture medium 
and 10% triton X-100 served as negative and positive controls, respectively. 
Percent viable cells were calculated using the Premixed WST-1 cell proliferation 
reagent according to manufacturer's protocol (Clontech, Mountain View, CA). 
Percent cytotoxicity of the placebo and CsA loaded NMF's was calculated. 
Lactate Dehydrogenase (LDH) assay 
 
In vitro plasma membrane damage assay for blank and CsA loaded NMFs 
was conducted on rPCEC cells and quantitatively measured with Takara LDH 
cytotoxicity detection Kit (Takara Bio Inc, CA, USA). rPCEC cells were grown on 
96-well plates and added 100 µL of serum free cell culture medium, 100 µL of 
blank and CsA loaded NMFs. Cells were incubated for 2h at 37º C. In this assay, 
cell culture media and 10% Triton-X 100 served as negative and positive controls, 
respectively. After 2h incubation, the plate was centrifuged and the amount of 
formazan formed in supernatant was measured with a 96-well micro titer plate 
reader absorbance set at 490 nm.  
% Cytotoxicity = Observed experimental value - cell culture medium value  * 100                  Eq. 4 
                                             TritonX-100 - cell culture medium value                  
          
 
Stability of CsA NMF  
 
Stability studies were conducted for 0.1% CsA NMF following 
international conference on harmonization (ICH) guide lines at 5 oC, 25 oC/60% 
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relative humidity (RH) and 40 oC/75% RH. Samples were withdrawn at 
predetermine time points for one months. Drug concentration, NMF size and 
polydispersity index were determined following the method described earlier. In 
these studies placebo or blank formulation served as control. 
 
In vivo studies 
Animals 
 
Adult female New Zealand albino rabbits weighing between 2.0 and 3.0 kg 
were obtained from Charles River (Durham, North Carolina, USA). This research 
was conducted under aseptic conditions strictly under the regulation of ARVO 
statement for the use of animals in ophthalmic and vision research. Animals were 
acclaimed for 7 days under Photoperiod: 12 hrs light/12 hrs darkness and at a 
temperature of 68 ± 2 °F.  Animals were allowed for ad libitum via water bottles 
with sipper tubes and were provided with Hi Fiber Rabbit Diet. Protocol for 
performing all the surgical procedure was also approved by Institutional Animal 
Care and Use Committee (IACUC) of the North Carolina State University. 
 
Randomization and Study Identification 
 
Animals were randomly assigned to four study groups by stratified body 
weight according to facility Standard Operating Procedures (SOPs).  Animals were 
uniquely identified by an ear tattoo and a corresponding cage card number. Animal 
treatment and group assignment are presented in Table 3. 
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Table 3. Rabbit identification and groups 
 
 
 
 
 
 
Treatment Group # 
Tissue 
Processing 
0.1% CsA with HCO-40 pH 7.0 (OD); BSS (OS) 2 Histopathology 
0.1% CsA with HCO-40 pH 7.0 (OD); BSS (OS) 2 Histopathology 
0.1% CsA with HCO-40 pH 7.0 (OD); BSS (OS) 2 Drug levels 
0.1% CsA with HCO-40 pH 7.0 (OD); BSS (OS) 2 Drug levels 
Placebo HCO-40 pH 7.0 (OD); BSS (OS) 6 Histopathology 
Placebo HCO-40 pH 7.0 (OD); BSS (OS) 6 Histopathology 
Placebo HCO-40 pH 7.0 (OD); BSS (OS) 6 Drug levels 
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Animals 
 
Studies were conducted in adult New Zealand White rabbits (Oryctolagus 
cuniculus) to determine ocular tissue drug concentrations, whole blood CsA levels 
and the in vivo performance of NMF after topical drop instillation into pre-corneal 
pocket. Placebo 0.05% CsA and 0.1% CsA loaded NMF were selected for in vivo 
studies. In these studies, Balanced Salt Solution (BSS, Alcon Laboratories, Fort 
Worth, TX) served as negative control.  In another study Restasis® was used as 
control. Each treatment consisted of 35 µL of placebo/0.05% CsA NMF/0.1% CsA 
NMF/BSS applied with a calibrated micropipette to the ocular surface of each eye.  
 
 
Ocular Examination and Irritation Scores 
 
A complete ocular examination, using a slit lamp and indirect 
ophthalmoscope, was done to evaluate ocular surface morphology, anterior 
segment and posterior segment inflammation, cataract formation, and retinal 
changes. Hackett-McDonald ocular scoring (Microscopic Ocular Grading System) 
of inflammation was recorded. Ocular examination was conducted to determine 
pre-dose-(pre-study) baseline data for each rabbit, followed by a pre-dose (prior to 
first daily dose) each day and then 30 min after last dose daily. Ocular tolerability 
was assessed in BSS control, placebo, and 0.1% CsA NMF treated eyes. 
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Intraocular Pressure 
 
Intraocular pressure (IOP) was measured in both eyes during the 
acclimation, then prior to initiation of treatment, and then every 24 hours for 5 days, 
an hour after the last treatment on each day. The measurement was done without 
use of topical anesthetic. The tip of the Tonovet tonometer probe was directed to 
contact the central cornea and 6 measurements were made consecutively. After the 
six measurements, IOP shown on the display was recorded. Prestudy IOPs were 
done at the same time of day that the post-treatment IOPs were conducted.   
 
Electroretinography 
 
Electroretinography (ERG) was performed prior to the study during 
acclimation and on day 4 of treatment, an hour after the last treatment. All animals 
were dark adapted for 15 minutes prior to ERG. Whole field ERGs were recorded 
from the right eye once during acclimation and on the day of euthanasia.  A 
monopolar contact lens electrode (ERG-jet, La Chaux des Fonds, Switzerland) was 
placed on the cornea to serve as an active electrode.  A subdermal electrode at the 
lateral canthus served as the indifferent electrode.  A Barraquer eyelid speculum 
was placed to maintain open eyelids and a subdermal needle electrode was inserted 
dorsally as the ground electrode.  ERGs were elicited by brief flashes at 0.33 Hz 
delivered with a mini-ganzfeld photostimulator (Roland Instruments, Wiesbaden, 
Germany) at maximal intensity.  Twenty responses were amplified, filtered, and 
averaged (Retiport Electrophysiologic Diagnostic Systems, Roland Instruments, 
Wiesbaden, Germany).   
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Single dosing 
 
 To study CsA concentrations in the individual ocular tissues or fluids with 
single topical drop administration, animals were divided into three groups (BSS, 
placebo and 0.1% CsA NMF) with two animals per group. Rabbits were manually 
restrained and upper eyelid was gently elevated to expose the cornea.  Both eyes 
were dosed with BSS, placebo, 0.1% CsA NMF (35 μL) without contacting the 
cornea. The rabbit was then allowed to blink several times to distribute the applied 
NMF/solution over the eye prior to returning the animal to the cage. After dosing, 
rabbits were left undisturbed in the cage for 60 mins. Post topical dosing (1h), 
approximately 3 mL of whole blood was collected. Following blood collection, 
animals were euthanized with intravenous injection of an AVMA-approved 
barbiturate-based euthanasia agent (Fatal-Plus™). Eyes were enucleated and were 
immediately frozen until further processing.  
 
Multiple dosing 
 
Animals were divided into two groups (placebo and 0.1% CsA NMF) with 
two animals per group. Right eye of the animal was treated with NMF (placebo or 
0.1% CsA) and the contralateral eye with BSS. This procedure was repeated 4 x/ 
day at two hour interval for 5 days. After last dosing on day 5, rabbits were 
tranquilized and 3 mL of whole blood was collected from the jugular vein. Animals 
were sacrificed; eyes were enucleated and immediately frozen until further 
processing. 
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Ocular Pharmacokinetic studies 
 
Single dose pharmacokinetic studies were conducted in female NZW 
rabbits. Animals were administered a formulation containing 0.05% or 0.1% CsA 
in nanomicellar formulation, or the formulation vehicle, or Restasis® (0.05% 
emulsion) to both eyes either as a single dose (single dose phase) or 4 times daily 
at approximately 2-hour intervals for 7 days (repeat dose phase) (Table 4). An 
additional group of 3 female rabbits were not treated to serve as pre-dose controls 
for both study phases. In both phases, the rabbits were examined for clinical signs, 
specifically including ocular and peri-ocular effects. Intraocular pressure was 
measured daily (repeat dose phase), and ERGs were recorded during acclimation 
and then 1-hour post-treatment on Day 6. 
 
Single Dose Phase 
 
In this study phase, two rabbits were administered a single dose of 
nanomicellar formulation vehicle were euthanized at 0.25 hour post-dose, and 2 
rabbits per time point in treated groups were euthanized at 0.25, 1, 4, and 12 h post-
dose for assessment of CsA tissue distribution (Table 4). Whole blood and ocular 
tissues, including aqueous humor, vitreous humor, conjunctiva, cornea, lens, 
iris/ciliary body, retina-choroid, sclera, eyelid, lacrimal gland, and tears were 
obtained for analysis of CsA concentration. 
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Table 4.  Formulation vehicle, or Restasis (0.05%) to both eyes either as a single 
dose (single dose phase) or 4 times daily at approximately 2-hour intervals for 7 
days (repeat dose phase)   
 aAll doses were 35 µL per eye (35 µL of Restasis 0.05%, cyclosporine 0.05% 
nanomicellar formulation and 0.1% nanomicellar formulation contained 17.5 µg, 
and 35 µg cyclosporine, respectively). bGroup 1 served as the pre-dose samples for 
Groups 2 9. cVehicle without active contained all excipients but no drug 
(cyclosporine). dCyclosporine in nanomicellar formulation.   
Group 
No. of 
Animals Per 
Group 
Formulation 
Administered 
(Bilateral)a 
Matrices 
Collected Sample Times 
1b 3 None Tear, blood, 
ocular tissues, 
histophathology 
samples 
Pre-dose (both 
eyes/animal) 
Single Dose  Tear, blood, 
ocular tissues  
 
2 2 Vehiclec 0.2 h post-dose 
3 8 Restasis 0.05% 0.25, 1, 4, and 
12 h post dose 
(both 
eyes/animal) 
4 8 Cyclosporine 
0.05% 
5 8 Cyclosporine 
0.1% 
Repeat Dose (0, 2, 4, and 6 h each day x 7 days)  
6 4 Vehiclec Tear, blood, 
ocular tisues (2 
rabbits), 
histopathology 
samples (2 
rabbits) 
12 h after the 
last dose (both 
eyes/animal) 
7 8 Restasis 0.05% Tear, blood, 
ocular tissues 
0.25, 1, 4 and 
12 h after the 
last dose (both 
eyes/animal) 
8 8 Cyclosporine 
0.05% 
9 10 Cyclosporine 
0.1% 
Tear, blood, 
ocular tissues (8 
rabbits), 
histopathology 
(2 rabbits) 
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Repeat Dose Phase 
 
In the repeat dose phase, two rabbits per time point were euthanized at 0.25, 
1, 4, and 12 hours after the last dose on Day 7 (Table 4) for assessment of CsA 
tissue distribution. Whole blood, ocular fluids/tissues (aqueous humor, vitreous 
humor, conjunctiva, cornea, lens, iris/ciliary body, retina-choroid, sclera, eyelid, 
lacrimal gland) and tears were obtained for analysis of CsA concentration. Ocular 
tissues were taken for histopathologic examination from the specified rabbits of the 
CsA-treated (0.1% CsA) and vehicle-treated groups.  
Eyes were dissected while frozen to isolate ocular tissues and to minimize 
drug diffusion to adjacent tissues during dissection.  Dissection was performed on 
a cooled ceramic tile that was placed on dry ice/isopentane bath to avoid any 
thawing of the eye during dissection. Care was taken to avoid cross contamination.  
Rabbit ocular tissues (conjunctiva, cornea, eyelid, iris-ciliary body, lacrimal 
gland, lens, retina-choroid and sclera) were homogenized in extraction buffer 
(20:80 ACN: 50 mM NH4OAc, pH 4.4). Tissue homogenates were subjected to 
protein precipitation extraction method with acetonitrile. The supernatant was 
further extracted using Waters Ostro 96-well plate. Similarly, aqueous and vitreous 
humors were subjected to protein precipitation CsA extraction method. Methanol 
was added to aqueous and vitreous humor samples (3:1) and vortex mixed. Samples 
were then centrifuged and supernatant was transferred to HPLC vials for analysis. 
Calibration curve was prepared in 3:1 methanol:rabbit aqueous or vitreous humor. 
CsA and internal standard were extracted from 250 μL of rabbit whole blood 
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(K2EDTA) by liquid-liquid extraction using methyl-t-butyl ether (MTBE) after 
acidification with HCl. The organic extract was then washed with an alkaline 
solution. After evaporation to dryness and reconstitution, the extracts were 
analyzed by LC-MS/MS.  
 
Euthanasia and Sample collection 
 
Rabbits were euthanized 1 hour after single dosing and final treatment on 
day 5.  Euthanasia was performed by intravenous injection of an AVMA-approved 
barbiturate-based euthanasia agent (e.g., Fatal-Plus™). Approximately 3 mL of 
whole blood was collected with the rabbits tranquilized from the jugular vein. Eyes 
were removed after euthanasia.  Eyes from two animals per group were fixed in 
modified Davidson’s solution, processed for histopathology, stained with H&E, 
and examined using light microscopy (see Table 3).  Eyes were also stained with 
Ki-67 immunostaining as a standard marker of proliferation. Conjunctiva was 
collected from eyes from two animals from the drug treated groups and one animal 
from the placebo groups (see Table 3).  Eyes from these animals were processed 
for drug levels and were removed and frozen immediately, tissues dissected while 
frozen (as described below), and stored at -80 ºC until processing.  The list of ocular 
tissues collected included aqueous humor, vitreous humor, cornea, conjunctiva, 
lens, iris/ciliary body, choroid/retina, and sclera. Eyes were dissected while frozen 
to isolate ocular tissues and to minimize drug diffusion to adjacent tissues during 
dissection.  Dissection was performed on a cooled ceramic tile that was placed on 
dry ice/isopentane bath to avoid thawing of the eye during dissection. In order to 
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prevent transfer of drugs between tissues of each eye, instruments were thoroughly 
rinsed with saline followed by methanol, followed by saline, and blotted dry. The 
globe was initially separated in half using a long razor blade (new blade was used 
for each eye) into a dorsal and ventral half.  The frozen aqueous humor was 
removed first and placed into pre-weighed vials. The cornea sections were removed 
next, followed by lens, and vitreous. The iris and ciliary body were removed 
together, followed by the retina and choroid.  The remaining sclera sections were 
then collected.   
 Rabbit ocular tissues (conjunctiva, cornea, eyelid, iris-ciliary body, lacrimal 
gland, lens, retina-choroid and sclera) were homogenized in extraction buffer 
(20:80 ACN: 50 mM NH4OAc, pH 4.4). Tissue homogenates were subjected to 
protein precipitation extraction method with acetonitrile. The supernatant was 
further extracted using Waters Ostro 96-well plate. Similarly, aqueous and vitreous 
humors were subjected to protein precipitation CsA extraction method. Methanol 
was added to aqueous and vitreous humor samples (3:1) and vortex mixed. Samples 
were then centrifuged and supernatant was transferred to HPLC vials for analysis. 
Calibration curve was prepared in 3:1 methanol:rabbit aqueous or vitreous humor. 
CsA and internal standard were extracted from 250 μL of rabbit whole blood 
(K2EDTA) by liquid-liquid extraction using methyl-t-butyl ether (MTBE) after 
acidification with HCl. The organic extract was then washed with an alkaline 
solution. After evaporation to dryness and reconstitution, the extracts were 
analyzed by LC-MS/MS. 
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Data and Statistical Analysis 
 
Data for in vitro experiments were conducted at least in quadruplicate and 
the results were expressed as mean ± standard deviation (SD). Statistical 
comparison of mean values was performed with Student's t-test. A p-value of <0.05 
was considered to be statistically significant. Parametric normally distributed data 
(i.e., IOP, ERG) were compared by time point for each group using one-way 
ANOVA models with Tukey-Kramer post-hoc analysis. For non-parametric data 
(i.e., clinical scores) Wilcoxon tests were conducted per animal by time point. 
Differences were considered significant at P<0.05.  Results and probabilities were 
calculated using computerized statistical software (JMP 10, SAS Inc. Cary, NC). 
 
Results 
 
CMC 
 
Critical micellar concentration was determined for HCO-40 and polymer 
blends with iodine as a probe. CMC of HCO-40 was found to be approximately 
0.0303 wt%. The other surfactant, Oc-40, generated a CMC value of 0.107 wt% 
(278) which is greater than the CMC of HCO-40. A combination of the surfactants 
in varying ratios lowered the CMC value from 0.03 wt% to 0.00707 wt%.  The 
results are presented in Table 5.  A combination of HCO-40 and Oc-40 at 1.0 wt% 
and 0.05 wt% resulted in reduced CMC.   
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Size, polydispersity indices and surface charge 
 
Placebo and CsA loaded nanomicelles presented a size range of 10 nm to 
80 nm (Figure 13A and B) when measured with DLS.  The average 0.1% CsA 
loaded nanomicellar size was around ~22.4  ± 0.411 nm. All the size determinations 
for increasing pay load of CsA are provided in Table 6. Similarly, all the NMF's 
were found to carry slight surface negative charge (Table 6).  
 
Visual appearance 
 
Visual appearance for all the formulations was found to be clear, transparent 
and devoid of any particulate matter. Absorbance at 400 nm was measured and 
results demonstrated that CsA loaded formulations have negligible absorbance. 
 
Transmission Electron Microscopy 
 
The prepared aqueous 0.10 % CsA nanomicellar formulation was clear, 
extremely small (Figure 14A), devoid of any visible particles to naked eye (Figure 
14A right vial).  The formulation appeared to be transparently clear similar to water 
(Figure 14A left vial) and free flowing.  TEM images for 0.10% CsA nanomicelles 
appeared to show smooth surface morphology with spherical shape and no 
aggregation (Figure 14B). The size distribution was visualized at a scale bar of 500 
nm (LS3600, 100.0KV, X60).   The TEM image is in agreement with the particle 
size measurement and the size distribution is between 10 nm to 80 nm.   
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Table 5. Table showing critical micellar concentration for HCO-40, Oc-40 and 
blend of both in varying ratios. HCO-40 = hydrogenated castor oil-40; Oc-40 = 
octoxynol-40 
 
 
 
 
 
 
 
 
HCO-40 and Oc-40 (wt% ratio) 
1.0 : 0 1.0:0.05 0.5:0.5 0.05:1.0 0.0:1.0 
30.0 x 10-3 7.07x10-3 7.14 x 10-3 88.0 x 10-3 107.0 x 10-3 
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Table 6. Nanomicellar average size (nm) and polydispersity indices. 
 
 
 
 
 
 
Formulation  
(wt %) Size (nm) 
Average  
Nanomicelle 
 size (nm) St.dev Polydispersity Index Average St.dev 
  1 2 3     1 2 3     
Placebo 24.5 24.4 24.6 24.5 0.100 0.164 0.171 0.154 0.163 0.009 
0.025 18.3 18.4 18.6 18.4 0.130 0.128 0.135 0.109 0.124 0.013 
0.050 20.3 20.6 20.5 20.5 0.147 0.178 0.164 0.185 0.176 0.011 
0.075 22.8 22.8 22.9 22.9 0.057 0.191 0.205 0.199 0.198 0.007 
0.100 22.9 22.1 22.2 22.4 0.411 0.144 0.144 0.139 0.142 0.003 
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Figure 13. (A) Placebo nanomicellar formulation (B) Cyclosporine-A (CsA) (0.1%) loaded nanomicellar formulation. 
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Figure 14. (A) Picture showing 0.1% cyclosporine-A (CsA) loaded nanomicellar formulation (right) in comparison to water (left); 
(B) Transmission Electron Microscopy image for 0.1% CsA loaded nanomicellar formulation. 
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Thermal dissociation 
 
In general, thermal dissociation temperature (DT) of nanomicellar 
formulations is about 20-40 oC higher than formulation containing drug. Low DT 
of the drug-containing NMF’s indicates that drug molecules are incorporated into 
nanomicelles, and thereby solubilized. With temperature rising above DT, 
nanomicelles appear to dissociate into individual monomer units. This disruption 
of nanomicelle structures causes drug release in surrounding aqueous medium. 
Such destabilization results in the formation of a cloudy or milky white solution. 
DT of the formulation appears to be high (> 45 °C) which provides stability to the 
formulation at room temperature (Table 7). 
 
Nanomicelle regeneration time 
 
NMF after attaining the DT are allowed to cool to room temperature under 
ambient room temperature. The time taken for the disappearance of the cloudiness 
and regeneration of transparent, clear formulation was recorded. This time was 
recorded as nanomicelle regeneration time (Table 7).   
 
Nanomicelle entrapment and loading efficiency 
 
The prepared NMF’s were subjected to entrapment and loading efficiency 
tests by determining CsA concentrations in the nanomicelles after breaking or 
reverse opening the nanomicelles.  The results demonstrated a high entrapment 
efficiency of > 95% and the loading CsA was improved to 8.85%.  The results are 
summarized in Table 7. 
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Dilution effect 
 
The effect of dilution on the NMF was studied following the size and 
polydispersity indices. There is no significant effect of size upon dilution with 
phosphate buffer. However, the polydispersity index was found to be increasing 
with dilution upto 500 times. Results indicate that the nanomicelles alter size 
distribution in the formulation.  The results are summarized in Table 8. 
 
Proton NMR studies 
 
1H NMR spectral analysis results are shown in Figure 15 through Figure 
18. In CDCl3, the resonance peaks corresponding to CsA and nanomicelles are 
observed. However, in D2O peaks corresponding to nanomicelles are only observed 
and no peaks for CsA were evident. These results clearly indicate, CsA was 
entrapped into the inner hydrophobic core of nanomicelles when CsA loaded 
nanomicelles are suspended in D2O (Figure 15 Figure 18). These results are 
similar to the dexamethasone and paclitaxel loaded polymeric nanomicelles in D2O 
(278, 284). 
 
Formulation viscosity 
 
The rehydrated NMF when resuspended in only 2X phosphate buffer 
generated viscosity nearly equal to water (0.9 cP). It was earlier reported that higher 
viscosity does not affect drainage rate unless viscosity exceeds a critical value of 
about 4.4 cP (285). Therefore, 0.6 wt% of povidone K-90 was added which raised 
NMF viscosity to 2.0 cP and maintained the viscosity well below critical value. 
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Addition of povidone K-90 improved the viscosity with negligible effect on flow 
property of the formulation.  
 
In vitro cytotoxicity 
 
Results with cell proliferation assay indicate that both, rPCEC and D407, 
cells displayed negligible cytotoxicity after NMF exposure (blank and CsA) and 
were comparable to negative control (culture medium) (Figure 19). On the other 
hand, triton X-100 exposure significantly reduced rPCEC and D407 cell number to 
24% and 25%, respectively relative to blank culture medium. In another set of 
experiments (LDH assay) on rPCEC cells NMF did not generate any significant 
release of LDH. The results were again comparable to negative control (culture 
medium) with negligible effect on cell plasma membrane. The positive control 
(triton X-100) caused significant release of LDH by damaging the rPCEC cell 
membrane (Figure 20) 
  
NMF stability 
CsA loaded NMF were subjected to three different temperatures. Results 
indicate that NMF was stable for more than one month. No significant difference 
was observed in NMF size and polydispersity index (Table 9). Moreover, CsA 
concentration was >90% at all three temperatures.  
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                   Table 7. Characterization of cyclosporine-A nanomicellar formulations. 
 
 
 
 
 
CsA 
formulations 
(wt%) 
Entrapment 
Efficiency 
(%) 
Loading 
Efficiency 
(%) 
Surface 
potential 
(mV) 
Osmolality 
(mOsm/kg) 
Dissociation 
Temperature 
( oC) 
Regeneration 
time  
Absorbance 
(400 nm) 
Placebo - - -0.039 290 79 33 sec 0.032 
0.025 98.2 2.34 -0.251 289 78 30 sec 0.029 
0.050 99.1 4.75 -0.157 312 70 3.7 min 0.042 
0.075 100.5 6.97 -0.189 333 62 3.6 min 0.028 
0.100 97.4 8.85 -0.179 305 47 9.0 min 0.035 
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Table 8. Effect of dilution on nanomicellar size. 
 
Dilution factor (x) Z average 
nanomicellar size (nm) 
Polydispersity Index 
0 20.80 0.147 
10 21.77 0.159 
20 23.39 0.215 
50 21.81 0.213 
100 22.65 0.226 
200 26.11 0.329 
500 24.52 0.360 
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Table 9. Cyclosporine-A (CsA)  nanomicellar stability at 5 °C, 25 °C/60% relative humidity (RH) and 40 °C at 75% RH. 
 
Time 
point 
(Weeks) 
Temperature/Relative humidity 
5 °C 25 °C/60% RH 40 °C/ 75% RH 
Average 0.1% 
CsA nanomicelle 
size (nm) 
Polydispersity 
Index 
Average 0.1% 
CsA nanomicelle 
size (nm) 
Polydispersity 
Index 
Average 0.1% 
CsA 
nanomicelle size 
(nm) 
Polydispersity 
Index 
0 17.7 0.156 17.7 0.156 17.7 0.156 
1 17.5 0.169 16.3 0.121 15.7 0.107 
4 17.4 0.137 15.7 0.1245 15.3 0.082 
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Figure 15. 1H NMR for cyclosporine-A in CDCl3  
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Figure 16. 1H-NMR spectra for placebo or blank nanomicelles 
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Figure 17. 1H-NMR for cyclosporine-A loaded nanomicelles suspended in CDCl3 (* = cyclosporine-A resonance peaks are evident) 
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Figure 18. 1H-NMR for cyclosporine-A loaded nanomicelles suspended in D2O (no resonance peaks are observed/identified for 
cyclosporine-A). 
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Figure 19. Cell proliferation assay for rPCEC and D407 cells incubated with NMF (placebo and CsA loaded) for a period of 1h. 
Values represent mean ± standard deviation (n= 4). A p-value of < 0.05 is considered to be statistically significant (*). 
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Figure 20. LDH assay for placebo and CsA loaded NMF for a period of 2h. Values represent mean ± standard deviation (n = 4). A 
p-value of < 0.05 is considered to be statistically significant (*). 
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Figure 21. Cumulative Hackett-McDonald irritation scores. Values represent mean +/- standard deviation 
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Figure 22. Intraocular pressure. Values represent mean +/- standard deviation 
 
 
  
1
3
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Scotopic electroretinography. Values represent mean +/- standard deviation 
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Figure 24.Ocular histopathology. Example of the ocular histopathology of the anterior segment of the eye (left) and the posterior 
segment (right).  c=cornea; conj=conjunctiva, i=iris; s=sclera; on = outer nuclear layer;  r=retina.  
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In vivo studies: LC-MS/MS method  
 
A sensitive LC-MS/MS method was developed and applied to quantify CsA 
concentrations in ocular tissues, fluids and whole blood. The established analytical 
ranges for Cys-A were 0.100 ng/mL – 100 ng/mL for whole blood, and 2.00 ng/mL 
– 2000 ng/mL for aqueous humor and vitreous humor.  The analytical ranges for 
the solid ocular tissues were 0.125 ng – 30 ng (low range) and 1.00 ng – 2500 ng 
(high range). Ocular tissue concentrations of CsA, collected one hour after single 
dosing and one hour following the last dose on Day-5 of multiple dosing are 
summarized in Table 10 (A and B). The results of the tissue analyses were 
converted to ng/g by correcting for the amount of tissue analyzed. CsA ocular tissue 
distribution, post single topical dosing showed higher drug concentrations in the 
anterior ocular tissues (cornea and conjunctiva) and tears. With single topical 
dosing conjunctival CsA concentrations was 1.71 times higher than cornea. Also, 
higher CsA levels were observed in sclera. All other ocular tissues produced low 
CsA concentrations. Whole blood CsA concentration was found to be 0.73 ng/mL. 
With repeat dosing, highest average CsA concentrations were observed in the 
treated eye. CsA levels in ocular tissues were found to be in the order: cornea 
conjunctiva  sclera  iris-ciliary body and aqueous humor. Lower CsA 
concentrations were observed in the lens retina-choroid and  vitreous humor 
(Table 10B). CsA concentrations in the contralateral eye treated with BSS were 
extremely low suggesting minimal systemic drug transfer.  CsA whole blood 
concentration with repeated topical dosing was found to be only 0.718 ± 0.295 
ng/mL. 
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Ocular Examination and Irritation Scores 
Mean cumulative Hackett-McDonald ocular irritation scores demonstrated 
very minimal scores for both BSS-treated left eyes and CsA treated right eyes 
throughout the study, both for pre-treatment and post-treatment examination times.  
Mean cumulative inflammatory scores of less than 2 were observed in eyes treated 
with the placebo, 0.1% CsA NMF and BSS.  These clinical scores represented mild 
conjunctival hyperemia (redness) and swelling.  However, there were no significant 
differences in mean cumulative Hackett-McDonald ocular irritation scores between 
the groups (Figure 21) suggesting no differences in irritation from topical 
application of 0.1% CsA NMF, the placebo and BSS.  
 
Intraocular Pressure 
 
Although there was some variation in mean IOP between the groups on any 
given day, there was no consistent elevation or decrease in IOP in any group and 
all values were within normal ranges for all rabbits (Figure 22).  
 
Electroretinography 
Pre-study and post-study ERGs were normal in each rabbit. There were no 
significant differences in a- and b-wave implicit times or amplitudes before and 
after treatment (Figure 23). 
 
Histopathology 
 
No toxicologic or inflammatory changes were observed histologically in the 
anterior (conjunctiva / cornea / iris) or posterior segments (vitreous / retina) of the  
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Table 10. Summary of Ocular distribution of cyclosporine-A in Rabbits (A) After 
a Single Topical Drop Administration (35 µL) (N = 4 eyes) (B) Topical ocular 
administration of 0.1% CsA HCO-40 (pH 7.0) formulation or placebo to the eye 
four times a day at 2 hour intervals for five days to New Zealand White rabbits  
 
Tissue/fluid 
CsA Concentration at 1 hr post 
dosing (N=4 eyes) 
 (ng/mL or ng/g)a ± S.E.M 
Aqueous humor 1.5 ± 0.398 
Conjunctiva 1417 ± 123 
Cornea 828 ± 53.2 
Eye lid 745 ± 190 
Iris Ciliary Body 8.2 ± 1.9 
Lacrimal gland 3.2 ± 0.4 
lens 1.0 ± 0.06 
Retina-Choroid 13 ± 2.4 
Sclera 216 ± 15 
Tears 800 ± 99  
Vitreous Humor 2.0 ± 0.8 
S.E.M = Standard Error of Mean 
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(B) Topical ocular administration of 0.1% CsA HCO-40 (pH 7.0) formulation or 
placebo to the eye four times a day at 2 hour intervals for five days to New Zealand 
White rabbits  
Group 
No. 
Treatment Matrix 
CsA Concentration at 1 hr 
post last dose 
(ng/mL or ng/g)a 
ODb Ave OSc Ave 
2 
0.1% CsA NMF 
administered 4 times 
a day (0, 2, 4, and 6 
hr) for 5 days 
Aqueous 
Humor 
133 
134.5 
5.51 
6.36 
136 7.21 
6 Placebo BQLd NAe 6.14 NA 
2 
0.1% CsA NMF 
administered 4 times 
a day (0, 2, 4, and 6 
hr) for 5 days 
Vitreous 
Humor 
11.3 
8.4 
1.89 
4.3 
5.44 6.71 
6 Placebo BQL NA 2.02 NA 
2 
0.1% CsA NMF 
administered 4 times 
a day (0, 2, 4, and 6 
hr) for 5 days 
Conjunctiva 
2700 
2125 
NCf 
NC 
1550 NC 
6 Placebo 40.0 NA NC NA 
2 
0.1% CsA NMF 
administered 4 times 
a day (0, 2, 4, and 6 
hr) for 5 days 
Cornea 
8130 
7805 
NC 
NC 
7480 NC 
6 Placebo NC NA NC NA 
2 
0.1% CsA NMF 
administered 4 times 
a day (0, 2, 4, and 6 
hr) for 5 days 
Lens 
73.4 
68.6 
NC 
NC 
63.8 NC 
6 Placebo NC NA NC NA 
2 
0.1% CsA NMF 
administered 4 times 
a day (0, 2, 4, and 6 
hr) for 5 days 
Iris-Ciliary 
Body 
274 
204 
NC 
7.8g 
134 15.7 
6 Placebo NC NA NC NA 
2 
0.1% CsA NMF 
administered 4 times 
a day (0, 2, 4, and 6 
hr) for 5 days 
Retina / 
Choroid 
85.0 
53.7 
NC 
11.3g 
22.4 22.5 
6 Placebo NC NA 27.3 NA 
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Group 
No. 
Treatment Matrix 
CsA Concentration at 1 hr 
post last dose 
(ng/mL or ng/g)a 
ODb Ave OSc Ave 
2 
0.1% CsA NMF 
administered 4 times 
a day (0, 2, 4, and 6 
hr) for 5 days 
Sclera 
786 
720 
22.7 
45.6 
655 68.6 
6 Placebo 12.2 NA 42.2 NA 
aAqueous humor and vitreous humor concentrations are expressed in ng/mL.  All 
other tissue concentrations are expressed in ng/g; bOD = Right eye; cOS = Left eye; 
dBQL = Below quantitation limit; eNA = Not applicable; fNC = Not calculated.  
Concentration below quantitation limit; gAverage value calculated by assuming NC 
= 0 
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Table 11. Group Mean Cyclosporine Toxicokinetic Parameters Whole Blood, Ocular Tissues and Tears Following Single Dose and 
Repeat Dose (7 Days) Topical Ocular Administration of Restasis (0.05%) or Cyclosporine Nanomicellar Formulations (0.05% or 
0.1%) to Female New Zealand White Rabbits 
 
 
 
 
 
 
 
 
 
 
 
                                 
Matrix Group Dose Treatments Cmaxb Tmax AUC0-t c,d 
Aqueous 
humor 
3 Single dose Restasis 0.05% 6.25 1 34.9 
4 
Cyclosporine 
0.05% 18.2 12 91.6 
5 Cyclosporine 0.1% 11.0 12 63.7 
7 Repeat 
dose 
Restasis 0.05% 30.8 12 359 
8 
Cyclosporine 
0.05% 80.0 4 854 
     
9 Cyclosporine 0.1% 206 1 1596 
Conjunctiva 3 Single dose Restasis 0.05% 710 1 4564 
4 
Cyclosporine 
0.05% 1553 0.25 7347 
5 Cyclosporine 0.1% 2665 0.25 8563 
7 Repeat 
dose 
Restasis 0.05% 920 0.25 6391 
8 
Cyclosporine 
0.05% 1883 0.25 8384 
9 Cyclosporine 0.1% 2630 0.25 12345 
  
1
3
9 
Matrix Group Dose Treatments Cmaxb Tmax AUC0-t c,d 
Cornea 3 Single dose Restasis 0.05% 279 1 2468 
4 
Cyclosporine 
0.05% 738 12 7099 
5 Cyclosporine 0.1% 828 1 7771 
7 Repeat 
dose 
Restasis 0.05% 1953 4 21096 
8 
Cyclosporine 
0.05% 4118 0.25 44325 
9 Cyclosporine 0.1% 6813 1 63978 
Eyelid 3 Single dose Restasis 0.05% 5925 12 30728 
4 
Cyclosporine 
0.05% 90 12 6721 
5 Cyclosporine 0.1% 845 0.25 4275 
7 Repeat 
dose 
Restasis 0.05% 11093 1 119645 
8 
Cyclosporine 
0.05% 12093 4 95361 
9 Cyclosporine 0.1% 9193 0.25 100589 
Iris/ciliary 
body 
3 Single dose Restasis 0.05% 6.2 1 21.42 
4 
Cyclosporine 
0.05% 9.3 12 72.32 
5 Cyclosporine 0.1% 15.7 0.25 8.77 
7 Repeat 
dose 
Restasis 0.05% 62.0 1 607 
8 
Cyclosporine 
0.05% 165 4 1507 
9 Cyclosporine 0.1% 184 1 2106 
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Matrix Group Dose Treatments Cmaxb Tmax AUC0-t c,d 
Lacrimal 
gland 
3 Single dose Restasis 0.05% 3.7 1 19.5 
4 
Cyclosporine 
0.05% 2.1 4 20.91 
5 Cyclosporine 0.1% 2.2 1 10.83 
7 Repeat 
dose 
Restasis 0.05% 53 4 472 
8 
Cyclosporine 
0.05% 24 1 230 
9 Cyclosporine 0.1% 26 4 266 
Lens 3 Single dose Restasis 0.05% 0.3 12 2.7 
4 
Cyclosporine 
0.05% 1.9 0.25 5.74 
5 Cyclosporine 0.1% 2.1 4 16.65 
7 Repeat 
dose 
Restasis 0.05% 13 12 144 
8 
Cyclosporine 
0.05% 47.8 4 524 
9 Cyclosporine 0.1% 86.838 12 930 
Retina-
choroid 
3 Single dose Restasis 0.05% 9 1 20.99 
4 
Cyclosporine 
0.05% 27 0.25 63.97 
5 Cyclosporine 0.1% 27 0.25 144 
7 Repeat 
dose 
Restasis 0.05% 50 1 372 
8 
Cyclosporine 
0.05% 56 4 517 
9 Cyclosporine 0.1% 59 4 628 
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Matrix Group Dose Treatments Cmaxb Tmax AUC0-t c,d 
Sclera 3 Single dose Restasis 0.05% 111 1 762 
4 
Cyclosporine 
0.05% 205 0.25 1167 
5 Cyclosporine 0.1% 263 0.25 1344 
7 Repeat 
dose 
Restasis 0.05% 315 4 2596 
8 
Cyclosporine 
0.05% 386 4 3435 
9 Cyclosporine 0.1% 701 0.25 4554 
Tears 3 Single dose Restasis 0.05% 10300 0.25 26135 
4 
Cyclosporine 
0.05% 958 12 8585 
5 Cyclosporine 0.1% 5833 0.25 8160 
7 Repeat 
dose 
Restasis 0.05% 12815 1 78824 
8 
Cyclosporine 
0.05% 24278 1 118225 
9 Cyclosporine 0.1% 34950 1 134330 
Vitreous 
Humor 
3 Single dose Restasis 0.05% 1.81 1 9.78 
4 
Cyclosporine 
0.05% 1.9 0.25 9.63 
5 Cyclosporine 0.1% 2.2 0.25 14.89 
7 Repeat 
dose 
Restasis 0.05% 8.7 1 62.2 
8 
Cyclosporine 
0.05% 7.2 12 76 
9 Cyclosporine 0.1% 7.0 0.25 66 
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Matrix Group Dose Treatments Cmaxb Tmax AUC0-t c,d 
Whole blood 3 Single dose Restasis 0.05% 0.15 1 0.44 
4 
Cyclosporine 
0.05% 0.52 0.25 1.64 
5 Cyclosporine 0.1% 0.77 0.25 3.4 
7 Repeat 
dose 
Restasis 0.05% 0.2 0.25 1.39 
8 
Cyclosporine 
0.05% 0.67 0.25 3.45 
9 Cyclosporine 0.1% 2.0 0.25 7.27 
 
aGroups 2-5 received single doses and Group 6-9 received 4 doses/day at 4-hour intervals for 7 days. 
bUnits are ng/mL for whole blood, aqueous humor, and vitreous humor and ng/g for all other matrices. 
cUnits are h×ng/mL for whole blood, aqueous humor, and vitreous humor and h×ng/g for all other matrices. 
dAUC0-t = AUC0-12 except Group 3 Whole Blood AUC0-4 
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eye of any groups (Figure 24).  Eyes were also stained with Ki-67 immunostaining 
as a standard marker of proliferation.  Ki-67 expression is usually estimated as the 
percentage of tumor cells positively stained by the antibody, with nuclear staining 
being the most common criterion of positivity. In corneal epithelium, but not in 
other tissues, Ki-67 was expressed at a very low level (< 1% of cells) with no 
difference among treatment groups. 
 
CsA concentrations in whole blood and ocular tissues 
 
Whole blood samples collected 1h  following the last dose on Day-5 from 
all seven rabbits, and selected ocular tissues (aqueous humor, vitreous humor, 
conjunctiva, cornea, iris-ciliary body, lens, retina-choroid, and sclera) collected 
from two rabbits that received 0.1% CsA NMF (OD), and BSS (OS), and from one 
rabbit that received placebo NMF (OD) and BSS (OS), were assayed for CsA by 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) as described 
earlier. CsA whole blood concentration was found to be 0.718 ± 0.295 ng/mL 
Concentrations of CsA in ocular tissues collected 1 hour following the single dose 
and last dose on Day-5 are summarized in Table 10 (A and B). The results of the 
solid tissue analyses were converted to ng/g by correcting for the amount of tissue 
analyzed.  Following repeated administration of the 0.1% CsA NMF, the highest 
average CsA concentrations in the treated eye were observed in cornea (7805 ng/g), 
followed by.conjunctiva (2125 ng/g), sclera (720 ng/g), iris-ciliary body (204 ng/g), 
and aqueous humor (134 ng/mL).  The lowest CsA concentrations were observed 
in the lens (68.6 ng/g), retina-choroid (54 ng/g), and vitreous humor (~8 ng/mL).  
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CsA concentrations in the collateral eye treated with BSS were quite low suggesting 
minimal systemic transfer of drug.   
All the pharmacokinetic parameters for Restasis®, 0.05% and 0.1% CsA 
nanomicellar formulations were determined with Winnonlin®. Summary for 
pharmacokinetic parameters are summarized in Table 11.  Group mean CsA PK 
parameters for whole blood, ocular tissues, and tears are presented in Table 11. In 
general, following either single or repeat (4 times per day at 2-hour intervals) dose 
administration of Restasis (0.05%) and CsA nanomicellar formulations (0.05% and 
0.1%), the highest exposure to CsA was observed in the tears and eyelid, followed 
by the cornea and conjunctiva. Intermediate exposure was observed in the sclera, 
aqueous humor, and iris/ciliary body. Low exposure was observed in the lens, retina 
choroid, lacrimal gland, and vitreous humor. Systemic exposure, as measured by 
whole blood concentrations and AUC values, was substantially lower than 
exposure in ocular tissues. 
In the repeat dose phase, CsA concentrations in the conjunctiva, cornea, 
aqueous humor, iris/ciliary body, sclera, lens, retina-choroid, and tears were highest 
after administration of CsA 0.1% in nanomicellar formulation followed by CsA 
0.05% in nanomicellar formulation, with Restasis 0.05% having the lowest 
concentrations (Table 11).   
Systemic exposure to CsA was also ranked in the same order (highest for 
the 0.1% nanomicellar formulation, followed by the 0.05% nanomicellar 
formulation and then Restasis), but systemic exposure to all three formulations was 
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substantially lower than exposure in ocular tissues (Table 11). In vitreous humor, 
CsA concentrations and AUC values were low but comparable after administration 
of both nanomicellar formulations and greater than those after administration of 
Restasis. CsA concentrations were reasonably comparable among all 3 CsA 
treatments for the eyelid. The CsA concentrations in lacrimal gland for all 3 
treatments were low. However, CsA concentrations and AUC values after 
administration of Restasis® were higher than for either of the nanomicellar 
formulations. 
Although CsA exposure in ocular tissues was lower after single doses 
compared to repeat doses, the rank orders of exposure between Restasis and the 
nanomicellar formulations after single dose administration were similar to those 
observed after repeat dose administration. Following both single and repeat dose 
administration, systemic exposure was substantially lower than exposure in ocular 
tissues. 
Discussion 
 
Therapeutic delivery with no ocular side effects after topical dosing, is a 
challenging task. Ocular static and dynamic barriers pose a challenge by impeding 
drug transport across cell membrane/tissues (286). After topical dosing, a large 
fraction of the dose is lost due to excessive tear production and/or drainage through 
nasolacrimal duct (14). Further sub-optimal physicochemical properties of drug 
will retard aqueous solubility thereby impeding drug delivery. In such a scenario, 
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clear aqueous nanomicellar formulations appear to be highly promising. 
Nanomicelles can encapsulate hydrophobic drugs inside the hydrophobic core 
improving aqueous solubility. Use of single polymer to encapsulate drug may result 
in clear aqueous nanomicelles, but may cause poor formulation stability. To 
improve the stability of micelles and lower their CMC a second polymer may be 
added. In our studies, we included Oc-40 as the second polymer. CMC is a point 
where the monomer surfactants start to aggregate and form micelles. Lower CMC 
indicates better stability of the nanomicelle formulation (14). For the blend of 
polymer surfactants CMC was determined. In the present study CMC for HCO-40 
and blend of surfactants was determined with iodine as a probe. Pure I2 is 
crystalline, fairly hydrophobic and particularly not soluble in water. Iodine 
solubility in an aqueous environment is improved by adding its salt, potassium 
iodide, to the solution. Addition of potassium iodide solubilizes water insoluble 
iodine by forming complexes, i.e., KI, KI2, KI3, KI4. As the iodine solution is added 
to polymer solution the solubilized iodine prefers to partition into the hydrophobic 
core of the nanomicelles. It prefers to interact with hydrophobic nanoenvironment 
of nanomicelles causing conversion of I3
- to I2 from excess KI in the solution. The 
ether oxygen of PEG groups in the surfactant molecules donate electrons to the 
vacant σ* orbital of I2 resulting in the formation of a surfactant-iodine donor-
acceptor type complex (287). A rise in absorbance for iodine entrapment indicates 
increase in micelle concentration. As the concentration of monomers in the 
formulation increases, a sudden rise in absorbance may be observed. Iodine 
intensity as a function of logarithm of surfactant mass concentration was plotted. A 
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combination of surfactants (HCO-40/Oc-40, 1.0:0.05) generated a lower CMC 
value, 0.00707 wt%, than the individual polymers (Table 5). Such low CMC value 
indicates that this combination of surfactants, at very low concentrations, will be 
able to entrap the hydrophobic drugs and can provide adequate solubility and 
stability.  
 To prepare CsA loaded NMF the blend of polymers (HCO-40/Oc-40, 
1.0:0.05) were selected due to their low CMC. An aqueous clear nanomicellar CsA 
formulation was successfully prepared following novel solvent casting technique. 
In another set of experiments, we tried to encapsulate 1mg of CsA following direct 
dissolution method.  Addition of CsA (0.1 wt%) to the blend of polymers in 
aqueous solution resulted in drug precipitation. Therefore, we selected solvent 
casting method to prepare CsA loaded NMF, which resulted in clear aqueous 
solution. NMF was devoid of any particulate matter. The prepared NMF needs to 
be maintained in the physiological range for osmolarity and pH. In general, to adjust 
tonicity; agents such as glucose, xylitol, glycerol, boric acid or sodium chloride is 
added. Tears have the tonicity equivalent to 0.9% solution of sodium chloride 
which produces osmolarity of ~305 mOsm/kg. Hypertonicity or hypotonicity of the 
topical drops may cause irritation to the eye. The pH of the eye ranges from 6.5 – 
7.6. Therefore, osmolarity and pH was maintained at ~ 300 mOsm/Kg and ~7.0, 
respectively. NMF produced much higher drug entrapment (> 95%) and loading 
efficiencies (8.85%). This NMF demonstrated a small particle size ranging between 
10 nm to ~80 nm. This data is also in agreement with real time TEM images. NMF 
after resuspending in phosphate buffer saline produced viscosity similar to that of 
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water (0.9 centipoise (cP)). Topical dosing results in immediate loss of drug due to 
tear drainage, spill on the cheeks, or by drainage through nasolacrimal duct (14). 
One method to improve viscosity is with addition of viscosity enhancer. Therefore 
NMF's (placebo and CsA loaded) contained viscosity enhancing agent, povidone 
K90. We selected povidone K-90 because povidone K90 imparts viscosity and 
bioadhesion to NMF (194). The dual nature of povidone K-90, viscosity 
improvement and bioadhesive property, may aid the formulation to improve 
viscosity and keep NMF in contact with pre-corneal pocket for longer time period. 
The surface potential for the formulations is slightly negative. This negligible 
charge may help to reduce repulsion of NMF with negative cell surface. Further, 
dilution studies of NMF were conducted to determine the stability of nanomicelles. 
In general, tears are produced at an average flow rate of 1.2 µL/min (14). An 
excessive tear production following NMF instillation should not cause NMF 
dissociation and drug release. Therefore, we examined the dilution effect on 
nanomicellar size and PDI up to 500 times (way above tear dilution that is expected 
in vivo). Dilution of NMF caused very small increase in mean micelle size. 
Similarly, PDI of NMF was slightly higher with dilution (up to 500x). The reason 
may be attributed to change in concentration of monomers in the NMF with 
dilution. The results obtained are similar and in agreement to the earlier results 
observed by Xu, et al. (288). Upon nanomicelle dilution, the outer hydrophilic 
polyethylene oxide segment may form large and loose complex clusters in aqueous 
solution. These new larger aggregates that are developed with dilution exhibit 
thermodynamically reversible association. Hydrophobic effect and hydrogen 
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bonding may be forcing the outer hydrophilic segment to cluster and form larger 
aggregates in aqueous solution. The clustering of outer hydrophilic segment may 
be the reason for increase in micelle size upon dilution. However, NMF sustained 
the dilution effect up to 500 times and produced negligible effect on their size and 
demonstrated high stability upon dilution.  Thermal dissociation and regeneration 
time of NMFs suggest a fairly robust formulation. The results may help to select a 
formulation with a high thermal dissociation temperature. Following thermal 
dissociation when NMFs is allowed to cool to room temperature under ambient 
conditions, nanomicelles regenerated within minutes resulting in optically clear 
solution. In general nanomicelles are unstable structures possessing two 
characteristic relaxation times i.e., fast (τ1) and slow (τ2). The results suggest that 
time taken to regenerate the nanomicelles is in minutes, because both polymers are 
non-ionic in nature and display longer nanomicellar relaxation times (τ2). This 
peculiar behavior of the formulation indicates that hydrophobic CsA is entrapped 
in the nanomicellar core even after being subjected to harsh conditions. 
 CsA has poor aqueous solubility of 12 ng/mL at room temperature (25 °C) 
(269).  There is a possibility that a small amount/concentration of CsA, due to its 
aqueous solubility, may be present in the outer aqueous solution of NMF. We 
conducted qualitative proton nuclear magnetic resonance (1H-NMR) studies that 
may determine the presence of free/unentrapped CsA molecules in solution at parts 
per million (ppm) levels. Formulations were prepared in different media such as 
CDCl3 and D2O. 
1H NMR spectroscopy studies were conducted for CsA, mixture 
of HCO-40/OC40 in CDCl3 and NMF with entrapped CsA in CDCl3 and D2O. 
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Excessive addition of CsA above its aqueous solubility results in drug precipitation. 
In NMF we did not observe any CsA precipitation indicating drug entrapment in 
NMF, at a level higher than its aqueous solubility. On the other hand, results show 
that in CDCl3, the resonance peaks corresponding to CsA and nanomicelles are 
present as evidenced from the spectra. However, in D2O peaks corresponding to 
nanomicelles are only detected whereas peaks for CsA were not evident (Figure 
18). These results clearly indicate that CsA is entrapped in the inner hydrophobic 
core of nanomicelles in D2O. Suspended nanomicelles when dried and resuspended 
in CDCl3, resonance peaks corresponding to CsA were evident and the spectra was 
similar to Figure 17.  These results indicate that the nanomicelles entrapped CsA 
in the inner core and when subjected to organic solvent as outer environment NMF 
reversed and released CsA. Therefore, 1H-NMR identified peaks corresponding to 
CsA in CDCl3.  However, in aqueous solvent (D2O) NMF entrapped CsA inside the 
core and the nuclear magnetic resonance signals are lost. In vitro stability studies 
for 0.1% NMF at three different temperatures (4 °C, 25 °C and 40 °C) at 60% and 
75% RH (Table 9) indicated that the CsA loaded NMF were highly stable and 
retained their original characteristics. There was no significant change in NMF size, 
polydispersity index (Table 9) and most importantly CsA concentration remained 
>90% after one month of exposure to 40 °C. The NMF formulation did not show 
any drug precipitation at the bottom of the vial. The formulation was clear, 
transparent and was comparable to that of DI water. 
 An important aspect of topical ocular drug delivery is to evaluate drug 
delivery vehicles for biocompatibility. Formulation components are expected to be 
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safe, reliable, and effective for its intended use. Also, these components are to be 
biodegradable and biocompatible. In vitro toxicity evaluation and ocular tissue drug 
distribution are the primary requirements to determine the safety of the carrier 
systems and their ability to deliver therapeutic drug levels to ocular tissues. In vitro 
toxicity tests are often conducted in cells. Therefore, selection of a cell line is 
crucially important because it should reproduce any toxic response that is similar 
to what occurs in vivo (289, 290). Therefore, we selected rPCEC and D407 as in 
vitro cell culture models to study the toxicity of CsA NMF. 
To evaluate the cytotoxic effect of NMFs (blank and CsA loaded), cell 
proliferation (rPCEC and D407) and LDH assays (rPCEC) were performed. Since 
eye drops are rapidly cleared from the pre-corneal pocket (291, 292) cell 
proliferation assay was performed for 1h. It was assumed that a 1 h incubation 
period would be sufficient to evaluate any toxicity. In the first set of experiments 
(cell viability assay), percent viable cells in NMFs was comparable to that of 
negative control (culture medium) (Figure 19). Triton-X 100 served as positive 
control and reduced the percent cell viability to ~25% of the total cell number 
(rPCEC and D407). In another set of studies, cell plasma membrane damage test 
(LDH assay) was conducted. A two hour incubation time is sufficient because these 
formulations are to be delivered as topical eye drops into the pre-corneal pocket. 
After topical drop instillation most of the formulation is lost within minutes (286). 
In these experiments, the amount of LDH released in the culture media directly 
correlates with cytotoxicity. Triton-X 100 caused significant toxicity/membrane 
damage and released high amounts of LDH. Percentage cytotoxicity to rPCEC cells 
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with exposure to NMF (blank and CsA loaded) appeared to be negligible (Figure 
20). Even 2 h continuous exposure, the formulations did not cause any cell 
membrane damage.  Results from these assays clearly suggest that NMFs does not 
cause cell death and/or damage to plasma membrane. NMF appears to be safe for 
topical ocular application. Therefore, in vivo studies with 0.1% CsA loaded NMF 
and placebo were conducted, where BSS served as negative control.   
 In vivo studies conducted in female New Zealand rabbits with single and 
multiple dosing (4 x / day, at an interval of 2 h, consecutively for five days) showed 
very high CsA levels in anterior ocular tissues. Whole blood concentrations of CsA 
were measurable (albeit at very low levels) in rabbits that received the 0.1% CsA 
NMF single and multiple doses for 5 days (Table 10 A and B).  The mean CsA 
whole blood concentration (0.718 ng/mL) in this study was similar to the Cmax 
(0.745 ng-eq/mL) value reported following single dose administration of an 
Allergan 0.2% 3H-CsA formulation in NZW albino rabbits (293). Anterior ocular 
CsA concentrations in the present study are higher than values reported following 
topical drop administration of CsA loaded MPEG-hexPLA copolymer micelles 
(294).  High CsA concentrations were delivered in aqueous humor, iris-ciliary body 
when compared to MPEG-hexPLA micelles indicating the better carrier ability of 
NMF. Considering that only a single time point (1 hour after the last dose) was 
sampled for analysis, the data were remarkably consistent between the two treated 
animals.  For instance, the CsA concentrations observed in the cornea were 8130 
ng/g and 7480 ng/g (Table 10B). The ocular tissue concentrations of CsA observed 
in this study were similar to or higher than those observed following repeat dose 
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administration (bid for 7 days) of an Allergan 0.2% 3H-CsA formulation to rabbits 
(293). From Table 10 A and B, it is evident that CsA loaded NMF is able to safely 
deliver high CsA concentrations in anterior and posterior ocular tissues.   
 Instillation of topical eye drops is the most preferred and convenient route 
of drug administration resulting in higher patient compliance. This novel CsA 
formulation was able to translocate across cornea and deliver high levels in the 
anterior ocular tissues. Interestingly, we also found high drug levels in the back-of-
the-eye tissues (retina-choroid) with CsA aqueous topical drops. There are two 
potential pathways for a molecule to reach the back-of-the-eye, following topical 
administration: (i) intraocular route, through cornea  aqueous humor  lens  
vitreous humor and finally  retina and (ii) trans-scleral or conjunctival-scleral 
route around the conjunctiva through sclerachoroid and to retina (295).  The first 
pathway is often unsuccessful for hydrophobic molecules such as CsA with high 
hydrophobicity, since the hydrophilic stroma becomes the rate limiting barrier for 
transcorneal absorption (296). Moreover, fluids in the anterior and posterior 
segments flow in opposite directions hindering the passage of molecules from the 
aqueous humor to lens and through to the vitreous humor, thus making this an 
unfavorable pathway. The second pathway offers a viable strategy to reach the 
back-of-the-eye for hydrophilic molecules by passive diffusion through the scleral 
aqueous channels/pores. But again, CsA being highly hydrophobic drug will 
encounter aqueous sclera as a potential barrier for permeation through the 
conjunctival-scleral route. CsA hydrophobicity limits the feasibility of formulating 
it into a clear aqueous solution at sufficient concentration to achieve therapeutic 
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levels in the ocular tissues. Hence, CsA is currently marketed as ophthalmic 
emulsion (Restasis®), which on chronic use may cause side effects 
(http://www.restasis.com/ accessed on 12/28/2013). For CsA to reach the back-of-
the-eye following topical administration, it is imperative to utilize the aqueous 
channels/pores of sclera (Figure 25). Hence, highly hydrophobic CsA when 
entrapped inside nanomicelle with a hydrophilic exterior/corona resulting in highly 
hydrophilic outer corona. The scleral aqueous pore size ranges between 20 and 80 
nm (63). Our CsA loaded NMF's have small size (10 nm  – 80 nm) with hydrophilic 
corona. We hypothesize that these nanomicelles utilize the hydrophilic corona and 
carry the CsA payload to the back-of-the-eye tissues following conjunctival scleral 
pathway. Also, ocular tissue CsA concentrations (conjunctiva > sclera > retina-
choroid) support our hypothesis of conjunctival-scleral route for CsA delivery.  
Moreover, these CsA nanomicelles upon reaching back-of-the-eye tissues such as 
Bruch’s membrane, RPE, choroid and retinal (Figure 25) may release CsA cargo 
by nanomicellar reversal as shown in Figure 26. The lipid bilayer of RPE and 
Bruch’s membrane may aid in lipid-lipid interactions of nanomicellar core and lipid 
bilayer causing CsA release into the cells. Further, CsA permeation into the 
hydrophilic or aqueous vitreous humor is prevented because of the hydrophobic 
nature of CsA, where it gets deposited into the highly lipophilic tissues (RPE, 
Retina).   
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Figure 25. Hypothetical representation of cyclosporine A (CsA) loaded nanomicelles reaching back-of-the-eye (retina-choroid) 
following conjunctival scleral pathway after topical drop administration.  
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Figure 26. (A) Cyclosporine loaded nanomicelles composed of hydrogenated castor oil-40 and octoxynol-40 (Oc-40), (B) partial 
reversal of cyclosporine loaded nanomicelles. (C) complete reversal of nanomicelles and cyclosporine release upon contacting 
lipoidal ocular tissues.  
(A) (B) (C)
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Conclusion 
 
In summary, an aqueous, clear nanomicellar CsA loaded formulation was 
successfully prepared and optimized with a blend of HCO-40/Oc-40 polymers. In 
vitro results indicate that these formulations are safe and well-tolerated. In vivo 
studies with topical drop application of BSS, placebo and 0.1% CsA loaded NMF 
showed very high CsA levels in anterior ocular tissues. Also, CsA concentrations 
in the back-of-the-eye tissues (retina-choroid) was much higher than the therapeutic 
level suggesting that NMF following the conjunctival-scleral pathway to reach 
retina-choroid.  After application of 0.05% and 0.1% CsA nanomicellar 
formulation or Restasis (0.05% CsA), the concentration in tears and eyelids is very 
high and very variable, suggesting wash out from the ocular surface. After ocular 
administration of Restasis (0.05% CsA), 0.05% CsA in nanomicellar formulation, 
and 0.1% CsA in nanomicellar formulation 4 times daily at 2-hour intervals for 7 
days, CsA exposures were highest after administration of 0.1% CsA in 
nanomicellar formulation followed by 0.05% CsA in nanomicellar formulation, 
with Restasis (0.05% CsA) having the lowest concentrations in the conjunctiva, 
cornea, aqueous humor, iris-ciliary body, sclera, retina-choroid, lens, and tears.In 
vitreous humor, exposures were low but comparable after administration of both 
nanomicellar formulations and greater than those after administration of 
Restasis.Exposures were reasonably comparable among all three CsA treatments 
for the eyelid. For the lacrimal gland, exposure after administration of Restasis® 
was low but higher than for either nanomicellar formulation. Systemic exposure, as 
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measured by whole blood concentrations, was substantially lower than exposure in 
ocular tissues. Maximum concentrations were less than 1 ng/mL after single 
applications and less than 2 ng/mL after application of 4 doses per day at 2-hour 
intervals for 7 days. Although exposures in ocular tissues were lower after single 
doses compared to repeat doses, in general, the rank orders of exposure among 
Restasis® (0.05% CsA), 0.05% CsA in nanomicellar formulation, and 0.1% CsA 
in nanomicellar formulation were comparable to those observed after repeat dosing. 
A blend of HCO-40 and Oc-40 are safe carrier to deliver drugs to anterior and back-
of-the-eye tissues in therapeutic concentrations with aqueous topical drop 
instillation. 
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Chapter 4 
TOPICAL AQUEOUS CLEAR RESOLVIN E1 ANALOG (RX-10045) 
NANOMICELLAR FORMULATION 
PART A: INTERACTION STUDIES OF RESOLVIN E1 ANALOG WITH 
EFFLUX TRANSPORTERS  
Rationale 
 
Resolvins are small endogenous mediator molecules that are enzymatically 
biosynthesized from omega-3 polyunsaturated fatty acids i.e., eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA) (297). Other methods of biosynthesis 
include aspirin triggered and/or non-aspirin dependent pathways (298). 
Cyclooxygenase-2 (COX-2) dependent reactions in the presence of aspirin and 
microbial P450-initiated pathways are reported to facilitate production of resolvins 
(298). These compounds belong to a family of potent lipid mediators that causes 
reversal of the inflammatory response back to a non-inflamed state (299). 
Biosynthesized resolvins act by shielding tissues from leukocyte mediated injuries; 
dampen leukocyte response/trafficking to the site of inflammation and counter 
regulating proinflammatory gene expressions, thus reducing tissue inflammation 
(298). Resolvins are currently being studied to ameliorate the ocular pathological 
conditions such as dry eye (300), retinal diseases (301) and uveitis (302). This class 
of drugs opens up an entirely novel approach to treat inflammatory ocular 
conditions. RX-10045 (Resolvyx) Figure 27 is a synthetic active pharmaceutical 
ingredient and an analog/derivative of naturally occurring resolvin E1(RvE1). 
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Figure 27. Structure of RX-10045 (resolvin E1 analog). 
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In vitro studies demonstrated a potent anti-inflammatory and cell survival benefits 
with RX-10045 (303). This novel molecule is highly effective against dry eye and 
goblet cell loss thereby accelerating tear production. Also, this compound can 
reduce corneal inflammation, epithelial damage and accelerate corneal tissue 
repair. In addition, RX-10045 can inhibit the release of several key pro-
inflammatory mediators from corneal epithelial cells (304). This drug is originally 
formulated as an aqueous solution using propylene glycol as a solubilizing agent 
and tested for the treatment of dry eye with topical drop application. The drug was 
shown to be highly efficacious in murine models of dry eye syndrome. However, 
in Phase II clinical trials, RX-10045, though safe and well tolerated, produced 
equivocal efficacy results (303). A possible explanation is that, disposition across 
the human cornea and conjunctiva may be limited due to efflux transporters 
expressed on the ocular surface and poor aqueous solubility and stability. 
Therefore, the study was initiated to determine the interaction of RX-10045 with 
efflux transporters expressed on the ocular surface, improve drug stability and 
delivery. Therefore, the objectives of this study are (A) to assess the affinity of RX-
10045 towards efflux transporters in polarized Madin-Darby canine kidney cells 
i.e., MDCKII-MDR1, MDCKII-MRP2 and MDCKII-BCRP and (B) development 
and optimization of RX-10045 nanomicellar formulation to improve drug 
solubility, stability and permeation across ocular tissues. 
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Materials and Methods 
 
RX-10045 was prepared by PPD (Middleton, WI,, USA; lot# SYN-72799-
05-11). GF and ketoconazole, a P-glycoprotein (P-gp) inhibitor, were acquired 
from Sigma Chemical Co, St. Louis, MO, USA.  MK571, a specific inhibitor of 
MRP was obtained from Biomol International (Plymouth Meeting, PA). 
GF120918, a BCRP inhibitor was a generous gift from GlaxoSmithKline Ltd. Beta 
estradiol was purchased from Sigma-Aldrich, USA. [3H] Digoxin (specific activity 
35.4 Ci/mMol) was obtained from PerkinElmer Life and Analytical Sciences 
(Boston, MA), [3H]Abacavir (specific activity 0.2 Ci/mMol) and [3H]Vinblastine 
(specific activity 3.6 Ci/mmol) were obtained from Moravek chemical company, 
USA. [3H] Digoxin, [3H] Abacavir, and [3H] vinblastine were used at 0.5 µCi/mL, 
0.5 µCi/mL and 0.25 µCi/mL, respectively. Stock solution of the RX-10045 (1 
mg/mL) was freshly prepared before an experiment. Briefly, RX-10045 (1 mg) was 
accurately measured and dissolved in 50 µL dimethyl sulfoxide (DMSO) (Thermo 
Scientific, Rockford, IL, USA) and the volume was made up with distilled 
deionized water. Further, aliquots of this stock solution were diluted in Dulbecco’s 
phosphate-buffered saline (DPBS, composition: 130 mM NaCl, 7.5 mM Na2HPO4, 
1.5 mM KH2PO4, 0.5 mM MgSO4, 1 mM CaCl2, 0.03 mM KCl and 5 mM glucose 
and pH 7.4) to achieve desired concentrations. Stock solutions of ketoconazole (10 
mg/mL), GF120918 (1 mg/mL), beta-estradiol (1 mg/mL) and MK571 (25 mg/mL) 
were prepared in DMSO and aliquots were diluted in DPBS to achieve the desired 
concentration. Culture flasks (75 cm2 growth area) were procured from MidSci (St. 
Louis, MO). Twelve well culture plates were purchased from Midwest Scientific, 
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St. Louis, MO. Twelve well transwell plates (Corning Incorporated, Corning, NY) 
with an insert membrane growth area of 1 cm2 were selected for transport studies. 
 
Cell Culture 
 
Madin-Darby canine kidney (MDCK) cells transfected with the human 
MDR1 gene (MDCKII-MDR1), human MRP2 gene (MDCKII-MRP2), and human 
BCRP gene (MDCKII-BCRP) were generously provided by Drs. A. Schinkel and 
P. Borst (The Netherlands Cancer Institute, Amsterdam, Netherlands). Dulbecco’s 
Modified Eagle’s medium (DMEM) was procured from Caisson Laboratories Inc, 
UT. Tryple Express, nonessential amino acids, and fetal bovine serum were 
procured from Invitrogen (Carlsbad, CA). Penicillin, streptomycin, sodium 
bicarbonate, lactalbumin, HEPES, amphotericin B, and polymyxin B sulfate were 
supplied by Sigma-Aldrich. MDCKII-MDR1, MDCKII-MRP2 and MDCKII-
BCRP cells were cultured as described previously (282). Cells were maintained in 
DMEM supplemented with 10% calf serum, 100 IU/mL penicillin, 100 mg/mL 
streptomycin and 20 mmol/L HEPES, pH 7.4. Cells were plated at a density of 
250000/cm2 in 12-well tissue culture treated plastic plates. Cells were incubated at 
37o C in an atmosphere of 5% CO2 and 95% humidity in air and were allowed to 
grow for 5 - 8 days. Similarly, human corneal epithelial (HCEC) cell line was 
procured as a generous gift from Dr. Araki-Sasaki (Kinki Central Hospital, Japan). 
HCEC cells are SV-40 virus transfected human immortalized corneal cells. These 
cell were cultured and maintained as reported previously [18]. HCEC was cultured 
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in DMEM/F-12 media supplemented with 15% FBS (heat inactivated), penicillin 
and streptomycin, 22 mM sodium bicarbonate, 15 mM HEPES, 10 ng/mL of human 
epidermal growth factor and 5mg/mL insulin. The cells were grown at 37 °C in a 
cell culture incubator, which maintained 5% CO2 and 90% relative humidity. 
 
Uptake Experiments 
 
Uptake studies were conducted according to previously published protocols 
(305). Briefly, cells (MDCKII-MDR1, MDCKII-MRP2, MDCKII-BCRP, and 
HCEC) were seeded in twelve well plate. After 5-7 days of seeding, the medium 
was aspirated and cells were rinsed three times with DPBS and then equilibrated 
with DPBS for 30 mins at 37 oC. Initial screening for uptake studies were conducted 
across MDCKII-MDR1, MDCKII-BCRP and MDCKII-MRP2 cells with a known 
concentration of RX-10045 (50 µM to 600 µM) solution containing [3H] Digoxin 
(0.5 µCi/mL) for P-gp, [3H] Abacavir (0.5 µCi/mL) for BCRP and [3H] Vinblastine 
(0.25 µCi/mL) for MRP2. In these studies, efflux pump inhibitors such as 
GF120918 and ketoconazole for P-gp; beta-estradiol for BCRP and MK571 for 
MRP2 were selected. Cells were treated with drug solution. The experiment was 
conducted at 37 oC for 30 mins. At the end of an experiment, drug solution was 
aspirated. To terminate the uptake process, cells were rinsed three times with ice-
cold stop solution (210 mM KCl, 20 mM HEPES [pH 7.4]). To determine the drug 
content, cell lysis was performed by adding 1 mL of lysis solution (0.3 M NaOH, 
0.1% Triton X-100). Cells were left undisturbed overnight at room temperature. 
 165 
 
Samples (500 µL) were transferred to scintillation vials containing 3 mL 
scintillation cocktail. The solutions were mixed and radioactivity was measured 
with a scintillation counter (Model LS 6500; Beckman Instruments Inc., Fullerton, 
CA). To normalize the uptake data cell protein content was measured by Bradford 
assay. A protein calibration curve was prepared with bovine serum albumin as 
standard and was used to determine the protein content in the samples. The amount 
of radioactive substrate accumulated inside the cell was determined using the 
following equation: 
Flux = dM/dT       or     V = Vmax [C]    + Kd[C]                           
    A                           Km + [C]                                                                 Eq 5 
 
Concentrations of donor and samples are represented as Csample and Cdonor. As 
represented in Eq.5, V is the total rate of uptake, Vmax is the maximum uptake for 
carrier mediated process, Kd is the rate constant and Km is the concentration at half 
saturation. 
 Following a similar procedure, dose dependent inhibition studies were 
performed. [3H]-Digoxin, [3H] Abacavir and [3H] Vinblastine were spiked with 
various concentrations of RX-10045 ranging from 25 µM to 800 µM. Studies were 
performed as described before and data was obtained to determine the half maximal 
inhibitory concentration (IC50) according to a previously published method (306, 
307). IC50 was calculated according to Eq. 6. 
 
Y = min   +       (max-min)                                                 
          1+ 10(Log IC50
-X)H                     Eq. 6 
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Y represents cellular accumulation of radioactive substrate, X denotes the 
logarithm of the RX-10045 concentration. Data was fitted to Eq. 6 with a 
transformed non-linear regression analysis program (Graphpad Prism version 4.0, 
San Diego, CA) to calculate IC50. H is the Hill constant. 
 
Permeability Studies 
 
Transport studies were performed on MDCKII-MDR1, MDCKII-MRP2 
and MDCKII-BCRP cells grown on transwell inserts. Cells were seeded on 
transwells at a density of 3 million cells/plate and allowed to grow for 5-7 days. 
Each day culture medium was removed and replaced with fresh medium. Apparent 
drug permeability from apical to basolateral (AP-BL) and vice versa (BL-AP) was 
examined indirectly by calculating the amount of radioactive substrate ([3H] 
Digoxin for MDCKII-MDR1, [3H] Abacavir for MDCKII-BCRP and [3H] 
Vinblastine for MDCKII-MRP2) transported into the receiver chamber. The donor 
chamber contained test solution whereas the receiver chamber contained DPBS. 
The concentration of RX-10045 to be employed for permeability studies were 
identified and selected from the earlier dose dependent inhibition (IC50 value) 
studies. At predetermined time points (0, 15, 30, 45, 60, 90, 120, 150, and 180 
mins), samples were withdrawn from the receiver chamber and was replaced with 
same volumes of DPBS to maintain sink condition. Further, the concentration of 
radioactive substrates transported across cell monolayer was determined by 
measuring radioactivity as described earlier. To determine apparent permeability 
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and efflux ratio, cumulative amount of radioactive substrate transported was plotted 
with time according to Eqs 7 – 9. 
J = (dM/dt)/A                      Eq. 7 
J represents flux; (dM/dt) represents amount of radioactive substrate transported 
across the cell monolayer over a specific interval of time and A represents the cross 
section area of transwell. 
P = J/Cdonor                      Eq. 8  
P represents apparent radioactive permeability and Cdonor represents concentration 
of radioactive substrate in the donor chamber 
Efflux ratio = P (BL-AP) / P(AP-BL)                    Eq. 9 
Drug efflux ratio may be calculated by the ratio of apparent permeability from BL 
to AP and AP to BL directions. 
 
Cytotoxicity Studies 
 
To evaluate the cytotoxicity of RX-10045, cell titer 96® aqueous non-
radioactive Cell Proliferation Assay Kit (Promega, Madison, WI) was utilized. In 
vitro cytotoxicity assays were conducted across MDCKII-MDR1, MDCKII-BCRP, 
MDCKII-MRP2, HCEC and human retinal pigment epithelial (D407) cells. In 
brief, cells were seeded at a density of 10,000 cells per well in 96 well plate. Since 
the permeability studies were conducted for 3 h, cells were treated with 100 µL of 
freshly prepared RX-10045 solutions and exposed for 3 h Cells treated with culture 
medium (containing no drug) served as negative control. Ten percent Triton-X100 
served as positive control. After 3 h incubation, 20 µL of aqueous MTS and PMS 
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reagent (prepared following manufacture’s protocol) were added to each well. The 
mixture was further incubated for 2.5h allowing tetrazolium compound ([3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl-2-(4-sulfophenyl)-2H-tetrazol-
ium, inner salt; MTS] and an electron coupling phenazine methosulfate (PMS)) 
reaction to take place. The amount of formazan formed was measured with a 96-
well micro titer plate reader (SpectraFluor Plus, Tecan, Maennedorf, Switzerland). 
Absorbance is measured at 490 nm which is directly proportional to the number of 
living cells in culture. 
 
Statistical Analysis 
 
All experiments were conducted at least in triplicate and results are 
expressed as mean ± S.D. For IC50, data are expressed as the mean ± S.E.M 
difference between mean values was considered significant at p ≤ 0.05. Fisher least-
significance difference method was applied to discriminate among the means. 
Results 
 
 
Uptake Studies 
 
Uptake of [3H] Digoxin was conducted in MDCKII-MDR1 cells in the 
presence of GF120918, and ketoconazole, P-gp inhibitors. Intracellular 
accumulation of [3H] Digoxin in MDCKII-MDR1 cells in presence of GF120918 
and ketoconazole was higher by 1.25 and 1.47 times, respectively. We conducted 
initial screening uptake experiments for RX-10045 from 50 µM to 600 µM in 
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MDCK cells transfected with MDR1, MRP and BCRP genes. Since RX-10045 at 
lower concentrations did not inhibit any substrates of efflux transporter the 
concentration was increased upto 600 µM, to determine if there is any interaction 
occurs. In presence of RX-10045 (300 µM) [3H] digoxin accumulation was ~2 
times higher than the control ([3H] digoxin) (Figure 28). Following similar protocol 
uptake of [3H]-vinblastine was performed on MDCKII-MRP2 cells. Cellular 
accumulation of [3H] vinblastine in presence of MK571 was increased by ~1.28 
time. RX-10045 (400 µM) also elevated the uptake of [3H] vinblastine to 1.31 times 
relative to control (Figure 29). In another set of experiments, similar results were 
observed in MDCKII-BCRP cells. Cellular accumulation of [3H] abacavir 
increased by 1.77 fold in the presence of estradial-β (25 µM) and 1.62 fold in the 
presence of RX-10045 (300 µM) (Figure 30). These results indicate that 
intracellular accumulation of efflux transporter substrates increased significantly in 
the presence of RX-10045 relative to control. 
Similarly, uptake studies were conducted in HCEC cells in the presence of 
MDCKII-MDR1, MDCKII-BCRP and MDCKII-MRP inhibitors. Results 
demonstrated that there was no significant difference in digoxin uptake in the 
presence of RX-10045.  Uptake of [3H] vinblastine was significantly enhanced by 
3.43 times in the presence of RX-10045 relative to [3H] vinblastine alone. However, 
uptake of [3H] abacavir was inhibited in the presence of RX-10045. Cellular 
accumulation of [3H] abacavir was 3.4 times lower than the control.   
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Figure 28. Uptake of [3H] digoxin in presence of inhibitors (GF120918 and Ketoconazole) and increasing concentrations of RX-
10045 on MDCKII-MDR1 cells, [3H] Digoxin served as control. Data are shown as mean ± S.E.M (n = 4). *p < 0.05 versus control 
(paired t-test). 
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Figure 29. Uptake of [3H] Vinblastine in presence of inhibitor (MK571) and increasing concentrations of RX-10045 on MDCKII-
MRP2 cells, [3H] Vinblastine served as control. Data are shown as mean ± S.E.M (n = 4). *p < 0.05 versus control (paired t-test). 
  
1
7
2
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Uptake of [3H] abacavir in presence of inhibitor (estrogen) and increasing concentrations of RX-10045 on MDCKII-
BCRP cells, [3H] abacavir served as control. Data are shown as mean ± S.E.M (n = 4). *p < 0.05 versus control (paired t-test). 
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Dose dependent inhibition studies 
 
Half-maximal inhibitory concentrations of RX-10045 were calculated by 
indirect method using different efflux transporters substrates such as [3H] digoxin 
for MDCKII-MDR1, [3H] vinblastine for MDCKII-MRP2, and [3H] abacavir for 
MDCKII-BCRP.  IC50 values for RX-10045 were calculated to be 239 ± 11.2 µM 
in MDCKII-MDR1, 291 ± 79.2 µM on MDCKII-MRP2, and 300 ± 42 µM in 
MDCKII-BCRP from dose response curves, respectively. Figure 31 shows half 
maximal inhibitory concentration in MDCKII-BCRP cells. For further studies such 
as permeability and cytotoxicity studies, half-maximal inhibitory concentrations 
were selected and used. 
 
Permeability studies 
 
Transport experiments were conducted across three (MDCKII-MDR1, 
MDCKII-MRP2 and MDCKII-BCRP) cell lines in both AP-BL and BL-AP 
direction.  These cells express efflux transporters on the apical side only. Apparent 
permeability of [3H] digoxin in AP-BL direction was not statistically significant in 
presence of RX-10045 relative to control [3H] digoxin 5.77 ± 0.379 x 10-6 cm/min. 
Similarly, transport of [3H] vinblastine across MDCKII-MRP2 cells was assessed 
in both AP-BL and BL-AP directions. Similar permeability values were observed 
as in earlier experiment. Apparent permeability from AP-BL direction for [3H] 
vinblastine rises in the presence of MK571 (1.66 times) and in the presence of RX-
10045 (2.53 times) whereas, apparent apical to basal permeability of control [3H] 
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Figure 31. Half maximal inhibitory concentration (IC50) for RX-10045 on MDCKII-BCRP cells. Data are shown as mean ± S.D 
(n = 4). 
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vinblastine was calculated to be 0.093 x 10-6 ± 0.79 cm/s (Figure 32) and vice versa 
and vice versa was 0.440 x 10-6 ± 0.0827 (Figure 33). In another set of experiments, 
transport of [3H] abacavir across MDCKII-BCRP cells was assessed in both AP-
BL and BL-AP directions. Apparent AP-BL permeability of [3H] abacavir in 
presence of estradiol (inhibitor) and RX-10045 was enhanced by 2.36 time and 2.42 
time, respectively. Apparent permeability of [3H] abacavir control was calculated 
to be 3.29 ± 1.26 x 10-6 cm/s. Cumulative transports of [3H] digoxin, [3H] 
vinblastine and [3H] abacavir in BL-AP direction in the presence of inhibitor or 
RX-10045 did not show significant difference.  
 
Cytotoxicity Studies 
 
Cytotoxicity of RX-10045 was evaluated in five cell lines (MDCKII-
MDR1, MDCKII-MRP2, MDCKII-BCRP, HCEC and D407) over 3h with 
different concentrations of RX-10045 ranging from 1 µM to 350 µM. We 
conducted initial screening uptake experiments from 50 µM to 600 µM in MDCK 
cells transfected with MDR1, MRP and BCRP genes. Since RX-10045 at lower 
concentrations did not inhibit any substrate of efflux transporter we increased the 
concentration up to 600 µM to determine if there is any interaction occurs. 
However, uptake studies of RX-10045 were conducted at less than 350 µM 
concentration. Moreover, the IC50 value of RX-10045 for all the cell lines was 
found to be less than 350 µM. Therefore, we conducted cytotoxicity studies up to 
350 µM.  Cells (MDCK-MDR1, MDCKMRP2, MDCK-BCRP, HCEC and D407) 
were examined for their viability following manufacturer’s protocol. Cells were 
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added with a dye solution containing MTS. Metabolically active cells in presence 
of dehydrogenase enzymes reduce MTS to a soluble formazan product. The amount 
of formazan formed is directly proportional to the number of live cells in culture. 
Percent cell viability was observed to be the same relative to positive control 
(culture medium without drug). Concentration range in the current study for RX-
10045 appeared to have no effect on cell viability. In this study, 10% Triton-X 100 
served as a positive control which significantly reduced cell viability (Figure 34 - 
Figure 35). 
Discussion 
 
RX-10045 is a resolvin E1 analog evaluated for the treatment of dry eye, 
ocular inflammation and ocular fibrosis. Interactions of resolvins with efflux 
transporters have not been previously investigated. This study therefore examined  
interactions between RX-10045 and efflux transporters P-gp, MRP2 and BCRP, 
whose expression and functional activity on corneal epithelium was previously 
reported (308-312). To evaluate drug interactions, MDCKII cell lines that are 
transfected with MDR1, MRP2 and BCRP human genes were selected for the 
current study. The rationale behind using MDCKII transfected cell lines which 
overexpress efflux transporters P-gp, MRP and BCRP was to delineate individual 
efflux transporter mediated interactions. These cell lines help in identification of 
the individual role of efflux transporters in reducing intracellular drug 
concentrations and permeability. Moreover results may help to modulate ocular  
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Figure 32. Apical to basal apparent permeability of [3H] Vinblastine in presence of inhibitor (MK571) and RX-10045 with [3H] 
Vinblastine alone as control. Data are shown as mean ± S.D (n = 4). *p < 0.05 versus control (paired t-test). 
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Figure 33. Basal to Apical apparent permeability of [3H] Vinblastine in presence of inhibitor (MK571) and RX-10045 with [3H] 
Vinblastine alone as control. Data are shown as mean ± S.D (n = 4). *p < 0.05 versus control (paired t-test). 
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Figure 34. Cell viability studies with increasing concentrations of RX-10045. Cell culture medium served as positive control and 
Triton X-100 served as negative control. A p value of < 0.05 is considered significant.  Data are shown as mean ± S.E.M (standard 
error of mean) (n = 8). *p < 0.05 versus control (paired t-test). 
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Figure 35. Cell viability studies with increasing concentrations of RX-10045 on D407 cells. Cell culture medium served as positive 
control and Triton X-100 served as negative control. A p value of < 0.05 is considered significant. Data are shown as mean ± S.E.M 
(standard error of mean) (n = 8). *p < 0.05 versus control (paired t-test).  
RX-10045 (µM) 
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drug delivery strategies for delivery of therapeutic amounts of RX-10045 to ocular 
tissues.  Intracellular accumulation of [3H] digoxin was significantly elevated in 
presence of P-gp inhibitors (GF 120918 and ketoconazole) and RX-10045 relative 
to [3H] digoxin only (309, 313, 314). This result indicates that RX-10045 may 
interact with P-gp similar to other P-gp inhibitors. This interaction results in higher 
cellular accumulation of [3H] digoxin. This observation suggests that RX-10045 
may be a substrate for P-gp. In another set of experiments conducted on MDCKII–
MRP2 cells with [3H] vinblastine revealed higher accumulation in cells treated with 
inhibitor (MK571) and RX-10045. This suggests that RX-10045 may also interact 
with MRP2 as competitive inhibitor, resulting in higher [3H] vinblastine uptake. 
Similarly, we conducted studies with MDCKII–BCRP cells with [3H] abacavir. 
Higher accumulation of [3H] abacavir in the presence of beta-estradiol and RX-
10045 was observed relative to control suggesting that this resolvin analog may be 
a substrate or inhibitor of BCRP. A significant rise in [3H] digoxin, [3H] vinblastine 
and [3H] abacavir uptake in the presence of GF120918, ketoconazole, MK571 and 
beta-estradiol indicates that P-gp, MRP2 and BCRP are highly expressed on 
MDCKII transfected cells and are functionally active. These results are consistent 
with our earlier results (307, 312, 315). Uptake experiments indicate that RX-10045 
may be a substrate or inhibitor for all three efflux transporters (P-gp, MRP2 and 
BCRP). Dose dependent inhibition (IC50) in uptake studies suggest affinity of RX-
10045 towards P-gp, BCRP and MRP2. RX-10045 inhibited MDCKII-MRP2 and 
MDCKII-BCRP mediated efflux in a dose dependent manner. 
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Efflux transporters such as P-gp, MRP2 and BCRP are involved in the 
extrusion of a variety of therapeutic agents. Since the efflux transporters (P-gp, 
BCRP and MRP2) are localized on the apical surface, [3H] digoxin, [3H] vinblastine 
and [3H] abacavir alone exhibited significantly lower transport in the AP-BL 
direction relative to BL-AP direction (Table 12).  The efflux ratio (ratio of BL-AP 
vs AP-BL) is considered to be an indicator to identify efflux transporter (P-gp, 
MRP2 and BCRP) substrates (316). When the ratio of apparent permeability (BL-
AP / AP-BL) approaches 1.0 then transport is equal in both directions. Efflux ratios 
of [3H] digoxin, [3H] vinblastine and [3H] abacavir were found to be 2.07, 4.75 and 
10.35 in MDCKII-MDR1, MDCKII-MRP2 and MDCKII-BCRP cells, 
respectively. A significant reduction in efflux ratio was evident in the presence of 
GF120918, MK-571 and beta-estradiol, confirming inhibition of P-gp, MRP2 and 
BCRP functional activities (Table 12). Furthermore, the presence of RX-10045 
affected AP-BL permeability of [3H] digoxin, [3H] vinblastine and [3H] abacavir. 
The efflux ratio is reduced in MDCKII-MDR1, MDCKII-BCRP and MDCKII-
MRP2 cells (Table 12). This significant reduction in efflux ratio further confirms 
substrate specificity of RX-10045 towards P-gp, MRP2 and BCRP. There was no 
significant difference observed in permeability of [3H] digoxin in presence of RX-
10045 indicating non interaction with P-gp compared to other transmembrane 
efflux proteins (MRP2 and BCRP). A significant reduction in efflux ratio was 
evident in the presence of MK-571 and beta-estradiol, confirming inhibition of 
MRP2 and BCRP functional activities (Table 12). Furthermore, the presence of 
RX-10045 affected AP-BL permeability of [3H] vinblastine and [3H] abacavir. The 
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Table 12. Apparent permeability of [3H] Digoxin, [3H] Vinblastine and [3H] Abacavir in presence of inhibitors and RX-10045. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell type  Apical to Basolateral  
(X 10-6) 
Basolateral to Apical 
(X 10-6) 
Efflux ratio 
MDCKII-MDR1 [3H] Digoxin  5.77 ± 0.38 11.96 ± 2.59 2.07 
GF (5µM) 6.07 ± 0.39 10.95 ± 1.57 1.80 
RX-10045 (350 µM ) 5.86 ± 0.30 11.13 ± 0.95 1.90 
MDCKII-MRP2 [3H]  Vinblastine 0.093 ± 0.028 0.440 ± 0.083 4.75 
MK571 (50µM ) 0.154 ± 0.050 0.389 ± 0.005 2.53 
RX-10045 (300 µM) 0.235 ± 0.079 0.430 ± 0.190 1.83 
MDCKII-BCRP [3H] Abacavir   3.29 ± 1.26 34.09 ± 2.73 10.35 
Estradiol-2  (25µM) 7.77 ± 0.883 27.61 ± 3.24 3.56 
RX-10045 (350 µM) 7.95 ± 1.38 31.96 ± 0.62 4.02 
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efflux ratio is reduced in MDCKII-BCRP and MDCKII-MRP2 cells, but not much 
in MDCKMDR1 cells (Table 12). This significant reduction in efflux ratio further 
confirms substrate specificity of RX-10045 towards MRP2 and BCRP. Uptake 
studies in HCEC cells demonstrated no effect of MDR1 (P-gp) on digoxin efflux in 
the presence of RX-10045. Results were comparable to MDCKII-MDR1 cells. 
However, uptake of MRP2 substrate ([3H] vinblastine) was significantly improved. 
We observed that the uptake of [3H] vinblastine was approximately 5 times higher 
in HCEC cells relative to MDCK-MRP2 cells possibly due to differences in 
isoforms expression in HCEC/MDCK-MRP2 cells. Tang F. Horie et al. reported 
that different isoforms of MRP2 are overexpressed in MDCK-MRP2 cells (150 kD) 
and Caco2 cells (190 kD) with a different kinetic profile (317).Therefore, these 
isoforms also make the difference in substrate specificity i.e, percent [3H] 
vinblastine uptake resulting in higher cellular accumulation. The uptake of [3H] 
abacavir along with RX-10045 was significantly reduced demonstrating reversal in 
drug accumulation relative to control [3H] abacavir alone (Figure 36). This 
surprising result prompted us to investigate the cause of inhibition of [3H] abacavir 
uptake in presence of RX-10045. Abacavir is a known substrate for organic cation 
transporter-1 (OCT), and HCEC cells highly express OCT-1 (318, 319). Therefore 
increase in HCEC cell uptake of [3H] abacavir may be due to uptake by the OCT-1 
transporter. The presence of RX-10045 inhibited the [3H] abacavir uptake because 
this resolvin can cause inhibition of OCT-1 transporter. To determine its inhibitory 
effect, uptake and inhibition studies of [3H] abacavir were performed in presence 
of 100 µM quinine (an OCT-1 inhibitor). Uptake of [3H] abacavir was significantly 
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reduced in presence of quinine and RX-10045 is a strong inhibitor of OCT-1 
(Figure 36). 
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Figure 36. Uptake studies in human corneal epithelial cells (HCEC) for tritiated digoxin, abacavir and vinblastine in presence of 
RX-10045 at IC50 concentrations. A p value of < 0.05 is considered significant. Data are shown as mean ± S.E.M (n = 4). *p < 
0.05 versus control (paired t-test). 
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PART B: FORMULATION OPTIMIZATION AND IN VIVO EVALUATION 
Materials and Methods 
 
Purified RX-10045 (physical state- solid; lot number: NR13799-969-143) 
was obtained from PPD. Hydrogenated castor oil-40 (HCO-40) of pharmaceutical 
grade was procured from Barnet Products, USA and Octoxynol-40 (Oc-40 or Igepal 
CA-897) was purchased from Rohdio Inc, New Jersey, USA. Ethyl acetate (HPLC 
grade) was purchased from Fischer Scientific, USA. PVP-K90 (lot # 56943447G0) 
was obtained from BASF Aktiengesellschaft 67056 Ludwigshafen Germany. 
Benzalkonium chloride was obtained from Sigma chemical Co. St. Louis, Missouri, 
USA. Disodium EDTA, sodium chloride and sodium citrate were purchased from 
Fischer Chemicals, USA. Citric acid was purchased from Sigma Chemical Co., 
USA. For buffer and formulation preparation double distilled deionized water was 
used. Water was degassed for 20 minutes prior to preparation. 
 
Methods 
 
Nanomicelle preparation 
 
To prepare 100 mL of nanomicellar formulation of RX-10045 the 
experimental procedure was divided into two steps (i) basic formulation preparation 
and (ii) rehydration step. 
(i) Basic formulation preparation: Briefly, 0.05 g and 0.1 g of RX-10045 
(0.05% and 0.1%) was accurately weighed in an Eppendorf tube, HCO-
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40 (1.0 %) and octoxynol-40 (0.05 %), were accurately weighed and 
dissolved separately in ethyl acetate.  All the solutions, in calculated 
amounts were mixed together to prepare a homogenized solution. 
Organic solvent was evaporated under high vacuum overnight to obtain 
a homogenized thin film. The film was resuspended in 40 mL of 0.1 M 
citrate buffer (pH 5.5) (see below). This resulted in a homogenous clear 
aqueous solution. The volume of the mixture was made upto 50 mL with 
0.1 M citrate buffer. 
 
(ii) Rehydration: The above obtained clear solution was divided equally (25 
mL each) into two round bottom flasks. To first flask, 25 mL of 
preservative free 2x citrate buffer (pH 5.5) was added and mixed 
thoroughly to obtain a homogenous clear aqueous solution. Similarly, 
the second round bottom flask (containing 25 mL of basic formulation 
of RX-10045) was mixed with 25 mL of 2x citrate buffer (pH 5.5) (see 
below for preparation) containing preservatives and was stirred for 
homogeneity. Both formulations i.e., with and without preservatives 
were filtered through 0.2 µm nylon filter. 
Following similar procedure as described above placebo formulations for the RX-
10045 were prepared. For the placebo formulation preparation RX-10045 was not 
added/used.  
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Citrate buffer (pH 5.5) preparation 
Citric acid monohydrate 21.01 g was dissolved in one liter of water (0.1M 
citric acid). Similarly, 29.41 g of trisodium citrate dehydrate was dissolved 
separately in water (0.1 M sodium citrate). To prepare 100 mL of 0.1 M citrate 
buffer 21.0 mL of citric acid (0.1 M) was transferred to a 250mL flask and the 
volume was made up with 0.1M sodium citrate (79 mL). The mixture was mixed 
by stirring to get a homogenous buffer solution. The pH of the buffer was adjusted 
to 5.5 with 0.1 N HCl or 0.1 N NaOH. 
Preparation of 2x Preservative free buffer 
To prepare 2x citrate buffer 40 mL of 0.1 M citrate buffer (pH 5.5) was 
added with 0.1 wt% of sodium chloride and dissolved under constant stirring. PVP-
K90 (0.6%) was accurately weighed and slowly dissolved under constant stirring 
until a clear homogenous solution is obtained.  The pH of the buffer was measured 
and adjusted, if required, to 5.5 with 0.1 N HCl or 0.1 N NaOH. Finally, the volume 
was made upto 50 mL with 0.1 M citrate buffer. 
Preparation of 2x buffer with preservatives 
To prepare 2x citrate buffer 40 mL of 0.1 M citrate buffer (pH 5.5) was 
added with 0.1 wt% of sodium chloride and dissolved under constant stirring. 
Disodium EDTA (0.05%) was added and dissolved. Similarly, benzalkonium 
chloride (0.003%) was added and dissolved. Further, PVP-K90 (0.6%) was 
weighed and slowly dissolved under constant stirring until a clear homogenous 
solution is obtained.  The pH of the buffer was measured and adjusted to 5.5 with 
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0.1 N HCl or 0.1 N NaOH, if required. Finally, the volume was made upto 50 mL 
with 0.1 M citrate buffer. 
HPLC Analysis  
In vitro analysis of RX-10045 was performed by a reversed phase RP-
HPLC method with a Shimadzu HPLC pump (Shimadzu, Shimadzu Scientific 
instruments, Columbia, MD), Alcott autosampler (model 718 AL), Shimadzu 
UV/Visible detector (Shimadzu, SPD-20A/20AV, USA), ODS column (5 μm, 150 
x 4.6 mm) thermostated at 40  ± 1 oC and Hewlett Packard HPLC integrator 
(Hewlett Packard, Palo Alto, CA). The mobile phase was comprised of methanol 
(MeOH), water and trifluoroacetic acid (TFA) (70:30:0.05% v/v) which was set at 
a flow rate of 0.5 mL/min. Detection wavelength was set at 272 nm. The sample 
tray temperature was maintained at 4 ºC.  Calibration curve (0.5 μg/mL to 5 μg/mL) 
for RX-10045 (injection volume 10 µL) was prepared by making appropriate 
dilutions from stock solution in 2-propanol.   
 
UPLC Analysis 
 
UPLC System consisted of Waters UPLC Acquity H Class with UPLC 
TUV& PDA Detector (230 nm) and data system: Waters Empower 2. Waters 
Acquity CSHTM C18 (1.7 µM, 2.1 × 50 mm) column was used for separation. 
Column temperature was maintained at 50 °C and autosampler temperature was set 
at 4 °C. The mobile phase was composed of phase A: 0.1% formic acid in water 
and Phase B: 0.1% formic acid in methanol and UPLC TUV Detector set at 230 
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nm. Injection volume was 2 µL. A gradient solvent system (see Table 13) was 
employed for separation and analysis.  
 
LC-MS/MS Analysis 
All in vivo ocular tissues, fluids and blood samples were analyzed with LC-
MS/MS described in Chapter 3 (Pg# 89). Selected ocular fluids/tissues (aqueous 
humor, vitreous humor, conjunctiva, cornea, iris-ciliary body, lens, retina/ choroid, 
and sclera) collected from rabbits in the RX-10045 (0.1% in HCO-40) treatment 
groups, and from one rabbit in each of the matching placebo groups, were assayed 
for compound RX-1001 and another resolvin by liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) with gradient mobile phase system (Table 13). 
Warfarin-d5 and 5-HDA were used as internal standards for the analysis of RX-
10045 and its active metabolite, RX-10008, respectively, in aqueous humor and 
vitreous humor. For other ocular tissues, Warfarin-d5 and phenyl acetic acid-d5 
(PAA-d5) were used as the internal standards for compound 1001 and RX-10008, 
respectively. The analytical range for ocular tissues ranged between 0.125-100 ng. 
The results of the ocular tissue analyses were converted to ng/g by correcting for 
the amount of tissue analyzed. 
 
Formulation Characterization 
 
The prepared RX-10045 nanomicellar formulations (with and without 
preservatives) were subjected to characterization following procedures described 
in Chapter 3 for entrapment efficiency, loading efficiency, size,  
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Table 13. UPLC gradient mobile phase composition for RX-10045 sample stability 
analysis. 
Time (min) Flow Rate A (%) B (%) 
0 0.5 70 30 
9 0.5 52 48 
10 0.5 70 30 
15 0.5 70 30 
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Table 14. Storage Conditions of RX-10045 Formulation Samples 
Preservative Preservative Preservative Preservative 
N2, amber, 0 Day, 4°C No N2, amber, 0 Day, 4°C N2, clear, 0 Day, 4°C No N2, clear, 0 Day, 4°C
N2, amber, 1 Day, 4°C No N2, amber, 1 Day, 4°C N2, clear, 1 Day, 4°C No N2, clear, 1 Day, 4°C
N2, amber, 9 Days, 4°C No N2, amber, 9 Days, 4°C N2, clear, 9 Days, 4°C No N2, clear, 9 Days, 4°C
N2, amber, 30 Days, 4°C No N2, amber, 30 Days, 4°C N2, clear, 30 Days, 4°C No N2, clear, 30 Days, 4°C
N2, amber, 2 Mo, 4°C No N2, amber, 2 Mo, 4°C N2, clear, 2 Mo, 4°C No N2, clear, 2 Mo, 4°C
N2, amber, 3 Mo, 4°C No N2, amber, 3 Mo, 4°C N2, clear, 3 Mo, 4°C No N2, clear, 3 Mo, 4°C
N2, amber, 4 Mo, 4°C No N2, amber, 4 Mo, 4°C N2, clear, 4 Mo, 4°C No N2, clear, 4 Mo, 4°C
N2, amber, 6 Mo, 4°C No N2, amber, 6 Mo, 4°C N2, clear, 6 Mo, 4°C No N2, clear, 6 Mo, 4°C
N2, amber, 0 Day, 25°C No N2, amber, 0 Day, 25°C N2, clear, 0 Day, 25°C No N2, clear, 0 Day, 25°C
N2, amber, 1 Day, 25°C No N2, amber, 1 Day, 25°C N2, clear, 1 Day, 25°C No N2, clear, 1 Day, 25°C
N2, amber, 9 Days, 25°C No N2, amber, 9 Days, 25°C N2, clear, 9 Days, 25°C No N2, clear, 9 Days, 25°C
N2, amber, 30 Days, 25°C No N2, amber, 30 Days, 25°C N2, clear, 30 Days, 25°C No N2, clear, 30 Days, 25°C
N2, amber, 2 Mo, 25°C No N2, amber, 2 Mo, 25°C N2, clear, 2 Mo, 25°C No N2, clear, 2 Mo, 25°C
N2, amber, 3 Mo, 25°C No N2, amber, 3 Mo, 25°C N2, clear, 3 Mo, 25°C No N2, clear, 3 Mo, 25°C
N2, amber, 4 Mo, 25°C No N2, amber, 4 Mo, 25°C N2, clear, 4 Mo, 25°C No N2, clear, 4 Mo, 25°C
N2, amber, 6 Mo, 25°C No N2, amber, 6 Mo, 25°C N2, clear, 6 Mo, 25°C No N2, clear, 6 Mo, 25°C
N2, amber, 0 Day, 40°C No N2, amber, 0 Day, 40°C N2, clear, 0 Day, 40°C No N2, clear, 0 Day, 40°C
N2, amber, 1 Day, 40°C No N2, amber, 1 Day, 40°C N2, clear, 1 Day, 40°C No N2, clear, 1 Day, 40°C
N2, amber, 9 Days, 40°C No N2, amber, 9 Days, 40°C N2, clear, 9 Days, 40°C No N2, clear, 9 Days, 40°C
N2, amber, 30 Days, 40°C No N2, amber, 30 Days, 40°C N2, clear, 30 Days, 40°C No N2, clear, 30 Days, 40°C
N2, amber, 2 Mo, 40°C No N2, amber, 2 Mo, 40°C N2, clear, 2 Mo, 40°C No N2, clear, 2 Mo, 40°C
N2, amber, 3 Mo, 40°C No N2, amber, 3 Mo, 40°C N2, clear, 3 Mo, 40°C No N2, clear, 3 Mo, 40°C
N2, amber, 4 Mo, 40°C No N2, amber, 4 Mo, 40°C N2, clear, 4 Mo, 40°C No N2, clear, 4 Mo, 40°C
N2, amber, 6 Mo, 40°C No N2, amber, 6 Mo, 40°C N2, clear, 6 Mo, 40°C No N2, clear, 6 Mo, 40°C
No preservative No preservative No preservative No preservative
N2, amber, 0 Day, 4°C No N2, amber, 0 Day, 4°C N2, clear, 0 Day, 4°C No N2, clear, 0 Day, 4°C
N2, amber, 1 Day, 4°C No N2, amber, 1 Day, 4°C N2, clear, 1 Day, 4°C No N2, clear, 1 Day, 4°C
N2, amber, 9 Days, 4°C No N2, amber, 9 Days, 4°C N2, clear, 9 Days, 4°C No N2, clear, 9 Days, 4°C
N2, amber, 30 Days, 4°C No N2, amber, 30 Days, 4°C N2, clear, 30 Days, 4°C No N2, clear, 30 Days, 4°C
N2, amber, 2 Mo, 4°C No No N2, amber, 2 Mo, 4°C N2, clear, 2 Mo, 4°C No N2, clear, 2 Mo, 4°C
N2, amber, 3 Mo, 4°C No N2, amber, 3 Mo, 4°C N2, clear, 3 Mo, 4°C No N2, clear, 3 Mo, 4°C
N2, amber, 4 Mo, 4°C No N2, amber, 4 Mo, 4°C N2, clear, 4 Mo, 4°C No N2, clear, 4 Mo, 4°C
N2, amber, 6 Mo, 4°C No N2, amber, 6 Mo, 4°C N2, clear, 6 Mo, 4°C No N2, clear, 6 Mo, 4°C
N2, amber, 0 Day, 25°C No N2, amber, 0 Day, 25°C N2, clear, 0 Day, 25°C No N2, clear, 0 Day, 25°C
N2, amber, 1 Day, 25°C No N2, amber, 1 Day, 25°C N2, clear, 1 Day, 25°C No N2, clear, 1 Day, 25°C
N2, amber, 9 Days, 25°C No N2, amber, 9 Days, 25°C N2, clear, 9 Days, 25°C No N2, clear, 9 Days, 25°C
N2, amber, 30 Days, 25°C No N2, amber, 30 Days, 25°C N2, clear, 30 Days, 25°C No N2, clear, 30 Days, 25°C
N2, amber, 2 Mo, 25°C No No N2, amber, 2 Mo, 25°C N2, clear, 2 Mo, 25°C No N2, clear, 2 Mo, 25°C
N2, amber, 3 Mo, 25°C No N2, amber, 3 Mo, 25°C N2, clear, 3 Mo, 25°C No N2, clear, 3 Mo, 25°C
N2, amber, 4 Mo, 25°C No N2, amber, 4 Mo, 25°C N2, clear, 4 Mo, 25°C No N2, clear, 4 Mo, 25°C
N2, amber, 6 Mo, 25°C No N2, amber, 6 Mo, 25°C N2, clear, 6 Mo, 25°C No N2, clear, 6 Mo, 25°C
N2, amber, 0 Day, 40°C No N2, amber, 0 Day, 40°C N2, clear, 0 Day, 40°C No N2, clear, 0 Day, 40°C
N2, amber, 1 Day, 40°C No N2, amber, 1 Day, 40°C N2, clear, 1 Day, 40°C No N2, clear, 1 Day, 40°C
N2, amber, 9 Days, 40°C No N2, amber, 9 Days, 40°C N2, clear, 9 Days, 40°C No N2, clear, 9 Days, 40°C
N2, amber, 30 Days, 40°C No N2, amber, 30 Days, 40°C N2, clear, 30 Days, 40°C No N2, clear, 30 Days, 40°C
N2, amber, 2 Mo, 40°C No No N2, amber, 2 Mo, 40°C N2, clear, 2 Mo, 40°C No N2, clear, 2 Mo, 40°C
N2, amber, 3 Mo, 40°C No N2, amber, 3 Mo, 40°C N2, clear, 3 Mo, 40°C No N2, clear, 3 Mo, 40°C
N2, amber, 4 Mo, 40°C No N2, amber, 4 Mo, 40°C N2, clear, 4 Mo, 40°C No N2, clear, 4 Mo, 40°C
N2, amber, 6 Mo, 40°C No N2, amber, 6 Mo, 40°C N2, clear, 6 Mo, 40°C No N2, clear, 6 Mo, 40°C
RX-10045 Mixed Nanomicellar Formulation (inert gas, time point, temperature (°C))
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Table 15. Storage Conditions of Placebo Formulation Samples 
 
 
 
 
 
 
 
 
 
 
Preservative Preservative Preservative Preservative 
N2, amber, 0 Day, 25°C No N2, amber, 0 Day, 25°C N2, clear, 0 Day, 25°C No N2, clear, 0 Day, 25°C
N2, amber, 30 Day, 25°C No N2, amber, 30 Day, 25°C N2, clear, 30 Day, 25°C No N2, clear, 30 Day, 25°C
N2, amber, 4 Mo, 25°C No N2, amber, 4 Mo, 25°C N2, clear, 4 Mo, 25°C No N2, clear, 4 Mo, 25°C
N2, amber, 4 Mo, 40°C No N2, amber, 4 Mo, 40°C N2, clear, 4 Mo, 40°C No N2, clear, 4 Mo, 40°C
N2, amber, 6 Mo, 4°C No N2, amber, 6 Mo, 4°C N2, clear, 6 Mo, 4°C No N2, clear, 6 Mo, 4°C
N2, amber, 6 Mo, 25°C No N2, amber, 6 Mo, 25°C N2, clear, 6 Mo, 25°C No N2, clear, 6 Mo, 25°C
N2, amber, 6 Mo, 40°C No N2, amber, 6 Mo, 40°C N2, clear, 6 Mo, 40°C No N2, clear, 6 Mo, 40°C
No preservative No preservative No preservative No preservative
N2, amber, 0 Day, 25°C No N2, amber, 0 Day, 25°C N2, clear, 0 Day, 25°C No N2, clear, 0 Day, 25°C
N2, amber, 30 Day, 25°C No N2, amber, 30 Day, 25°C N2, clear, 30 Day, 25°C No N2, clear, 30 Day, 25°C
N2, amber, 4 Mo, 25°C No N2, amber, 4 Mo, 25°C N2, clear, 4 Mo, 25°C No N2, clear, 4 Mo, 25°C
N2, amber, 4 Mo, 40°C No N2, amber, 4 Mo, 40°C N2, clear, 4 Mo, 40°C No N2, clear, 4 Mo, 40°C
N2, amber, 6 Mo, 4°C No N2, amber, 6 Mo, 4°C N2, clear, 6 Mo, 4°C No N2, clear, 6 Mo, 4°C
N2, amber, 6 Mo, 25°C No N2, amber, 6 Mo, 25°C N2, clear, 6 Mo, 25°C No N2, clear, 6 Mo, 25°C
N2, amber, 6 Mo, 40°C No N2, amber, 6 Mo, 40°C N2, clear, 6 Mo, 40°C No N2, clear, 6 Mo, 40°C
Mixed Nanomicellar Formulation without RX-10045 (inert gas, time point, temperature (°C))
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polydispersity index, surface potential, and proton NMR studies. HPLC-UV was 
used for determining entrapment and drug loading. 
Formulation stability studies were conducted at three different temperatures 
(4 oC, 25 oC and 40 oC) by dividing the formulations into different sub-groups and 
subjecting them to various conditions (Table 14 and Table 15). At predetermined 
time points (0 day, 1 day, 9days, 30 days, 2 month, 3 month, 4 month and 6 month) 
both placebo and RX-10045 loaded nanomicellar formulation samples were 
collected into 200 µL HPLC inserts/vials and immediately stored at -80 ºC until 
further analysis with Ultra performance liquid chromatography (UPLC). After 
collecting samples the nitrogen gas labeled/containing formulation vials were filled 
with nitrogen gas, immediately sealed and the cap was wrapped with paraffin to 
prevent any leaks. 
 
In vivo studies 
A study was conducted in New Zealand White rabbits (2-3 kg) following 
the protocol described in Chapter # 3 to test the tolerance and ocular tissue 
distribution of 0.1% nanomicellar for formulations of compound 1001 (RX10045) 
(containing preservatives) against matching placebo and balanced saline solution 
(BSS). One topical drop (approximately 35 µL) of formulation (placebo/RX-10045 
loaded) was applied o.d. 4X/day at two hour intervals for 5 days. One drop of BSS 
was applied to the contralateral eye. The tolerance parameters evaluated were 
physical examination (acclimation study release); viability (daily); clinical 
observations (daily); Hackett-McDonald Ocular Irritation scores (pre-dose) 
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baseline data for each rabbit and then a pre-dose (prior to first daily dose) each day 
and then 30 min after last dose daily, intraocular pressure (IOP) pre-dose base line 
data for each rabbit and then 30 minutes after the evening examinations each day, 
electroretinography (ERG) pre-dose (pre-study) baseline data for each rabbit and 
then one hour after the last treatment, and ocular histopathology at euthanasia. 
Ocular tissues, fluids (vitreous and aqueous humor) and blood samples were 
collected following similar protocol described previously in Chapter # 3.  
Results 
 
RX-10045 is a yellow oily viscous resolvin analog. It is highly unstable at 
room temperature and easily susceptible to degradation upon exposure to light and 
air. Therefore, pure yellow oily RX-10045 is stored at -80 oC with nitrogen 
atmosphere in dark. Nanomicellar formulations of RX-10045 (0.05% and 0.1%) 
were successfully prepared with the blend of HCO-40 and Oc-40 (Figure 37). The 
ratio of HCO-40/Oc-40 was set at 1.0:0.05 due to its low critical micellar 
concentrations relative to individual polymers. The size of placebo and RX-10045 
(0.05% and 0.1%) loaded nanomicellar formulation was 10.37 ± 0.3 nm, 11.7 ± 1.2 
nm and 11.2. ± 1.3 nm, respectively. The surface potential was slightly negative or 
negligible (-0.0237 mV). Proton nuclear magnetic resonance studies clearly 
demonstrated the absence of free RX-10045 in nanomicellar formulation (Figure 
38 - Figure 41). Drug peaks were evident in organic solvent (CDCl3) while the 
same drug peaks disappeared when resuspended in aqueous (D2O) solution. 
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 Stability studies for RX-10045 (0.1%) loaded nanomicellar formulation was 
conducted at different temperatures. Samples pulled/collected at predetermined 
time points appear clear/transparent to the naked eye (no yellow color development 
observed). Further the concentration of RX-10045 remaining in the formulation 
was quantified. The drug RX-10045 if degraded it is converted to its active parent 
molecule RX-10008. Both, resolvin E1 analog and the RX-10008 were quantified 
in long term stability studies. Figure 42 through Figure 46 represents, respective 
chromatograms for stability studies. Below description is provided for stability 
evaluation of RX-10045. All the results for RX-10045 stability for 6 months are 
summarized in Table 16. 
 
Stability evaluation 
 
The stability of RX-10045 in the various formulations under the storage 
conditions employed was evaluated by comparing RX-10045 peak area percent of 
the storage samples relative to that of the corresponding Day-0 sample.  
For Example:  Day-30 Stability by 
RX-10045 Peak Area %: =  RX-10045 Area % (Day-30)/RX-10045 Area % (Day-0) x 100               Eq 10 
 
In vivo studies 
Tolerability studies for placebo and RX-10045 nanomicellar formulations 
indicated that the formulations were safe and well tolerated. No IOP increase was 
observed with multiple topical drop administration of RX-10045 formulation. 
Results for tolerability studies are presented in Table 17. Mean ocular tissue and  
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Figure 37. Image showing nanomicellar formulation (A) blank/placebo formulation 
and (B) RX-10045 (0.1%) loaded nanomicellar formulation. 
A B 
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Figure 38. 1H NMR spectrum for RX-10045 oily pure drug in CDCl3 
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Figure 39. 1H NMR spectrum for placebo HCO-40 polymer micelles in CDCl3 
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Figure 40. 1H NMR spectrum for nanomicellar formulation of 0.1% RX-10045 resuspended in CDCl3. Symbol (*) represents RX-
10045 drug peaks evident in the formulation along with HCO-40 polymeric peaks 
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Figure 41. 1H NMR spectrum for nanomicellar formulation of RX-10045 (0.1%) resuspended in D2O. 
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Figure 42. Representative UPLC-UV Chromatogram of RX-10045 Standard. 
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Figure 43. Representative UPLC-UV Chromatogram of Placebo Formulation. 
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Figure 44. UPLC-UV Chromatogram of Day-0 RX-10045 Formulation, No 
Preservative, No N2, Clear, 4 °C Sample. 
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Figure 45. UPLC-UV Chromatogram of Month-6, RX-10045 Formulation, No 
Preservative, No N2, Clear, 4 °C Sample. 
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Figure 46. UPLC-UV Chromatogram of Month-6, RX-10045 Formulation, 
Preservative, No N2, Clear, 40 °C Sample. 
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Table 16. RX-10045 Formulation Stability Analysis 
 
 
Preservative 
Stability 
(% day 0) Preservative 
Stability 
(% day 0) Preservative 
Stability 
(% day 0) Preservative 
Stability 
(% day 0)
N2, amber, 0 Day, 4 °C 100 No N2, amber, 0 Day, 4 °C 100 N2, clear, 0 Day, 4 °C 100 No N2, clear, 0 Day, 4 °C 100
N2, amber, 1 Day, 4 °C 99.9 No N2, amber, 1 Day, 4 °C 100 N2, clear, 1 Day, 4 °C 100 No N2, clear, 1 Day, 4 °C 100
N2, amber, 9 Days, 4 °C 100 No N2, amber, 9 Days, 4 °C 100 N2, clear, 9 Days, 4 °C 101 No N2, clear, 9 Days, 4 °C 101
N2, amber, 30 Days, 4 °C 99.8 No N2, amber, 30 Days, 4 °C 99.7 N2, clear, 30 Days, 4 °C 100 No N2, clear, 30 Days, 4 °C 100
N2, amber, 2 Mo, 4 °C 97.2 No N2, amber, 2 Mo, 4 °C 97.0 N2, clear, 2 Mo, 4 °C 98.7 No N2, clear, 2 Mo, 4 °C 98.9
N2, amber, 3 Mo, 4 °C 96.8 No N2, amber, 3 Mo, 4 °C 96.0 N2, clear, 3 Mo, 4 °C 98.2 No N2, clear, 3 Mo, 4 °C 98.2
N2, amber, 4 Mo, 4 °C 96.5 No N2, amber, 4 Mo, 4 °C 95.4 N2, clear, 4 Mo, 4 °C 98.3 No N2, clear, 4 Mo, 4 °C 97.5
N2, amber, 6 Mo, 4 °C 95.3 No N2, amber, 6 Mo, 4 °C 91.8 N2, clear, 6 Mo, 4 °C 96.2 No N2, clear, 6 Mo, 4 °C 94.3
N2, amber, 0 Day, 25 °C 100 No N2, amber, 0 Day, 25 °C 100 N2, clear, 0 Day, 25 °C 100 No N2, clear, 0 Day, 25 °C 100
N2, amber, 1 Day, 25 °C 99.9 No N2, amber, 1 Day, 25 °C 100 N2, clear, 1 Day, 25 °C 100 No N2, clear, 1 Day, 25 °C 101
N2, amber, 9 Days, 25 °C 98.6 No N2, amber, 9 Days, 25°C 98.6 N2, clear, 9 Days,25 °C 99.8 No N2, clear, 9 Days, 25 °C 99.6
N2, amber, 30 Days, 25 °C 96.9 No N2, amber, 30 Days, 25 °C 96.6 N2, clear, 30 Days, 25 °C 97.4 No N2, clear, 30 Days, 25 °C 96.8
N2, amber, 2 Mo, 25 °C 95.7 No N2, amber, 2 Mo, 25 °C 94.0 N2, clear, 2 Mo, 25 °C 95.6 No N2, clear, 2 Mo, 25 °C 93.9
N2, amber, 3 Mo, 25 °C 95.2 No N2, amber, 3 Mo, 25 °C 93.2 N2, clear, 3 Mo, 25 °C 95.0 No N2, clear, 3 Mo, 25 °C 92.3
N2, amber, 4 Mo, 25 °C 94.3 No N2, amber, 4 Mo, 25 °C 92.4 N2, clear, 4 Mo, 25 °C 94.6 No N2, clear, 4 Mo, 25 °C 91.1
N2, amber, 6 Mo, 25 °C 89.9 No N2, amber, 6 Mo, 25 °C 83.6 N2, clear, 6 Mo, 25 °C 89.0 No N2, clear, 6 Mo, 25 °C 79.7
N2, amber, 0 Day, 40 °C 100 No N2, amber, 0 Day, 40 °C 100 N2, clear, 0 Day, 40 °C 100 No N2, clear, 0 Day, 40 °C 100
N2, amber, 1Day, 40 °C 99.6 No N2, amber, 1 Day, 40 °C 99.3 N2, clear, 1 Day, 40 °C 100 No N2, clear, 1 Day, 40 °C 99.9
N2, amber, 9Days, 40 °C 97.2 No N2, amber, 9 Days, 40°C 96.3 N2, clear, 9 Days,40 °C 98.0 No N2, clear, 9 Days, 40 °C 97.7
N2, amber, 30 Days, 40 °C 94.1 No N2, amber, 30 Days, 40 °C 92.5 N2, clear, 30 Days, 40 °C 96.0 No N2, clear, 30 Days, 40 °C 94.2
N2, amber, 2 Mo, 40 °C 90.6 No N2, amber, 2 Mo, 40 °C 86.7 N2, clear, 2 Mo, 40 °C 90.7 No N2, clear, 2 Mo, 40 °C 88.7
N2, amber, 3 Mo, 40 °C 86.3 No N2, amber, 3 Mo, 40 °C 82.6 N2, clear, 3 Mo, 40 °C 85.9 No N2, clear, 3 Mo, 40 °C 83.6
N2, amber, 4 Mo, 40 °C 84.3 No N2, amber, 4 Mo, 40 °C 78.5 N2, clear, 4 Mo, 40 °C 82.9 No N2, clear, 4 Mo, 40 °C 78.7
N2, amber, 6 Mo, 40 °C 74.9 No N2, amber, 6 Mo, 40 °C 62.9 N2, clear, 6 Mo, 40 °C 67.6 No N2, clear, 6 Mo, 40 °C 60.3
No preservative
Stability 
(% day 0) No preservative
Stability 
(% day 0) No preservative
Stability 
(% day 0) No preservative
Stability 
(% day 0)
N2, amber, 0 Day, 4 °C 100 No N2, amber, 0 Day, 4 °C 100 N2, clear, 0 Day, 4 °C 100 No N2, clear, 0 Day, 4 °C 100
N2, amber, 1 Day, 4 °C 100 No N2, amber, 1 Day, 4 °C 100 N2, clear, 1 Day, 4 °C 101 No N2, clear, 1 Day, 4 °C 100
N2, amber, 9 Days, 4 °C 101 No N2, amber, 9 Days, 4 °C 101 N2, clear, 9 Days, 4 °C 101 No N2, clear, 9 Days, 4 °C 101
N2, amber, 30 Days, 4 °C 101 No N2, amber, 30 Days, 4 °C 101 N2, clear, 30 Days, 4 °C 101 No N2, clear, 30 Days, 4 °C 101
N2, amber, 2 Mo, 4 °C 99.6 No N2, amber, 2 Mo, 4 °C 100 N2, clear, 2 Mo, 4 °C 101 No N2, clear, 2 Mo, 4 °C 100
N2, amber, 3 Mo, 4 °C 99.9 No N2, amber, 3 Mo, 4 °C 100 N2, clear, 3 Mo, 4 °C 101 No N2, clear, 3 Mo, 4 °C 100
N2, amber, 4 Mo, 4 °C 99.8 No N2, amber, 4 Mo, 4 °C 99.6 N2, clear, 4 Mo, 4 °C 100 No N2, clear, 4 Mo, 4 °C 100
N2, amber, 6 Mo, 4 °C 98.2 No N2, amber, 6 Mo, 4 °C 97.8 N2, clear, 6 Mo, 4 °C 99.0 No N2, clear, 6 Mo, 4 °C 98.6
N2, amber, 0 Day, 25 °C 100 No N2, amber, 0 Day, 25 °C 100 N2, clear, 0 Day, 25 °C 100 No N2, clear, 0 Day, 25 °C 100
N2, amber, 1 Day, 25 °C 101 No N2, amber, 1 Day, 25 °C 101 N2, clear, 1 Day, 25 °C 101 No N2, clear, 1 Day, 25 °C 101
N2, amber, 9 Days, 25 °C 101 No N2, amber, 9 Days, 25°C 101 N2, clear, 9 Days,25 °C 100 No N2, clear, 9 Days, 25 °C 101
N2, amber, 30 Days, 25 °C 100 No N2, amber, 30 Days, 25 °C 99.9 N2, clear, 30 Days, 25 °C 98.7 No N2, clear, 30 Days, 25 °C 99.1
N2, amber, 2 Mo, 25 °C 99.2 No N2, amber, 2 Mo, 25 °C 97.4 N2, clear, 2 Mo, 25 °C 97.5 No N2, clear, 2 Mo, 25 °C 96.3
N2, amber, 3 Mo, 25 °C 98.1 No N2, amber, 3 Mo, 25 °C 96.9 N2, clear, 3 Mo, 25 °C 96.4 No N2, clear, 3 Mo, 25 °C 94.6
N2, amber, 4 Mo, 25 °C 97.8 No N2, amber, 4 Mo, 25 °C 96.1 N2, clear, 4 Mo, 25 °C 95.8 No N2, clear, 4 Mo, 25 °C 93.4
N2, amber, 6 Mo, 25 °C 93.6 No N2, amber, 6 Mo, 25 °C 89.9 N2, clear, 6 Mo, 25 °C 87.6 No N2, clear, 6 Mo, 25 °C 83.1
N2, amber, 0 Day, 40 °C 100 No N2, amber, 0 Day, 40 °C 100 N2, clear, 0 Day, 40 °C 100 No N2, clear, 0 Day, 40 °C 100
N2, amber, 1Day, 40 °C 101 No N2, amber, 1 Day, 40 °C 101 N2, clear, 1 Day, 40 °C 101 No N2, clear, 1 Day, 40 °C 101
N2, amber, 9Days, 40 °C 99.1 No N2, amber, 9 Days, 40°C 100 N2, clear, 9 Days,40 °C 99.9 No N2, clear, 9 Days, 40 °C 99.8
N2, amber, 30 Days, 40 °C 97.4 No N2, amber, 30 Days, 40 °C 96.1 N2, clear, 30 Days, 40 °C 98.0 No N2, clear, 30 Days, 40 °C 97.4
N2, amber, 2 Mo, 40 °C 95.3 No N2, amber, 2 Mo, 40 °C 92.9 N2, clear, 2 Mo, 40 °C 95.8 No N2, clear, 2 Mo, 40 °C 94.0
N2, amber, 3 Mo, 40 °C 94.0 No N2, amber, 3 Mo, 40 °C 90.4 N2, clear, 3 Mo, 40 °C 93.5 No N2, clear, 3 Mo, 40 °C 90.9
N2, amber, 4 Mo, 40 °C 93.0 No N2, amber, 4 Mo, 40 °C 87.7 N2, clear, 4 Mo, 40 °C 91.8 No N2, clear, 4 Mo, 40 °C 88.2
N2, amber, 6 Mo, 40 °C 85.3 No N2, amber, 6 Mo, 40 °C 75.6 N2, clear, 6 Mo, 40 °C 82.2 No N2, clear, 6 Mo, 40 °C 75.6
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 Table 17. Ocular tolerability study results in New Zealand White rabbits for RX-10045 (0.1%) nanomicellar formulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hackett-McDonald Composite Scores (mean ± s.d). 
Dose Placebo nanomicellar 
formulation 
RX-10045 (0.1%) 
nanomicellar formulation 
Day 1 Predispose 0.0 – 0.0  0.0 – 0.0 
Day 1 Postdispose 1.75 – 1.5 0.5 – 0.1 
Day 2 Predispose 0.0 – 0.0  0.0 – 0.0 
Day 2 Postdispose 2.0 – 0.0  0.0 – 0.0  
Day 3 Predispose 0.0 – 0.0  0.0 – 0.0  
Day 3 Postdispose 1.3 – 1.2  0.0 – 0.0  
Day 4 Predispose 1.3 – 1.2  0.0 – 0.0  
Day 4 Postdispose 1.3 – 1.2  0.0 – 0.0  
Day 5 Predispose 0.0 – 0.0  0.5 – 1.0  
Day 5 Postdispose 1.3 – 2.3 0.0 – 0.0  
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Table 18. Comparison of mean ocular distribution of RX-10008 (active metabolite 
of RX-10045) after four times a day at 2 hour intervals for 5 days to New Zealand 
White Rabbits with topical drop administration 
Ocular tissue or fluid Treatment with 0.1% RX-10045 
nanomicellar formulation (RX-10008) 
(N = 2) ng/g or ng/mL   
Cornea 17725   
Conjunctiva 879   
Iris-Ciliary body 2655   
Sclera 701   
Lens 165   
Aqueous Humor 3205   
Vitreous Humor 16 
Retina-Choroid 323   
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fluid (vitreous and aqueous humors) RX-10008 concentrations are presented in 
Table 18. The reason for RX-10008 quantification instead of RX-10045 is due to 
rapid hydrolysis of RX-10045 to RX-10008 in ocular tissues in fluids.  The trend 
for drug concentration followed the same that was observed with CsA nanomicellar 
formulation. The highest drug concentrations of RX-10008 were found in the 
cornea, followed by iris-ciliary body, conjunctiva, and sclera. Moreover, high 
concentrations of RX-10008 were quantified in aqueous humor. Lower amounts 
were found in retina-choroid and lens. The lowest levels of RX-10008 were found 
in the vitreous humor. However, very low/sporadic concentrations of RX-1001 
ester prodrug were observed in the sclera and conjunctiva. Compound RX-1001 
was either not detected or was below quantitation limit of the assay. The results 
suggest that RX-10045 rapidly hydrolyzed to its active metabolite (RX-10008). 
Discussion 
 
The resolvin E1 analog suffers from poor aqueous solubility and stability 
(data not shown from Auven Therapeutics). Encapsulation of RX-10045 in 
nanomicellar formulation resulted in higher stability. But, for topical drop 
application formulation pH should be regulated. Therefore, to improve the stability 
and maintain the pH of the solution citrate buffer was used. Stability studies at 
different concentration of citrate buffer were conducted. All the stability studies are 
conducted at higher temperatures i.e., under accelerated conditions to save time and 
determine the shelf-life for the drug/formulation. These accelerated stability studies 
i.e, studies at higher temperatures (40 oC, 50 oC, 60 oC and so on) cause drug 
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degradation to be faster and help to determine the shelf life.  In other words, drug 
is supposed to be degraded at higher temperatures which help to determine the shelf 
life in less time. 
Results from stability studies indicate that at 25 oC, 0.05 M and 0.1 M citrate 
buffer concentration was very high and caused catalysis and degradation of the drug 
in the formulation. On the other hand, 0.005 M citrate buffer was not sufficient 
enough to maintain the pH for the entire length of time and therefore was prone to 
Rx-10045 degradation. Similar effects were observed at 40 oC.  Citrate buffer at a 
concentration of 0.01 M provided sufficient pH stability, which is evident from the 
HPLC results. Data reveals that at 25 oC RX-10045 was ~ 100% and at 40 oC RX-
10045 was ~ 97% remaining in the formulation at pH 6.0 i.e, only 3.2% of RX-
10045 was degraded in one month.  However, when the citrate buffer concentration 
was increased to 0.05 M, degradation of RX-10045 was observed because the 
citrate buffer itself was causing catalysis and showed drug degradation. In other 
words, at 0.05 M and 0.1 M citrate buffer (pH = 6.0 and 5.5) RX-10045 is more 
pronounced to degradation because of citrate buffer. While at concentration of 
citrate buffer less than 0.01 M i.e., 0.005 M was not effective in maintaining the pH 
and this led to drug degradation.  
 In vivo studies revealed no significant IOP changes in eyes treated with BSS 
or RX-10045 nanomicelles. No toxicological response or changes in retinal 
function were noted with ERG after 5 days of treatment with RX-10045 
nanomicellar formulation. Moreover, no toxicological or inflammatory responses 
were observed histologically in the anterior (conjunctiva/cornea/iris) or posterior 
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segments (vitreous/retina) of the eye indicating the formulations are safe and well-
tolerated. Ocular tissue distribution studies reveal high drug concentrations in the 
anterior tissues (cornea and conjunctiva). Moreover, results suggests that 
nanomicelles utilized conjunctival-scleral pathway to reach posterior ocular tissues 
and deliver RX-10045 into retina-choroid.  
Conclusion 
 
The delivery of drug into ocular cells may be inhibited due to the presence of 
membrane bound functional efflux transporters. For the first time, we have 
demonstrated a resolvin E1 analog (RX-10045) to be a substrate/inhibitor for efflux 
transporters (MRP2 and BCRP). It is observed that permeability of [3H] digoxin 
was not affected in presence of RX-10045 indicating there may be negligible 
interaction with P-gp. It remains to be determined whether this is a class property 
of the resolvins; however, this report suggests that efflux transporters may impede 
the translocation of RX-10045 across some target cell membranes. A significantly 
reduced uptake of [3H] abacavir in presence of RX-10045, compared to quinine (a 
known inhibitor of OCT-1), clearly suggests that RX-10045 is a strong 
substrate/inhibitor of OCT-1. Knowledge of resolvin interaction with efflux 
transporters can allow pharmaceutical scientists to develop new strategies and 
formulations (278, 320) to circumvent efflux barrier and deliver therapeutic 
concentrations of resolvin into target ocular tissues. A clear, aqueous nanomicellar 
RX-10045 formulation was successfully developed and optimized. Stability of the 
formulation was significantly improved when incorporated in nanomicellar 
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formulation with optimized citrate buffer. In vivo tolerability studies suggest that 
formulations are safe and well-tolerated. Ocular tissue distribution in New Zealand 
White rabbits suggest that RX-10045 was rapidly hydrolyzed to RX-10008 which 
was quantified in anterior and posterior ocular tissues. A trans-scleral pathway is 
hypothesized for nanomicellar formulation to reach and deliver the cargo to back-
of-the-eye tissues.   
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Chapter 5 
TOPICAL AQUEOUS CLEAR DEXAMETHASONE NANOMICELLAR 
FORMULATION: OPTIMIZATION AND IN VIVO TISSUE 
DISTRIBUTION 
Rationale 
 
Dexamethasone (DEX), a glucocorticoid, is widely indicated as an anti-
inflammatory and immunosuppressive drug (321) following cataract surgery or 
corneal procedure (322, 323).  DEX is also used in the treatment of posterior 
segment eye diseases such as uveitis and macular edema (324, 325).  DEX has a 
poor aqueous solubility (0.159 mg/mL) (326) and is a substrate for efflux proteins 
(327). Moreover, efflux pumps expressed on corneal epithelial cells (328) may pose 
a barrier for DEX permeation and lower intracellular DEX concentrations. 
Encapsulating DEX inside the core of nanomicellar formulation may improve its 
solubility and drug delivery. Amphiphilic molecules such as Vitamin E TPGS and 
Oc-40 may aid in developing a stable, clear, aqueous DEX nanomicellar 
formulation.  
Vitamin E TPGS is a safe and FDA approved water-soluble derivative of 
vitamin E. It is a non-ionic polymer with a hydrophilic lipophilic balance (HLB 
index) of about 13 (329). It is generally added to lipid based drug delivery systems 
as a stabilizer. Oc-40 is a non-ionic surfactant approved by FDA as a food additive 
and other pharmaceutical applications. Oc-40 (IGEPAL CA-897) has HLB index 
of about 18. Polymeric hydrophilic corona interacts with the external aqueous phase 
and prevents drug interaction with aqueous solution resulting in a stable aqueous 
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solution. Also, the interaction between encapsulated drug and polymers may sustain 
drug release. Additionally, these polymer combinations may lower critical micellar 
concentration. This perfect blend of polymers is optimal to formulate concentrated 
aqueous DEX solution. The steroid is not very soluble in aqueous medium (159 
µg/mL) with partition coefficient (log Ko/w) of 1.72 (326).  
Amphiphilic nature of Vit. E TPGS and Oc-40 allows spontaneous 
formation of spherical nanomicelles with a hydrophobic interior and hydrophilic 
corona in aqueous milieu. It allows high concentrations of hydrophobic DEX to be 
incorporated into the micellar core. Therefore, the objective of this study was to 
optimize and develop a clear, stable, aqueous DEX loaded nanomicellar 
formulation (NMF) with full factorial statistical design of experiments (DOE). 
Standard least square fit analysis was performed to identify the ideal polymeric 
blend to encapsulate DEX. Our method of DEX formulation preparation is simple, 
reproducible, easy to scale up for large scale production (330) and most importantly 
minimizes drug loss in the manufacturing process. 
Materials and Methods 
 
Dexamethasone and prednisolone (PD) were obtained from Tokyo chemical 
industry Co., Ltd, Japan.  Vitamin E TPGS was purchased from Peboc division of 
Eastman Company, UK.  Oc-40 (Igepal) was obtained from Rhodio Inc., New 
Jersey, USA. HPLC grade methanol, acetonitrile, and dichloromethane were 
procured from Fisher Scientific, USA. Ethanol was purchased from Aaper alcohol 
and chemical Co., Shelbyville, Kentucky, USA. Sodium phosphate monobasic and 
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Sodium phosphate dibasic were purchased from Mallinckrodt, USA.  Povidone K 
90 (PVP-K-90, Kollidon® 90 F, Ph.Eur., USP) was purchased from Mutchler, Inc. 
Pharmaceutical ingredients, Harrington Park, New Jersey, USA. 
 
Methods 
HPLC analysis 
Analysis of DEX were performed by a reversed phase RP-HPLC method 
with a Waters 515 HPLC pump (Waters corporation, Milford, MA), Alcott 
autosampler (model 718 AL), Alcott 795 UV-visible detector, Zorbax SB-phenyl 
column (5 µm, 25 x 4.6 mm) (Agilent Technologies, Santa Clara, CA) and Hewlett 
Packard HPLC integrator (Hewlett Packard, Palo Alto, CA). The mobile phase was 
comprised of ACN, water and trifluoroacetic acid (TFA) (40:60:0.1% v/v), which 
was set at a flow rate of 1 mL/min. Detection wavelength was set at 254 nm. 
Calibration curve (0.5 to 1.5 μg/mL) for DEX was prepared by making appropriate 
dilutions from the stock solution. Prednisolone (1 mg/mL) was appropriately 
diluted and used as internal standard. An injection volume of 50 μL was injected 
into the HPLC column for analysis.  
Sensitivity of the method was established with limit of detection (LOD) and 
limit of quantification for DEX with signal to noise ratio of 5:1. LOD and LOQ 
were determined by injecting a series of known concentrations of DEX. Precision 
was carried out at the LOQ level by injecting six replicates of DEX preparations at 
LOQ concentration by calculating relative standard deviation for each peak area. 
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Intra-day and inter-day (three different days) RSD of < 2.0 % was considered to be 
acceptable for analytical method sensitivity. 
LC-MS/MS Analysis 
For quantitative determination of DEX in ocular tissues a selective and 
sensitive LC-MS/MS method was developed. Chromatographic analysis was 
carried out on API 2000 triple quadruple linear ion QTrap mass spectrometer. High 
performance liquid chromatographic system consists of Agilent 1100 LC 
Quaternary pump, Agilent 1100 well plate, autosampler (Agilent technologies, 
Wilmington, DE) with a reversed phase gemini C18 column (50 mm × 4.6 mm i.d., 
5 m, Phenomenex, Torrance, CA). Isocratic mobile phase composed of 30% of 
acetonitrile in water, containing 0.1% of formic acid, was at a flow rate of 0.2 
mL/min.  
 
Mass spectrometer operating conditions  
MDS Sciex API 2000 Triple Quadrupole linear QTrap mass spectrometry 
(Applied Biosystems/MDS Sciex, Faster City, CA) system interfaced by turbo ion 
spray (TIS) with positive ion source in MRM mode was applied for detection. Ultra 
high pure nitrogen served as collisionally activated dissociation (CAD) at 4 psi and 
curtain gas at 20 psi. Nebulizer and turbo gas were optimized at 40 and 50 psi 
respectively. The TIS temperature was maintained at 200 oC, with source voltage 
and dwell time optimized at 5200 V and 400 ms respectively. Mass dependent 
parameters were tuned and optimized for DEX, and PD. Parent and daughter ions 
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obtained by direct infusion mode (10 µL min-1) was injected with built-in Harvard 
infusion syringe pump and were optimized.  
 
Experimental design 
As a preliminary study to screen the weight percent of polymers, effects of 
formulation variables on DEX entrapment, NMF size and polydispersity index 
(PDI) were evaluated based on statistical design of experimental (DOE) protocol. 
Student version of JMP® 9.0 software (SAS institute, USA) was used to develop 
the experimental design and analyze the data. Two independent (X1 and X2) and 
three dependent variables (Y1, Y2, and Y3) were identified. Independent variables 
X1 and X2 are Vit. E TPGS and Oc-40, respectively. Dependent variables Y1, Y2 
and Y3 represent percent entrapment efficiency, micellar size and polydispersity 
index, respectively. “Screening design” option in JMP® was selected to create a 
design that included the categorical variables that cannot be quantified. In the same 
way, other continuous variables (polymer concentration in weight percent (wt%)) 
were selected. A three level full factorial design with 9 runs was chosen from the 
“design list” (Table 19). Coded values -1, 0, +1 were assigned to the weight percent 
levels for the two polymers.  
 
Preparation of DEX-loaded nanomicelles 
Nanomicellar formulation of DEX was prepared by solvent evaporation 
method. The interactions between the hydrophobic core of polymers and the drug 
(0.1 wt%) improve the drug entrapment. Direct addition of the drug to the aqueous 
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polymeric solution leaves most of the added drug unentrapped.  Therefore, the 
novel DEX loaded formulations were prepared following similar protocol 
described in Chapter 3 with minor modifications in step 2. In step 2, the resultant 
thin film was hydrated with 50 mL of double distilled deionized water and kept 
under sonication for 20 minutes in a water bath sonicator (50/60 Hz, 125 W). The 
volume of the rehydrated formulation was made up with 2X phosphate buffer 
solution, (pH 6.8).  Further to improve the viscosity of the NMF povidone K 90 
(solution viscosity enhancer) was added and mixed to obtain a clear solution. The 
solution was filtered through 0.2 μm nylon filter membrane to remove the 
unentrapped drug aggregates and other foreign particulates.  
 
Characterization of nanomicelle formulation 
The prepared DEX loaded nanomicellar formulations were subjected to 
characterization following procedures described in Chapter 3 for entrapment 
efficiency, loading efficiency, size, polydispersity index, surface potential, CMC 
and proton NMR studies. CMC for the blend of polymers (Vit. E TPGS and Oc-40) 
was determined following procedure described previously. HPLC-UV was used for 
determining entrapment and drug loading. Formulation stability studies were 
conducted at three different temperatures (4 oC, 25 oC and 40 oC). At predetermined 
time points both placebo and DEX loaded nanomicellar formulation samples were 
collected into 200 µL HPLC inserts/vials and immediately stored at -80 ºC until 
further analysis with HPLC. 
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Nanomicelle stability 
Stability studies were conducted for F1 NMFs. DEX-loaded and blank 
nanomicelles, were stored at 40 °C, room temperature and 4 °C. To avoid microbial 
growth during long term storage sodium azide, 0.025% w/v, was added. At 
predetermined time intervals, each sample was collected, centrifuged at 10,000 g 
for 5 min. The supernatant was collected and DEX was extracted from NMF 
following the procedure described for entrapment efficiency. The concentration of 
DEX remaining in solution was measured using RP-HPLC. Also, the size of 
nanomicelles was determined at each time point following the previously described 
procedure. 
 
In vitro cytotoxicity  
Cell viability and plasma membrane damage studies were conducted 
following the manufacturer’s protocol described in Chapter 3 on rPCEC cell lines. 
For cell viability studies triton X-100 served as positive control and serum free cell 
culture medium with no NMF served as negative control. However, in LDH assay 
the control were triton X-100 as positive control and cell culture medium served as 
negative control.  
 
In vivo Studies 
New Zealand albino adult male rabbits, weighed between 2.0 and 2.5 kg, 
were obtained from Myrtle’s Rabbittry (Thompson Station, TN) and housed in 
accordance with US Department of Agricultural and Association for Assessment 
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and Accreditation of Laboratory Animal Care international guidelines. All 
protocols were reviewed and approved by Animal Care and Use Committee of 
University of Missouri Kansas City. Studies performed were in accordance with 
the Association for Research in Vision and Ophthalmology Regulations and 
Standards (ARVORS) guidelines. Rabbits were anesthetized with subcutaneous 
ketamine (30 mg/kg). Ten minutes after anesthesia, the rabbit’s head was held to 
keep the left eye horizontal and 50 µL of 0.1% dexamethasone a novel nanomicellar 
formulation (Vitamin E TPGS – 4.5% and Oc-40 – 2.0%) eye drops were instilled 
using a micropipette at the center of lower cul-de-sac. During the instillation, the 
lower eyelid was pulled slightly away from the globe and was returned to normal 
position immediately after instillation. After 60 min, rabbits were euthanized using 
1 mL of intravenous injection of Fatal-Plus® (Vertech Pharmaceuticals 
Corporation, Dearborn, Mich) (39% sodium pentobarbital) into the marginal ear 
vein. Following euthanasia, the eye ball was enucleated immediately (on an average 
within 150 s) and transferred to a beaker containing ice-cold phosphate buffer (pH 
7.4). Repetitive washings were carried out in cold phosphate buffer to remove any 
adsorbed drug on to the surface. Aqueous humor was withdrawn by limbal 
paracentesis and then vitreous humor was aspirated using a 1 mL tuberculin syringe 
after making a tiny incision at sclera–limbus junction. The enucleated eyeball was 
cut open and the following tissues were dissected: cornea, iris–ciliary body (ICB), 
lens, retina–choroid (RC) and sclera were all collected into pre-weighed 
eppendorfs. After dissection, the tissues were dried with Kimwipes® and weighed. 
Protein content in the aqueous and vitreous humor was measured by the method of 
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Bradford (Bio-Rad protein estimation kit, Hercules, CA). All tissue samples were 
stored at −80 oC until further analysis. 
 
Preparation of samples 
Tissues were homogenized in 500 L chilled (4 oC) phosphate buffer (pH 
7.4) for about 4 min with a tissue homogenizer (Tissue Tearor, Model 985-370; 
Dremel Multipro, Racine, WI) in an ice bath, with the exception of sclera, which 
required 1.5 mL. One hundred microliters of aqueous humor (AH) and vitreous 
humor (VH) were collected for analysis without further processing. Subsequently 
100 L of the tissue homogenates (cornea, iris–ciliary body, lens, retina–choroid and 
sclera), aqueous humor and vitreous humor were collected for further sample 
processing. 
 
Dexamethasone ocular tissue sample extraction 
Dexamethasone was extracted from ocular tissue homogenates by a simple 
liquid–liquid extraction as described previously. All tissue samples were analyzed 
with freshly prepared calibration curve and quality control standards. Calibration 
curve (2.70–617.60 ng/mL) and QC standards were prepared by spiking appropriate 
abounds in seven different blank ocular matrices (control tissues) with varying 
concentrations of dexamethasone with PD as an IS. All standards and samples were 
analyzed with LC–MS/MS. 
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Statistical Analysis 
 
The experimental design and the data analysis were performed by student version 
of JMP® 9.0 software. Standard least squares were used to fit the models. Data for 
in vitro experiments were conducted at least in quadruplicate (n = 4) and the results 
were expressed as mean ± standard deviation (SD). Statistical comparison of mean 
values was performed with Student’s t-test. A P-value of <0.05 was considered to 
be statistically significant. 
Results 
 
Nanomicellar formulations of DEX were prepared following solvent 
evaporation and rehydration method. Statistical design of experiments was used to 
optimize the NMF with respect to entrapment efficiency, size and polydispersity 
index. However, size and polydispersity index had no significant effect on the 
formulation optimization. Therefore, were negated from optimization parameters. 
The optimal blend ratio of Vit. E TPGS and Oc-40 were 4.5 wt% and 2.0 wt%, 
respectively which had the lower CMC (0.012 wt%) relative to individual polymers 
(Vit. E TPGS = 0.022 wt% and Oc-40 = 0.108 wt%). This polymeric ratio had lower 
CMC and was used to entrap DEX (0.1%). In vitro studies on rPCEC cells 
demonstrated DEX NMF to be safe, well-tolerated and results were comparable to 
that of negative control.  
Quantitative determination of DEX in different ocular tissues after topical 
administration showed higher concentrations in anterior ocular tissues.  DEX was 
identified in cornea, iris-ciliary body, sclera and retina-choroid. Aqueous humor 
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had small amounts of DEX. However, no DEX identified (below limit of 
quantitation i.e., less than 2.7 ng/mL) in lens and vitreous humor. 
Discussion 
 
Selection of critical (or meaningful) factors based on experimental design 
In this study we selected full factorial design of experiments (DOE) to 
screen essential independent factors for outcomes (entrapment, size and PDI). All 
the formulations were subjected to other characterizations such as loading 
efficiency, CMC, optical absorbance, osmolality, pH, dissociation temperature, 
regeneration time, osmolality, viscosity and surface potential (Table 19 and Table 
20). The results for dependent variables (Y1, Y2 and Y3) from 9 sets of NMFs are 
presented in Table 19. The standard least square fit analysis via JMP® 9.0 software 
(331) was performed to identify the most influencing factors for each dependent 
variable. The model fit was significant when one of the formulations (F8 in Table 
19) was excluded from the analysis. Therefore eight sets of formulations were 
considered for formulation optimization following standard least square fit 
analysis. The main effects of one-factor and two factor interaction effects were 
taken into consideration. The rationale behind this selection was higher interactions 
are less significant. The parameters that exhibited most significant outcome were 
selected and processed with standard least square regression model to fit those 
parameters. 
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Table 19. Results of full factorial design 
aNMF code pattern: (+) high, (0) medium, (-) low; NMF = Nanomicellar Formulation; PDI = Polydispersity Index; CMC = 
Critical Micellar Concentration; nm = nanometer; wt% = weight percent; N.D =Not Determined  
Formulation 
code/number 
NMF 
code 
patterna 
Vit. E 
TPGS 
(wt%) 
Oc-40 
 
(wt%) 
% 
Entrapment 
efficiency 
NMF effective 
diameter (nm) 
NMF  
PDI 
Loading 
efficiency 
CMC 
(wt% X 10-3) 
F1 ++ 4.5 2.0 99 ± 5.5 10.5 0.086 1.50 12 
F2 +0 4.5 1.05 92 ± 2.3 11.3 0.099 1.64 59 
F3 +- 4.5 0.1 86 ± 3.4 12.2 0.078 1.85 90 
F4 0+ 3.5 2.0 93 ± 2.7 10.1 0.057 1.66 103 
F5 00 3.5 1.05 82 ± 5.8 11.9 0.123 1.79 127 
F6 0- 3.5 0.1 26 ± 3.5 10.2 0.078 0.70 420 
F7 -+ 2.5 2.0 82 ± 3.2 11.0 0.132 1.79 218 
F8 -0 2.5 1.05 81 ± 4.2 12.2 0.085 2.25 172 
F9 -- 2.5 0.1 23 ± 5.7 13.4 0.089 0.86 620 
Vit. E TPGS  4.5 0.0  67± 3.7 10.0 0.069 1.45 25 
Oc-40  0.0 2.0 N.D N.D N.D N.D 107 
  
2
2
7
 
 
Table 20. Characterization of nanomicellar formulation 
 
D.T = Dissociation Temperature; R.T = Regeneration Time; mOsm/kg = milliOsmols/kilogram; cP = centipoise; mV = millivolts; 
A.D.T. = above detection point (> 100 oC); N.D = Not determined. In osmolality columns “before” means before addition of 
tonicity enhancing agent and “after” means improved tonicity after addition of tonicity enhancer.  
 
Formulation 
code/ 
number 
Absorbance 
at 400 nm 
± S.D 
D.T (° C)  
± S.D 
R.T (sec)  
±S.D 
Osmolality (mOsm/kg) Viscosity 
 (cP) 
Zeta potential 
(mV) 
Before After 
F1 0.040 ± 0.001 A.D.T N.D 205 299 1.79 -2.26 
F2 0.013 ± 0.002 84 ± 0.87 9 ±  1.00 218 307 1.68 -1.67 
F3 0.020 ± 0.001 76 ±  1.49 40 ± 1.70 219 315 1.72 -2.92 
F4 0.046 ± 0.001 93 ±  0.87 16 ± 2.31 253 289 1.59 -1.63 
F5 0.025 ± 0.001 76 ±  0.76 28 ± 1.73 203 315 1.74 -1.32 
F6 0.044 ± 0.001 74 ± 0.87 42 ± 12.0 222 308 1.65 -2.30 
F7 0.046 ± 0.001 71 ±  0.81 18 ±  2.31 201 295 1.69 -3.41 
F8 0.044 ± 0.001 91 ±  0.30 15 ±  1.00 214 301 1.75 -2.47 
F9 0.025 ± 0.001 71 ± 0.79 40 ± 5.00 216 298 N.D -1.89 
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Table 21. Summary showing fit to the model prediction of entrapment, size and PDI. 
 
 
 
 
 
  
Entrapment 
efficiency (%Y1) 
NMF Size 
(nm) (Y2) 
NMF 
PDI 
(Y3) 
R square 0.88032 0.413733 0.228791 
R square adjusted 0.790559 -0.020597 -0.34962 
Root mean square 
error 13.91169 1.154439 0.028684  
Mean of Response 72.85 11.29625 0.09275 
Observations 8 8 8 
                            NMF = Nanomicellar formulation; PDI = Polydispersity index 
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We could fit the model for percent entrapment efficiency but not for size and 
PDI. The summary for fit model for entrapment efficiency is presented in 
Table 21. Further, analysis of variance (ANOVA) for entrapment efficiency 
showed a significant effect with F ratio (probability > F) of 0.026. 
 
Master formula (Prediction Equation) 
The fit model developed the following polynomial equations for the output: 
entrapment efficiency (Eq 4), NMF size (Eq 5) and PDI (Eq 6): 
 
Y1 = -24.46 + 20.3X1 + 22.80X2 + (-12.08)(X1-3.625)(X2-1.0375)  Eq. 11 
Y2 = 13.33 - 0.354X1 – 0.723X2 + (-0.198)(X1-3.625)(X2-1.0375)             Eq.12        
Y3 = 0.126 - 0.010X1 – 0.00367X2 + (-0.009421) (X1-3.625)(X2-1.0375)  Eq 13         
 
(where X1 = Vit. E TPGS level/experimental code; X2 = Oc-40 
level/experimental code and X1X2 are the interaction levels/experimental 
code of Vit. E TPGS and Oc-40).  
 
After interpreting the data obtained (Eqs. 11, 12 and 13), polynomial 
equation for the response variable (Y1, Y2 and Y3) for three level, two factor 
variables was developed. Since the polynomial equations for Y1 fit well (R2 = 
0.880), it was used for optimization process. The other two polynomial equations 
for Y2 and Y3 did not fit (R2 = 0.41 and 0.23). The possible reasons for low fit 
may be due to extreme small size range of nanomicelles. Results show that there 
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is no significant difference in nanomicellar size and PDI (Table 19). Therefore, 
the obtained polynomial equation for entrapment efficiency (Y1) was applied to 
predict entrapment efficiencies of NMFs by adjusting the levels of input 
variables. Of all the predicted entrapment efficiencies, NMF F1 was predicted to 
be (102.33 %) when both polymers are set at high levels.  
Pareto chart was developed for each individual outcome. It is used to 
determine which factors and interactions are relevant. These charts are 
developed using the absolute value obtained from the half the value of main 
effects. The bars in the chart that extend past the line indicate values reaching 
statistical significance (α = 0.05). In the case of entrapment efficiency both 
factors, Vit. E TPGS and Oc-40, are found to pass the line indicating their 
statistically significant effect on entrapment efficiency (Figure 47A). But, 
interactions between these two input factors did not cross the line and was not 
significant for DEX entrapment efficiency. Similarly, effects of input 
variables on the NMF size and PDI outcomes were determined with Pareto 
chart and found to have negligible effect (Figure 47B and C). These results 
indicate that only DEX entrapment was dependent on individual input 
variables (Vit. E TPGS and Oc-40). As said earlier, we were unable to fit the 
model for nanomicellar size and PDI. Other models have to be tried to fit the 
model. From the obtained results in Table 19 there appeared no significant 
difference in nanomicellar size and PDI. Therefore, we did not make any 
attempts to use the fit model results. Also, the results obtained from the 
standard least square fit model for nanomicellar size and PDI revealed that 
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there is no statistically significant difference in the outcome (data not shown). 
Prediction profiler for entrapment efficiency, size and PDI was developed 
(Figure 48). Prediction profiler helps to determine the levels of input 
variables to be adjusted in a combination where the outcome can be predicted. 
We found that when both the input variables (Vit. E TPGS and Oc-40) kept 
at high levels (4.5:2.0) resulted in high entrapment efficiency (98.7 ± 5.5), 
which is evident from the results. The prediction profiler results and the 
experimental results are in agreement. Therefore, the combination of 
variables at high level with high entrapment efficiency was assumed to be the 
better formulation. To further determine the effects of the input variables on 
the entrapment efficiency a contour plot analysis was developed (data not 
shown). A contour plot is a three dimensional representation for the outcome 
when the input variables are adjusted. From the contour plot one can estimate 
the levels of the input variables and determine the outcome (present on the 
surface of the box). The shaded region in contour plot indicates the lower 
entrapment region of DEX. On the other hand, the unshaded region represents 
the higher entrapment. We observed that when both variables (Vit. E TPGS) 
set at high level, high entrapment efficiency was predicted. Experimental 
design results and our experimental outcome suggest that when the polymer 
combination is kept at high level results in higher entrapment. The results 
appear to be in agreement with the outcome. 
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Figure 47. Pareto charts (A) Entrapment efficiency for DEX (B) nanomicellar size (C) Polydispersity Index. 
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Figure 48. Prediction profiler for optimal nanomicellar formulation 
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From the prediction equation and contour plot high entrapment efficiency was 
predicted when input variables were set at high levels. Taking input levels at 
high levels, entrapment efficiency was predicted to be 101.44%. We 
conducted NMF preparation following the procedure described earlier and the 
entrapment efficiency was determined according to the RP-HPLC method. 
Results confirmed that percent DEX entrapment into NMF to be 97.5 ± 2.5, 
which is in agreement with the DOE.  
Entrapment and loading efficiency 
DEX entrapment and loading into the nanomicelles was determined with 
RP-HPLC method described earlier. All the NMFs showed excellent drug 
entrapment and loading efficiencies, which are summarized in Table 19. Among 
the formulations prepared and from the experimental design results it can be 
concluded that formulation F1 has the highest entrapment efficiency with optimal 
drug loading. Before conducting further characterization for F1 formulation, all the 
formulations were commonly subjected to appearance, viscosity, osmolality, size, 
PDI, surface charge, dissociation temperature and regeneration time tests (Table 
20).  
 
Micellar size, polydispersity, surface charge and morphology 
 
Nanomicellar size and polydispersity indices were determined for all the prepared 
formulations. Results show a size range between 10 and 40 nm (Table 19). 
Polydispersity indices were observed to be in the range of 0.080 – 0.135 (Table 
19). DEX loaded NMF are slightly larger than blank NMF.  Blank NMF (Vit. E 
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Figure 49. Size distribution for nanomicelles (A) Blank nanomicelles effective diameter 10.2 ± 0.3 nm (B) DEX loaded 
nanomicelles effective diameter 10.46 ± 0.3 nm. 
 
  
2
3
6
 
 
 
 
 
 
 
 
Figure 50. TEM image of DEX encapsulated nanomicellar formulation, A) TEM picture of DEX encapsulated nanomicelles 
(scale bar = 100 nm) and B) 0.1% DEX nanomicellar formulation on the left compared with DI water on right. 
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TPGS: Oc-40; 4.5:2.0) and optimally DEX loaded NMF (F1) exhibited a size of 
10.2 ± 0.3 nm and 10.46 ± 0.3 nm respectively (Figure 49). We assume that the 
size of NMF to be sufficiently suitable to traverse across aqueous scleral 
channels/pore that have a size range between 20 and 80 nm (63). Also, these 
micelles display a narrow and unimodal particle size distribution. However, no 
significant changes in micelle size or size distribution were noted. Since these 
NMF's are in the same size range as membrane receptors, proteins, and other 
biomolecules, such carriers may have the ability to bind with cellular barriers.  
Surface charge of NMFs was found to carry a slight negative charge (Table 20). 
Surface morphology of DEX loaded NMFs was studied with TEM and results 
revealed that the NMFs are spherical in shape with smooth surface architecture 
without any aggregation (see Figure 50). The particle size visualized by TEM were 
in agreement with the size obtained by DLS. 
 
Optical clarity / Appearance 
One of the major objective of this study was to prepare an aqueous clear 
solution of DEX. Optical clarity/appearance refers to 90% or greater 
transmission of light of 400 nm wavelength in a 1.0 cm path.  Micelle size, 
typically smaller than the smallest wavelength of a visible light radiation 
(about 350 nm), denotes clarity of the solution. In general, light scattering 
occurs when any particle interferes with the visible light wavelengths. Due to 
extremely small size of the nanomicelles light is not scattered, which denotes 
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a transparent/clear aqueous solution. Ophthalmic compositions of the present 
DEX formulations are substantially clear with an absorption units below 0.05 
measured at 400 nm (data not shown). The low absorbance of the formulation 
indicates the clarity of the formulation which is devoid of any particulate 
matter. For example, absorbance data for the formulation (F1) used for the 
characterization studies was (0.040 ± 0.001). The optical clarity of the 
formulation was compared with distilled deionized water as blank. This study 
indicates that all the NMFs are similar to water with no particulate matter 
present. 
 
Viscosity 
Viscosity of the formulation is another critical factor that needs to be maintained.  
Optimal viscosity helps to increase the mean residence time of NMF at the 
administration site (precorneal and under eye lid pocket). Therefore, bioadhesive 
polymers such as PVP-K-30, hydroxypropyl methyl cellulose, hydroxyethyl 
cellulose or polycarbophil could be used. The high concentrations of these 
polymers were required to improve viscosity which resulted in undesirable 
outcomes like increase in NMF size, PDI or reduced NMF dissociation temperature 
(data not shown). However, PVP-K-90 polymer had negligible effect on the NMF 
and raised the dissociation temperature. Therefore, PVP-K-90 was selected as a 
bioadhesive and viscosity enhancing excipient/agent. Formulation viscosity was 
adjusted to be less than 2.0 centipoise (cP) (well below critical point of 4.4 cP) to hold 
formulation in the cul-de-sac and which does not affect rate of tear drainage (285).  
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Thermal dissociation and regeneration time 
The NMF has to be robust and the parameters used, in general, include 
thermal dissociation and regeneration time. DEX loaded NMF with very high 
thermal dissociation temperature (DT) indicates the formulation is stable at high 
temperature. Following thermal dissociation when NMFs are allowed to cool to 
room temperature under ambient conditions, micelles were regenerated within less 
than one minute resulting in optically clear solutions.  In general micelles are 
unstable structures possessing two characteristic relaxation times i.e., fast (τ1) and 
slow (τ2).  The results show the time taken to regenerate the micelles is in seconds 
(Table 20), because both surfactants are non-ionic in nature. This peculiar behavior 
of the formulation indicates that the hydrophobic DEX is entrapped in the 
nanomicellar core even after being subjected to harsh conditions. Thermal 
dissociation/dissociation temperature of the blank NMF is about 20-40 oC higher 
than the formulation containing drug.  With temperature rising above DT, micelles 
appear to dissociate into individual monomer units. Such disruption of micelle 
structures causes drug release in surrounding aqueous medium. Such 
destabilization of nanomicelles results in the formation of a cloudy or milky white 
solution. DT of the optimized formulation appears to be extremely high (>100 oC) 
which provides maximal stability to the formulation at normal room temperature. 
The results clearly show that increase in concentration of Oc-40 raises the DT at 
constant Vit. E TPGS. 
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Critical micellar concentration 
Ocular drug delivery is impeded from delivering therapeutic concentrations of 
drug due to ocular static and dynamic barrier which includes tear/tear dilution (332).  
CMC is a critical factor that regulates premature release of drug due to tear dilution 
after topical drop administration. Of the total volume applied, only 20% of the 
formulation is available for absorption (14). The applied formulation occupies the 
space in pre-corneal pocket by replacing lacrimal fluid. The total volume of tear 
that pre-corneal pocket can hold without overflowing is 10 µl (333). Tear turnover 
rate is ~0.7 µl/min (333).  The formulation applied will be continuously diluted by 
tears.  This tear dilution may disrupt the micelles and release the drug at the site of 
application.  To prevent the disruption of micelles by dilution a low CMC of the 
formulation is desired (334). To reduce the CMC of the polymeric surfactants a 
blend of non-ionic polymers is used.  This low CMC provides the DEX entrapped 
NMF with high stability after topical drop application. In the current study, CMC 
was determined for Vit. ETPGS, Oc-40 and for the blend of polymer mixtures (see 
Table 19) with iodine as a probe.  A lowering in CMC is an indicator of stable 
formulation at low surfactant concentrations. The results obtained were plotted for 
iodine intensity versus log wt% of polymer or blend of polymers was plotted to 
determine the intersection, which is CMC. CMC of Vit. ETPGS was found to be 
approximately 0.025 wt%, which is in agreement with the literature value.  The 
other polymer, Oc-40, generated a CMC value of 0.107 wt% which is greater than 
the CMC of Vit. ETPGS. A combination of the surfactants in varying ratio 
decreased the CMC value to 0.012 wt% (Formulation F1). The obtained individual 
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results were subjected to student t-test. The obtained CMC values are significant at 
p < 0.05 level.   
 
1
H NMR characterization 
 
1H NMR analysis is used to determine the presence of drug molecules in 
solution at parts per million (ppm) levels. NMFs were prepared in different media 
such as CDCl3 and D2O. 
1
H NMR spectroscopy studies were conducted for DEX ( 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51), mixture of polymers dissolved in CDCl3 ( 
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Figure 52) and entrapped drug in CDCl3 and D2O. The concentration of 
DEX entrapped in the NMF is ~6.3 times higher than its aqueous solubility (0.159 
mg/mL) (326). Addition of higher concentration of DEX in the aqueous 
environment leads to drug precipitation at the bottom of the vial due to insolubility. 
In our studies, we did not observe any precipitate at the bottom of the vial. Also, 
due to DEX aqueous solubility a small amount of unentrapped DEX may be present 
in the outer aqueous environment (D2O), which may not be identified visually or 
with naked eye. Results show that in CDCl3, the resonance peaks corresponding to 
DEX and nanomicelles are present ( 
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Figure 53). In D2O, peaks corresponding to nanomicelles are only detected 
and no peaks for DEX were evident ( 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 54). These results clearly indicate, DEX was entrapped into the inner 
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hydrophobic microenvironment/core of nanomicelles. Also, study suggests that no 
free/unentrapped DEX was present in the NMF. These results are similar to earlier 
shown results for paclitaxel loaded mixed polymeric micelles in D2O (280, 284).    
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Figure 51. 1H NMR for DEX and nanomicellar formulation. (A) 1H NMR dexamethasone in CDCl3 
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Figure 52. 1H NMR blank nanomicelles in CDCl3 
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Figure 53. 1H NMR nanomicellar formulation of dexamethasone in CDCl3. The symbol “*” indicates the resonance peaks 
corresponding to dexamethasone  
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Figure 54. 1H NMR dexamethasone entrapped nanomicellar formulation in D2O   
 249 
 
In vitro cytotoxicity 
 
To evaluate the cytotoxic effect of NMFs (blank and DEX loaded), MTS 
and LDH assays were performed on rPCEC cells. Since eye drops are rapidly 
cleared from the pre-corneal pocket (335, 336) MTS assay was performed for 1 h. 
It was assumed that a 1 h incubation period would be sufficient to evaluate any 
toxicity. Percent viable cells for all the NMFs were comparable to that of negative 
control (culture medium) (Figure 55A). Triton-X 100 served as positive control 
and reduced the percent cell viability to 10% of the total cell number. In another set 
of studies, cell plasma membrane damage test (LDH assay) studies were conducted 
following manufacturer’s protocol for 2 h, 6 h and 24 h incubation and examined 
for LDH release. The amount of LDH released in the culture media directly 
correlates with cytotoxicity. Triton-X 100 caused significant toxicity/membrane 
damage. Percentage cytotoxicity to rPCEC cells post exposure to NMFs (blank and 
DEX loaded) appeared to be negligible (Figure 55B) indicating NMFs did not 
cause cell membrane damage.  Results from these assays clearly suggest that our 
NMFs do not cause cell death or damage to plasma membrane and are safe for 
topical ocular application. 
 
 
In vitro DEX release 
 
In vitro release kinetics of DEX from Vit. ETPGS and nanomicelles (F1) 
were investigated at a physiological pH of 7.4 at 37 oC. An equal quantity of DEX 
(1 mg) was dissolved in 1 mL of absolute ethanol that served as a control. DEX 
release from ethanolic solution was much more rapid than DEX in Vit. ETPGS and  
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Figure 55. Cytotoxicity of blank and 0.1% DEX loaded nanomicellar formulations on rabbit primary corneal epithelial cells 
(rPCEC). (A) Cytotoxicity of blank and DEX loaded nanomicellar formulations on rabbit primary corneal epithelial cells (rPCEC), 
1 h exposure time, Triton-X 100 positive control and culture medium negative control; (B) Cell membrane damage (LDH assay) 
studies on rPCEC cells, 24 h incubation time, Triton-X 100 positive control and culture medium negative control (Formulation 
abbreviation are described in Table 19). Data are shown as mean ± S.E.M (n = 4). *p < 0.05 versus control (paired t-test). 
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nanomicelles. Almost 100 % DEX release occurs in approximately four hours for 
ethanolic DEX. The release kinetic profiles of ethanolic and encapsulated DEX 
from the nanomicelles have been depicted in Figure 56. Nanomicellar DEX release 
half-lives were slow and not associated with any significant burst effect. The results 
suggest a sustained release of DEX from the core of nanomicelles over a period of 
4.2 days. Results suggest that under physiological conditions, topical 
administration of DEX NMF helps to sustain release of DEX. As a result it aids in 
achieving therapeutic concentrations of DEX in ocular tissues thereby reducing 
dosing frequency. 
 
Nanomicelle stability 
  
The stability of NMFs is a very important segment in the formulation 
development process. In order to determine the stability of the novel NMF, we 
selected F1 formulation for long term stability studies. NMF F1 has low CMC, high 
entrapment efficiency, small size, narrow polydispersity index and high 
dissociation temperature. Formulation F1 was stored at 40 oC, 25 oC and 4 oC for 6 
months. Samples were monitored for time-dependent changes in nanomicellar size 
and drug content during the storage period. At predetermined time points, NMF 
sample was collected, centrifuged at 10,000 rpm for 10 mins at 4 oC, supernatant 
was collected and analyzed for DEX with RP-HPLC. Analysis shows that the drug 
concentration was low (Figure 57).  A plot of ln [DEX] versus time (h) was used 
to determine the shelf and half-lives of NMF.  The formulation stored at 
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Figure 56. In vitro dexamethasone release studies.  Graph showing dexamethasone release under in vitro conditions (N = 4). (▲) 
dexamethasone release from ethanolic solution. Dexamethasone was completely released in 4 h (▄) dexamethasone release from 
Vit. ETPGS alone. Dexamethasone release was sustained up to ~22 h and (♦) dexamethasone release from blend of Vit. ETPGS 
and Oc-40 (4.5:2.0) mixture for more than 100 h.  
  
2
5
4
 
 
 
 
 
 
 
 
 
 
 
 
Figure 57. Formulation stability studies (N= 4) at 40 oC.    
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40 oC exhibited a shelf life (t90) of 4.2 days and half-life of 27.7 days respectively 
(Figure 57). Simultaneously, nanomicellar size determination studies were 
conducted. No difference in micellar size for the samples was observed (data not 
shown).  The micellar size for the formulation remained the same in the stability 
studies conducted at 40 oC, room temperature (25 oC) and 4 oC.  NMF of DEX 
stored at 25 oC and 4 oC are stable for more than three and six months respectively 
(data not shown). Quantitative estimation of remainder DEX in the aqueous NMF 
was conducted with RP-HPLC as described earlier. At high temperature the 
formulation showed decreasing DEX concentration with time. Free drug 
precipitated out of the formulation and settled at the bottom of the vial, which was 
confirmed by RP-HPLC after separation of precipitate from the aqueous NMF.  
 
In vivo studies 
Quantitative determination of DEX in different ocular tissues after topical 
administration is shown in  
Concentration 
(ng/g tissue) 
Set 1  Set 2  Set 3  Set 4  Average 
± SD  
Cornea 
 
1415.01  1459.60  652.73  675.58  1051 ± 
446.8  
ICB 
 
922.2  630.27  265.98  299.76  530 ± 
309.1 
Sclera 
 
180.2  77.49  54.06  ---  104 ± 
67.1 
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Table 22. Sixty minutes after topical application to a rabbit eye, DEX 
concentration in the anterior segment (cornea, aqueous humor, iris ciliary bodies 
and lens) and posterior tissues (sclera, vitreous humor, and retina-choroid) was 
determined. DEX concentrations of 1415.01, 1459.60, 652.73 and 675.58 ng/g 
(four times dilution factor was applied to those cornea samples, values are 353.75 
× 4, 364.90 × 4, 163.18 × 4 and 168.90 × 4 ng/g respectively) of tissue and 464.80, 
401.05, 314.94 and 195.13 ng/mg protein were quantified in the cornea 
RC 
 
27.36  80.15  50.29  36.27  49 ± 
23.1  
AH 
(ng/mg protein)  
464.8  401.05  314.94  195.13  344 ± 
117  
Lens 
 
BLOQ BLOQ BLOQ BLOQ BLOQ 
VH 
(ng/mg protein)  
BLOQ BLOQ BLOQ BLOQ BLOQ 
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Table 22. DEX drug levels in ocular tissues from 0.1% nanomicellar formulation after topical administration. 
BLOQ: Below limit of quantification; LOQ: limit of quantification (2.70 ng/mL). a Dilution factors: cornea (4X) and ICB (2X); “—
“ tissue lost due to experimental error. 
Concentration (ng/g tissue) Set 1  Set 2  Set 3  Set 4  Average ± SD  
Cornea 
 
1415.01  1459.60  652.73  675.58  1051 ± 446.8  
ICB 
 
922.2  630.27  265.98  299.76  530 ± 309.1 
Sclera 
 
180.2  77.49  54.06  ---  104 ± 67.1 
RC 
 
27.36  80.15  50.29  36.27  49 ± 23.1  
AH 
(ng/mg protein)  
464.8  401.05  314.94  195.13  344 ± 117  
Lens 
 
BLOQ BLOQ BLOQ BLOQ BLOQ 
VH 
(ng/mg protein)  
BLOQ BLOQ BLOQ BLOQ BLOQ 
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and aqueous humor respectively. For the posterior segment, DEX concentrations in 
the sclera, retina-choroid and iris ciliary bodies were observed to be 180.20, 77.49 
and 54.06 ng/g of tissue, and 27.36, 80.15, 50.29 and 36.27 ng/g of tissue, and 
922.20, 630.27 ng/g (two times dilution factor is applied values are 461.10 × 2 and 
315.14 × 2 ng/g), 265.98 and 299.76 ng/g of tissue respectively. DEX concentration 
in the lens and vitreous humor were below LLOQ (LLOQ = 2.7 ng/mL). Mean 
concentration and standard deviations of DEX in various ocular tissue matrices are 
summarized in  
Table 22. A novel 0.1% nanomicellar formulation of DEX showed high 
concentration levels in back-of-the-eye (retina-choroid = 49 ng/g of tissue) 
suggesting conjunctival scleral (trans-corneal) pathway of nanomicelles carrying 
Concentration 
(ng/g tissue) 
Set 1  Set 2  Set 3  Set 4  Average 
± SD  
Cornea 
 
1415.01  1459.60  652.73  675.58  1051 ± 
446.8  
ICB 
 
922.2  630.27  265.98  299.76  530 ± 
309.1 
Sclera 
 
180.2  77.49  54.06  ---  104 ± 
67.1 
RC 
 
27.36  80.15  50.29  36.27  49 ± 
23.1  
AH 
(ng/mg protein)  
464.8  401.05  314.94  195.13  344 ± 
117  
Lens 
 
BLOQ BLOQ BLOQ BLOQ BLOQ 
VH 
(ng/mg protein)  
BLOQ BLOQ BLOQ BLOQ BLOQ 
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the payload to back-of-the-eye tissues (retina-choroid). 
Conclusion 
 
A clear, stable, aqueous DEX loaded NMF was prepared and optimized with full 
factorial statistical DOE. Results indicate that DEX entrapment efficiency was 
dependent on two input factors Vit. ETPGS and Oc-40. A specific blend of Vit. 
ETPGS and Oc-40 at a particular wt% ratio (4.5:2.0) produced excellent drug 
entrapment, loading and small nanomicellar size as well as narrow PDI. This 
method of drug entrapment can minimize drug loss during large scale production. 
Since this aqueous DEX NMF is highly stable for prolonged period and it appears 
from the in vitro cytotoxicity results that it may not be very toxic. In vivo ocular 
tissue distribution demonstrates high DEX levels in anterior ocular tissues. 
Moreover, therapeutic drug concentrations were detected in retina-choroid. No 
drug was detected in lens and vitreous humor suggesting a transscleral 
(conjunctival-scleral) pathway of drug delivery to retina-choroid.
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Chapter 6 
TOPICAL AQUEOUS CLEAR RAPAMYCIN (SIROLIMUS) 
NANOMICELLAR FORMULATION: DEVELOPMENT AND IN VIVO 
TISSUE DISTRIBUTION 
Rationale 
 
Rapamycin is extremely hydrophobic with an octanol/water partition 
coefficient (log P) of 5.77 and an aqueous solubility of 2.6 µg/mL (337). Also, 
rapamycin is pH and light sensitive (338). Oral or intravenous administration of 
rapamycin for back-of-the-eye delivery is not medically acceptable. Rapamycin, an 
immunosuppressant, may severely compromise immune function if administered 
through systemic route (339). To deliver rapamycin locally to the eye, various 
strategies such as route of administration (periocular, subconjunctival, intravitreal 
implants/injections), and formulations (nanoparticles, liposomes) based have been 
implemented (11, 337, 340). Strategies such as periocular, subconjunctival and 
intravitreal implants/injections of rapamycin are invasive and associated with side 
effects such as retinal detachment or damage, endophthalmitis, and 
pseudoendophthalmitis. Polyethylene glycol-b-poly(Ɛ-caprolactone) micelles have 
been previously developed to improve solubility. This micellar formulation resulted 
in an improvement of solubility up to a concentration of 1 mg/mL (341).  
 Among the ocular delivery routes topical drop instillation is the most patient 
acceptable route of drug administration. Static and ocular barriers impede drug 
permeation from front to the back-of-the-eye tissues (retina-choroid). Therefore, 
the objectives of this work are to improve rapamycin aqueous solubility, develop a 
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novel clear, aqueous, nanomicellar formulation (NMF) and deliver therapeutic 
rapamycin levels in back-of-the-eye tissues with topical drop instillation. To 
achieve this objective we have employed a blend of polymers Vit. E TPGS and Oc-
40.  Vit. E TPGS is a FDA approved amphiphilic polymer.  In pharmaceutical 
industry it is employed as an emulsifier, solubulizer, absorption enhancer and a 
vehicle for hydrophobic drugs (342).  This HLB value of Vit. E TPGS renders it to 
be a more lipophilic (343)  polymer relative to the second polymer (Oc-40, HLB = 
18.0). Also, Vit. E TPGS is a potent inhibitor of multi-drug efflux pumps (P-
glycoprotein, P-gp), facilitates drug translocation across cell membrane, modulates 
drug pharmacokinetics and improves bioavailability (344, 345). Another polymer, 
Oc-40 employed in this study is also FDA approved for human use. A unique ratio 
of these polymeric blend (4.5:2.0, for Vit. E TPGS and Oc-40) was selected due to 
their low critical micellar concentration (0.012 wt%) of the combination relative to 
individual polymers (Table 19) (278, 346). 
Materials and Methods 
Materials   
Rapamycin and erythromycin were purchased from LC laboratories USA 
and Sigma Chemicals (St. Louis, MO), respectively. HPLC grade methanol, 
acetonitrile, triethylamine, and formic acid were procured from Fisher Scientific 
(New Brunswick, NJ). Ultrapure water from MilliQ-system (Millipore, Molshecin 
France) was used through the study. All chemicals were of HPLC grade and used 
as received without further purification. An Xterra reverse phase HPLC column 
 262 
 
procured from Waters Corporation USA.Vitamin E TPGS was purchased from the 
Peboc division of Eastman Company, UK Limited, UK. Igepal (Oc-40) was 
obtained from Rhodio Inc, New Jersey, USA. Kollidon(R) 90F (povidone K 90) 
Ph. Eur., USP was procured from Mutcher, Inc., Pharmaceutical ingredients, 
Harrington Park, New Jersey, USA.   HPLC grade methanol and acetonitrile were 
procured from Fisher Scientific, USA. Ethanol was purchased from Aaper Alcohol 
and Chemical Co. Shelbyville, Kentucky, USA. For all the formulation 
preparations Hyclone cell culture water, Hyclone, USA, was utilized.  
 
RP-HPLC method 
To determine concentration of entrapped drug within the core of NMF RP-
HPLC analysis was performed utilizing C8 column (Phenomenex C8, 5 µm; 150 
mm X 2.1 mm), an autosampler (Alcott, model 718 AL), a column heater (Flatron 
CH-30 column heater, Flatron Systems Inc., USA) set at 40 oC, a pump (model SD 
20, shimadzu) set to deliver 1.0 mL/min, a UV detector (Shimadzu, SPD 20A) set 
at 278 nm and an integrator to collect data. The mobile phase comprised of 
acetonitrile-methanol-water (30:35:35 v/v/v). Since the mobile phase contained 
higher organic phase it was prepared freshly before analysis. A 50 µL sample was 
injected into the HPLC system.  
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Method of preparation  
Rapamycin loaded nanomicellar formulations (NMF) were prepared by a 
novel solvent evaporation method as described previously in Chapter 5 (278). A 
blank formulation was also prepared following a similar procedure without 
rapamycin. 
 
Characterization of nanomicellar formulation 
Rapamycin loaded nanomicellar formulations were subjected to 
characterization following procedures described in Chapter 3 for entrapment 
efficiency, loading efficiency, size, polydispersity index, surface potential and 
proton NMR studies. HPLC-UV was used for determining entrapment and drug 
loading efficiencies. 
  
In vitro cytotoxicity  
Cell viability and plasma membrane damage studies were conducted 
following the manufacturer’s protocol described in Chapter 3 on rPCEC cell lines. 
Similarly, cell viability studies were conducted on D407 cells with NMF and 
placebo formulations. 
 
LC-MS/MS method 
Solutions and validation samples 
Rapamycin and erythromycin as internal standard (IS) were dissolved in 
methanol to obtain, 1.0 mg/mL stock solutions, and were gradually diluted by the 
 264 
 
serial dilution method using calibrated pipettes (2-20 μL, 10-100 μL and 100-1000 
μL), in order to obtain working stock dilutions at decreasing concentrations (10, 
8.5, 7.5, 5.0, 2.5, 1.0, 0.1 and 0.023 μg/mL). These solutions were used for the 
preparation of mass spectrometry optimization, calibration curve and quality 
control standards in methanol and ocular tissue homogenates. These stock solutions 
and stock dilutions were stored at below 10 oC, and at -20 oC, respectively. For the 
preparation of calibration curve standards, aliquots of 200 μL of blank ocular tissue 
homogenates were spiked with 20 μL of each of the rapamycin working stock 
dilutions in order to obtain eight calibration curve standards at decreasing 
concentrations (1000, 850, 750.0, 500.0, 250.0, 100.0, 10.0 and 2.3 ng/mL). 
Similarly, quality control (QC) samples were independently prepared at four levels 
of concentration (800.0, 480.0, 10 and 2.3 ng/ mL) in tissue homogenates from the 
working stock dilutions. Stock concentration was corrected by the formula below. 
 
Corrected conc.= Amount weighed (mg) * Mol. Weight (free form) * Potency (purity)   *100            Eq 14 
                                    Volume madeup (mL) Mol. Weight (salt form)                         
 
 
Mass spectrometry optimization 
Mass spectrometry parameters optimization of rapamycin and erythromycin 
was carried out by a standard stock dilution (200.0 ng/mL) in methanol through 
direct infusion into the mass spectrometer with the inbuilt Harvard infusion pump. 
Data from rapamycin and erythromycin were first acquired in full scan from the 
range between m/z 50–1000 in order to identify the most suitable parent ion for 
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MS/ MS experiments. The sodium adduct [M+Na]+ at m/z 936.6 was selected as 
the parent ion for rapamycin and fragmented. The MS/MS parent ion was still 
preserved as a parent in the MS2 spectrum and it was together with two other 
daughter ions at m/z 345.5 and 409.3. Erythromycin was also detected by using the 
proton adduct [M+H]+ ion at m/z 734.4 as the parent (under the same instrumental 
parameters), daughter ions at m/z 158.2 and 576.5 were optimized. 
 
LC-MS/MS chromatographic separation  
LC-MS/MS chromatographic separation was achieved on reversed phase 
C8 silica gel material. The column oven temperature was maintained at 40 oC. 
Extracted calibration and QC samples were reconstituted in 200 μL of mobile 
phase. Twenty microliters was injected on LC-MS/MS. Ionspray source 
temperature 350 oC and ionspray voltages 5500V were optimized. Mass 
spectrometry data was acquired in positive ion mode and processed using Analyst 
software (version 1.4.2, AB Sciex). An LC-MS/MS analysis, rapamycin was 
determined at retention time 3.011 min and erythromycin, as IS was at 1.318 min. 
The curtain gas (CUR) was at 40.0 psi, the nebulizer source gas 1 at 40.0 psi, and 
the turbo ion source gas 2 at 45.0 psi was utilized. Declustering potential 105.0 V, 
and entrance potential 10.0 V were optimized. Rapamycin fragmentation was 
induced by collisionally activated dissociation (CAD) with nitrogen gas. The 
collision gas pressure was set at 2.0 psi for multiple reaction monitoring (MRM) 
quantitation. The collision energy 75.0 V for rapamycin and 30.0 V for 
erythromycin and the collision cell exit potential 10.0 V for rapamycin and 8.0 V 
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for erythromycin were utilized. The erythromycin scan was optimized by the proton 
adduct [M+H]+ ion at m/z 734.4 as parent ion. The daughter ion at m/z 576.5 was 
selected. Dwell time 200 ms was employed. 
 
Sample preparation and extraction 
Homogenates of rabbit ocular blank tissue were used for calibration curve 
and QC standards. A simple, clean and easy protein precipitation extraction 
technique was developed. Two hundred microliter aliquot of tissue homogenate 
sample was mixed with 25 μL (5 μg/mL) of internal standard. The mixture was 
vortex-mixed for 30 seconds, then 25 μL of a 50% triethyl amine in methanol was 
added, and the solution was vortex mixed for additional 2.0 min. One mL of 
methanol was added and this mixture was again vortex-mixed for 2 min in order to 
precipitate tissue protein. The final mixture was centrifuged at 10000 rpm for 30 
min at 40 oC. The supernatant was collected and dried under speed vacuum 
(Genevac DD-4X evaporator, Genevac Inc., 815 Route 208, Gardiner, NY 12525 
USA) at 37 oC for 90 min. Dried samples were stored at -80 oC until further analysis. 
Samples were reconstituted in 200 μL of mobile phase and analyzed by LC-
MS/MS. 
 
The Specificity and selectivity of rapamycin 
The specificity and selectivity of the method were tested by analyzing six 
ocular blank samples. We processed LLOQ (n=6) in order to assess the blank 
interference at the peak of interest. The percentage of blank interference was 
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calculated by comparing mean peak area of LLOQ of the analyte for peak response 
obtained from the blank samples. Peak areas of blanks co-eluting with the analyte 
should not be more than 20% of the mean peak area at the LLOQ. 
 
Precision and accuracy of rapamycin 
Intra-day and inter-day precision and accuracy experiments were performed 
by analyzing extracted calibration curve and QC standards. The standard samples 
were prepared based on the procedure described in our previously published LC-
MS/MS method (347). Accuracy was reported as the percentage difference between 
the mean concentrations divided by the nominal concentration multiplied by 100. 
Accuracy of the method must be between 85 - 115% of the nominal value in all the 
standards, except at the lower limit of quantitation (LLOQ) level, which is 80-120 
% according to the guidance for industry bioanalytical method validation in Food 
and Drug Administration guidelines of May 2001 (www.fda.gov). Precision was 
calculated using the coefficient of variation (CV) (standard deviation/mean 
concentration) multiplied by 100. Precision of the method should be within 15% of 
the nominal concentration except at the LLOQ, which is within 20%. 
 
Matrix effect 
Matrix effect was evaluated by analyzing six replicates of each two sets at 
low, middle and high quality control standards of post-spiked (extracted blank 
tissue homogenates), and spiked in aqueous samples (represents no matrix effect) 
at the same concentration for rapamycin. One concentration of IS spiked in both 
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the sets. Ion suppression was calculated by comparing mean peak area ratios of 
analyte and IS generated from the post-spiked quality controls of ocular tissue 
homogenate samples to aqueous spiked quality control standards. A relative matrix 
effect was estimated by comparing mean peak area ratios of the analytes to internal 
standard obtained from the post-spiked QC (blank ocular matrix samples versus 
aqueous standards). Thirty-six blank ocular matrix samples were processed and 
extracted for low, middle, and high QC standards according to the sample 
preparation and extraction procedure. Quality control standards, LQC, MQC and 
HQC were prepared in a blank reconstitution solution to obtain the same 
concentrations (800.0, 480.0 and 10.0 ng/mL). 
 
Recovery 
Extraction recovery of rapamycin was estimated by analysis of two sets of 
six replicates of each at three quality control standards of spiked and post-spiked 
(representing 100% recovery) samples with the IS. Extraction recovery was 
measured by comparing mean peak area ratios of analyte and IS of ocular 
tissue/fluid homogenates to unextracted (post-spiked) quality control standards. 
Recovery quality control samples were made in a blank matrix and were extracted 
to get equal concentrations (800.0, 480.0 and 10.0 ng/ mL). 
 
Stability in ocular matrix 
Stability samples were prepared in tissue homogenates and were stored at 
−80 oC and −20 oC for several weeks to estimate the degradation of analyte in the 
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matrix. Stability QC samples were extracted along with the freshly spiked 
calibration curve standards and were tested on the same day. The extracted QC 
samples were stored for 2 days at 4 oC, and analyzed with the freshly spiked and 
processed calibration standards for in-injector and post-processed stability. The 
stability samples were frozen and stored for the next 6 weeks at −80 oC. Freeze–
thaw stability QC samples were freeze-thawed for three cycles, and the analysis 
were conducted. 
Stability experiments have shown that rapamycin had an adequate stability 
in matrix. These samples were stored for 6 weeks to anticipate the original samples 
storage conditions (Bench top, freeze storage, freeze thaw and processed storage 
stability) (347). 
 
HPLC chromatographic separation conditions 
Chromatographic separation was carried out on a UFLC Shimadzu 
prominence system consisting of LC-20AD liquid chromatography low pressure 
gradient pump, SPD-M20A diode array detector, SIL-20AST auto sampler, and 
DGU-20As degasser (Shimadzu USA manufacturing Inc., 3111 Lomita Boulevard, 
Torrance, California 90505, USA) with a reverse phase Xterra MS C8 column 50 
x 4.6 mm, i.d, 5μm (Waters Corporation, 32 Maple Street, Massachusetts 01757-
3696, USA). Isocratic mobile phase composed of 80% acetonitrile in water mixture 
containing 0.05 % of formic acid at a flow rate of 0.25 mL/min was used. As sample 
injection volume of 20.0 μL was used, and total analytical run time was 6.0 min. 
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In vivo studies 
Animals: New Zealand white male rabbits weighing between 2.0 to 2.5 kg 
were employed for in vivo studies. Animals were obtained from Myrtle's rabbittry 
(Thompson, TN) and acclaimed for 24 h in the animal care facility. Animal care 
and treatment in this investigation was in compliance with the Association for 
Research in Vision and Ophthalmology (ARVO) statement for the use of animals 
in ophthalmic and vision research. 
 
Ocular tissue dissection 
Animals were anesthetized prior to an experiment with ketamine HCl (35 
mg/kg) and xylazine (3.5 mg/kg) administered intramuscularly. For the treatment, 
N=10 eyes were utilized. Anesthesia was maintained throughout the experiment. A 
50 µL of 0.2% rapamycin NMF was instilled into each conjunctival sac. After a 
period of 60 minutes, euthanasia was performed under deep anesthesia with an 
intravenous injection of sodium pentobarbital through the marginal ear vein. 
Following euthanasia, the globe was immediately enucleated within a period of 2 
minutes and was transferred to the ice cold Dulbecco's phosphate buffer saline 
(DBPS, pH = 7.4). Enucleated eyes were rinsed twice in the ice cold DPBS to 
remove any traces of drug adsorbed onto the surface of the tissue. The sample of 
aqueous humor was withdrawn using 27 guage needle by limbal paracentesis. A 
small incision was made at the back of the globe and the vitreous humor was 
aspirated with the tuberculin syringe. Care was taken to avoid contamination by 
other tissues such as lens. The lens was carefully separated and collected. The iris-
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ciliary body was removed and cornea was excised by incision along the sclera-
limbus junction. Retina-choroid layer was removed and separated from the sclera. 
All the collected tissues were dried with Kimwipes®. Dissected posterior ocular 
tissues (sclera and retina-choroid) transferred to preweighed eppendorf tubes and 
stored at -80 oC until further extraction and analysis. Vitreous humor was 
transferred to a 15 mL falcon tube and stored at -80 oC until further analysis. 
 
Drug extraction: For rapamycin extraction, a volume of 200 µL of tissue 
homogenate was used. For vitreous humor a volume of 100 µL was aspirated. 
Rapamycin was extracted from eye tissues following a previously described 
protocol from our laboratory (348). Briefly, to extract rapamycin protein 
precipitation method was used. Erythromycin was selected as an internal standard 
(IS). To all the tissue homogenates, except blank, 25 µL of IS at a concentration of 
5.0 µg/mL was added and vortexed for one minute. Twenty five microliters of 50% 
triethylamine in methanol (v/v) was added to all the samples and then vortexed 
vigorously for 2 minutes. Proteins were precipitated by addition of 800 µL of 
methanol. All the tissue homogenate samples were vortexed for another 2 minutes. 
Samples were centrifuged at 10,000 rpm for 30 mins at 4 oC. A volume of 500 µL 
supernatant was separated and evaporated using SpeedVac® (Savant Instruments, 
Inc, Holbrook, NY). A 100µL of HPLC mobile phase was added to the dry residue 
and reconstituted by vortexing for 2 mins. This solution was centrifuged for 1 
minute at 1000 rpm and the supernatant was injected into HPLC for rapamycin 
quantification.     
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Statistical Analysis 
Data for in vitro experiments were conducted at least in quadruplicate and 
the results were expressed as mean ± standard deviation (SD). Statistical 
comparison of mean values was performed with Student's t-test. A p-value of <0.05 
was considered to be statistically significant.  
 
Results 
 
In the present study rapamycin (0.1% and 0.2%) loaded NMFs were 
successfully prepared. The NMF particles were optically clear and were 
comparable to that of distilled deionized water.  Viscosity of the aqueous clear 
NMF was similar to water. However, the viscosity of the formulation was improved 
by adding PVP-K90 (0.6%). Osmolality was adjusted to physiological range of 
~300 mOsm/kg with sodium chloride solution. Blank NMF (Vit. E TPGS/Oc-40; 
4.5:2.0) exhibited an average nanomicellar size of 10.98 ± 0.089 nm. However, the 
size of 0.1% and 0.2% were 10.54 ± 0.089 and 10.84 ± 0.11 respectively (Table 
23) (Figure 58A and B). Entrapment efficiency for both formulations was also > 
90 %. Surface potential was found be slight negative and architecture was found to 
be smooth surface, spherical in shape and devoid of aggregation (Figure 59A). 
Qualitative 1H NMR study demonstrated that no free rapamycin was available in 
the aqueous environment of NMF (Figure 60 through Figure 63). Results were 
comparable to that of formulations prepared in earlier chapters. Dilution studies 
were conducted  
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Table 23. Characteristics of the nanomicellar formulation. 
Sample Entrapment 
Efficiency 
(%) ± S.D 
Loading 
Efficiency 
(%) ± S.D 
Micelle size (nm) ± 
S.D 
Polydispersity 
index 
Surface 
potential 
(mV) 
Appearance 
(400 nm) 
Placebo - - 10.98 ± 0.09 0.08 -0.812 0.036 
0.1% 98 ± 1.5 1.5 ± 0.02 10.54 ± 0.09 0.07 -0.580 0.042 
0.2% 100 ± 1.2 3.0 ± 0.03 10.84 ± 0.11 0.05 -0.789 0.041 
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(A) Nanomicellar size distribution for placebo NMF. 
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(B) Nanomicellar size distribution for 0.2% rapamycin loaded MNF 
 
Figure 58. Nanomicellar size distribution for (A) placebo and (B) 0.2% rapamycin loaded NMF. 
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Figure 59. (A) Real time Scanning Transmission Electron Microscope (STEM) image of 0.2% rapamycin loaded nanomicellar 
formulation (x147,000). Scale bar 200 nm. (B) Image showing visual appearance 0.2% rapamycin loaded NMF on left side in 
comparison to water on right side.  
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Figure 60. 1H NMR spectral studies; 1H NMR for pure rapamycin in CDCl3 
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Figure 61. 1H NMR for placebo nanomicelles in CDCl3. 
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Figure 62. 1H NMR for rapamycin loaded nanomicelles in CDCl3. The symbol "*" indicates rapamycin  
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Figure 63. 1H NMR for rapamycin loaded nanomicelles in deuterated water (D2O).   
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Figure 64. Effect of dilution on nanomicellar size. 
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Figure 65. Cell proliferation assay demonstrating percent cell viability for blank and 0.2% rapamycin NMF on rPCEC and D407 
cells after 1h exposure time. Triton-X 100 (10%) is positive control and culture medium is negative control. Data are shown as 
mean ± S.E.M (n = 4). *p < 0.05 versus control (paired t-test). 
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Figure 66. LDH assay results for placebo and 0.2% rapamycin NMF on rPCEC cells indicating negligible LDH release upon 2h 
NMF exposure. Triton-X 100 (10%) is positive control and culture medium is negative control. Data are shown as mean ± S.E.M 
(n = 4). *p < 0.05 versus control (paired t-test). 
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for NMF. Mean micelle increased with dilution without any significant impact. The 
reason may be attributed to decrease in concentration of monomers in the NMF 
with dilution (Figure 64). In vitro studies with MTT and LDH assay on rPCEC 
cells demonstrated to be safe and well-tolerated (Figure 65 and Figure 66). 
 
Bioanalytical Rapamycin Analysis 
 
Specificity, selectivity, limit of quantification and linearity of calibration standards 
Rapamycin and erythromycin (Figure 67) both were clearly extracted and 
separated from endogenous peaks originating from the blank matrix. The mass 
spectrums corresponding to rapamycin and erythromycin are provided in Figure 
68 and Figure 69. The total ion count spectrum is obtained for rapamycin and 
erythromycin (Figure 70). The assay condition had adequate specificity for 
rapamycin, while no interfering peaks were observed at its retention times as shown 
in Figure 70 and Figure 71. Erythromycin was used as an IS in this method because 
it is readily available in our laboratory and has structural similarity. It is also 
economical compared to other drugs which were used as IS such as deuterated 
rapamycin (rapamycin 13Cd3), 27-demethoxy-sirolimus, 32-demethoxy 
rapamycin, tacrolimus and secomycin. However, it also shows consistent recovery 
and served our purpose of research. The lower limit of quantitation (LLOQ) for 
rapamycin was set to 2.3 ng/mL. Modifying mobile phase composition and column 
heater temperature have increased chromatographic resolution significantly. The 
chromatogram represents that the peak response of rapamycin was proportional to 
the concentration from LLOQ to ULOQ. In Figure 72 and Figure 73, we have 
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shown one of the best illustrations of an extracted chromatogram at both the LLOQ 
and ULOQ level with IS along with the extracted blank. The signal to noise ratio 
(S/N) of rapamycin was determined at LLOQ level, and it was greater than 50. The 
S/N ratio explains the extraction efficiency and capability that removes all 
interfering endogenous components which are usually present in the biological 
matrix. 
 
Accuracy and Precision 
The best linear fit and least-square residuals for the calibration curve were 
achieved with a 1/X2 weighing factor, giving a mean linear regression equation for 
the calibration curve. The assay was linear over the range 2.3 -1000 ng/mL with r2 
(n=6) ≥ 0.993 with a mean and standard deviation (s.d.). A regression equation for 
rapamycin, y = 0.0208(0.0016) x + 0.0043(0.0073) was obtained. Inter-and intra-
day performance of validation quality control results are summarized in Table 24, 
showing both accuracy and precision for the drug concentrations of 2.3 to 800 
ng/mL. The lower limit of quantitation (LLOQ) with inter-day coefficients of 
variation ranged between 0.3–17.2% for cornea, iris ciliary body, lens, aqueous 
humor, sclera, vitreous humor, and retina choroid as shown in Table 24. The 
regression constant describes the relationship between expected results and 
analyzed results and was linear, r2 ≥ 0.9998 for rapamycin, in the entire tissue 
matrix (Table 24). Figure 72 and Figure 73 represents an example of extracted 
validation quality control of LLOQQC (2.5 ng/mL), LQC (10 ng/mL), MQC (480 
ng/mL) and HQC (800 ng/mL) chromatogram peak responses in ocular matrix. The 
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chromatogram result explains the methods robustness and accuracy. Figure 72 and 
Figure 73 shows the correlation of results for all the tissue homogenates derived 
by the method. Figure 70 and Figure 71 MRM chromatogram demonstrates the 
total ion (TIC) counts and extracted ion (XIC) counts in positive mode. These 
figures have shown the peak response with two different transitions (i) with the 
same retention times for rapamycin and erythromycin but with varying response. 
 
Mass spectrometry characterization MS/MS 
Most reported LC-MS/MS methods have used ammonium acetate or 
formate buffers in the mobile phase system. Eventually, ammonium adducts of 
rapamycin were selected for analysis. Usually, ammoniated buffer mobile phase 
systems will enhance ionization of analytes, but at the same time which may 
generally clog the peak tubes, pump seals, and rapamycin might also degrade faster 
at high buffer concentrations at pH 7.4. Therefore, we optimized rapamycin with a 
sodium adduct [M+Na]+ in positive ion mode in a formic acid mobile phase system. 
Formic acid containing mobile phase mixtures has the advantage that they never 
clog the peak tubes and the seals.  
The instrument parameters were determined monthly on a routine basis as 
per our in-house protocol by calibration with polypropylene glycol standards as 
recommended by the manufacturer. The orifice voltage was adjusted to obtain 
maximum signal intensity and CAD experiments were carried out after obtaining 
maximum signal intensity using the orifice voltage as described in the experiment 
section before. High pure liquid nitrogen gas was employed as CAD and collision 
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gas with the collision energy. Molecular ion full-scan spectrums were acquired for 
both the rapamycin and erythromycin in positive ion mode as shown in Figure 68 
and Figure 69.  The MS2 spectrum with sodium adducts were also matched with 
the previously reported method (349). The two most abundant fragment ions 
[M+Na]+ m/z at 409.3 and 345.3 were selected for MRM analysis. In which, the 
m/z 936.3→409.3 transition has shown higher intensity and reproducible results 
than the 936.3→345.5 ion pair. Eventually, the 936.3→409.3 ion was selected for 
entire MRM quantitative analysis as shown in Figure 70. Earlier reports also 
described how rapamycin sodium adduct [M+Na]+ show relatively greater response 
than the proton adduct[M+H]+ in positive mode with the electrospray ionization 
(350, 351). We also observed that sodium adducts of rapamycin has exhibited 
minimal matrix effect with the optimal response in all the ocular tissue matrices. 
Transition pairs were selected for erythromycin in which 734.4→158.5 have higher 
intensity than 734.4→576.5 in MRM Figure 70. 
 
Recovery 
Recovery of rapamycin was high and reproducible in this extraction method. 
Several extraction techniques such as protein precipitation, liquid–liquid extraction 
and its combination of procedures with different solvent and solvent systems such 
as ethyl acetate, methyl (t)-butyl ether (MTBE), dichloromethane, chloroform, 
cyclohexane, hexane, ether, ethanol, 2-propanol, perchloric acid, triethylamine, 
acetonitrile and methanol were tested. All the tissue proteins were precipitated with  
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Figure 67. Chemical structures, formulas and molecular masses of rapamycin and erythromycin. 
Rapamycin (sirolimus)  
Formula: C
51
H
79
NO
13
 
Mol. Mass: 914.172 g/mol  
Erythromycin 
Formula: C
37
H
67
NO
13
 
Mol. Mass:733.93 g/mol 
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Figure 68. Coupled mass spectrum of rapamycin in electrospray ionization (ESI) positive scan mode with sodium adduct, precursor 
ion mass to charge ration (m/z) [M + Na]+: 936.6 Da, product ions m/z (m1) 409.3 and (m2) 345.3 Da 
Coupled mass spectrum of rapamycin in positive scan mode 
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Figure 69. Coupled mass spectrum of erythromycin in Electrospray Ionization (ESI) positive scan mode with proton adduct, 
precursor ion mass to charge ration (m/z) [M-H]- : 734.4, product ion m/z (m1) 576.3 and (m2) 158.2 Da. 
 
Coupled mass spectrum of erythromycin in positive scan mode 
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Figure 70. Total ion count (XIC) of positive scan MRM chromatograms of rapamycin with precursor ion [M + Na]+ product ion 
(m1) Q1/Q3 m/z : 936.6/409.3 and precursor ion [M + Na]+ product ion (m2) Q1/Q3 m/z : 936.6/345.3 (right side peaks at retention 
time 3.1 min ), Erythromycin with precursor ion [M + H]+ product ion (m1) Q1/Q3 m/z : 734.4 /576.3 and precursor ion [M +H]+ 
product ion (m2) Q1/Q3 m/z : 734.4 /158.2 (left side peaks at retention time 1.5 min) in ocular matrix. 
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Figure 71. Extracted ion count (XIC) of positive scan MRM chromatograms of rapamycin with precursor ion [M + Na]+ product 
ion (m1) Q1/Q3 m/z : 936.6/409.3 and precursor ion [M + Na]+ product ion (m2) Q1/Q3 m/z : 936.6/345.3 (top two columns); 
Erythromycin with precursor ion [M +H]+ product ion (m1) Q1/Q3 m/z : 734.4 /576.3 and precursor ion [M +H]+ product ion 
(m2)Q1/Q3 m/z : 734.4 /158.2 (bottom two columns) 
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Figure 72. Integration algorithmic typical MRM chromatograms for selected extracted samples at lower and upper limit of 
quantitation (LLOQ and ULOQ) with IS. It shows endogenous peak in extracted blank sample (top). Signal to noise ratio (S/N) for 
rapamycin peak at LLOQ level was greater than 50. LLOQ, (2.3 ng/mL), and ULOQ, 800.0 ng/mL) in the left column from top to 
bottom, erythromycin as an internal standard (IS) blank, at LLOQ level and ULOQ level in the right column from top to bottom in 
ocular matrix. 
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Figure 73. A typical example of extracted LLOQ (2.3 ng/ml), Low QC (10 ng/mL), middle QC (480 ng/mL) and high QC (800 
ng/ml) Rapamycin (analyte) (m/z) [M+Na]+ : 936.6/409.3, Erythromycin (internal standard) : (m/z) [M+H]+ 734.4/576.5 MRM 
quantitation chromatograms in ocular tissue matrices. 
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Table 24. Ocular tissue homogenate validation results , quality control each (n = 6 of 1 of 3 batches) 
 Lower limit of 
quality control (2.3 
ng/mL) 
Low quality 
control (10 ng/mL) 
Middle quality control 
(480  ng/mL) 
High quality control 
(800 ng/mL) 
 Cornea 
Mean concentration 
(ng/mL) 
2.1 10.7 499.0 829.0 
Inter run % CV 10.3 8.5 5.7 1.8 
Inter run  % Bias -10.9 6.8 3.9 3.6 
 Iris Ciliary Body 
Mean concentration 
(ng/mL) 
2.0 10.3 472 847 
Inter run % CV 10.9 3.8 2.0 2.8 
Inter run  % Bias -15.2 2.9 -1.6 5.9 
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 Lower limit of 
quality control (2.3 
ng/mL) 
Low quality control 
(10 ng/mL) 
Middle quality control 
(480  ng/mL) 
High quality control 
(800 ng/mL) 
 Lens 
Mean concentration 
(ng/mL) 
2.1 9.8 562 807 
Inter run % CV 17.2 7.9 1.0 4.0 
Inter run  % Bias -10.9 -2.2 -3.7 0.9 
 Aqueous humor 
Mean concentration 
(ng/mL) 
2.0 10.3 495 824 
Inter run % CV 7.1 4.0 4.6 3.0 
Inter run  % Bias -13.0 
 
2.8 3.1 3.0 
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 Lower limit of 
quality control (2.3 
ng/mL) 
Low quality control 
(10 ng/mL) 
Middle quality control 
(480  ng/mL) 
High quality control 
(800 ng/mL) 
 Sclera 
Mean concentration 
(ng/mL) 
2.2 9.7 432.1 797.4 
Inter run % CV 9.9 8.2 10.9 2.3 
Inter run  % Bias -6.5 -3.3 -10.0 -0.3 
 Vitreous humor 
Mean concentration 
(ng/mL) 
2.6 10.2 452 825 
Inter run % CV 0.0 11 17 2.6 
Inter run  % Bias 13.0 2.4 -5.8 3.2 
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 Lower limit of 
quality control (2.3 
ng/mL) 
Low quality control 
(10 ng/mL) 
Middle quality control 
(480  ng/mL) 
High quality control 
(800 ng/mL) 
 Retina-Choroid 
Mean concentration 
(ng/mL) 
2.4 9.5 410 840 
Inter run % CV 15.0 14.0 3.7 0.0 
Inter run  % Bias 2.2 -4.9 -14.7 5.0 
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the methanol, and triethylamine digested all the tissues and broke their integrity. 
By using this procedure we got the highest recovery of rapamycin. Mean recovery 
of rapamycin was found between 85-90% for the cornea, 89-91% for iris ciliary 
body, 81-93% for lens, 78-87% for aqueous humor, 82-93% for vitreous humor 81-
94% for sclera and 86-90% for retina-choroid at LQC, MQC and HQC levels. 
 
Matrix effect 
Ion suppression expresses the matrix effect on ionization of analytes of 
interest. Usually, most results obtained from LC-MS/MS analysis are inconsistent 
because of ineffective sample preparation and extraction techniques. These 
problems may be overcome by modifying the sample extraction procedure (352). 
Liquid–liquid and solid-phase extraction are generally the most effective approach, 
but they are expensive and laborious. The elimination of undesirable water soluble 
compounds, including non-volatile materials like phosphates and sulfates are 
important in electro spray ionization. Reconstitution solution also plays a key role 
in ionization of analytes. Six replicates of LLOQ were processed and tested for its 
matrix effect. Found the ionization and peak response was increased when it was 
reconstituted in acetonitrile: water: formic acid mixture (80:20:0.05) compared to 
other reconstitution solutions such as acetonitrile, methanol and its mixtures. In this 
technique, triethylamine and methanol were able to generate clear and clean 
samples from the water-soluble compounds, such as phosphates and zinc sulfates. 
The zinc sulfate and phosphate were inhibiting the ionization of analytes during the 
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ESI (353, 354). The percentage of matrix was found 16%, 20 % and 26 % at HQC, 
MQC, and LQC levels, respectively. 
Stability evaluation in ocular matrices 
All stability experiments, linear regression, correlation coefficients with 
calibration curve and QC standards are presented in Table 25 and Table 26. 
Accuracy and precision results of each stability experiment are also given in Table 
26. Rapamycin was stable for three freeze-thaw cycles at -80 oC and six weeks at 
freezer storage temperature in all tissue homogenates. It was also stable for four 
hours on bench top at 25 oC 2 days for in-injector storage, and 15 days for post 
extracted storage at -80 oC. All the stability results of anterior and posterior tissue 
are presented in Table 24. 
 
Quantitative determination of rapamycin in ocular homogenate 
For an LC-MS/MS analysis, extraction procedure, pH, and reconstitution 
solvent are important parameters to obtain better chromatographic separation, 
reproducible and reliable results. Rapamycin was estimated in the anterior eye 
tissues such as cornea, lens, iris ciliary body and aqueous humor. The calibration 
curve accuracy and precision, retention times and linearity results of individual eye 
tissues are displayed in the Table 26. 
 
Sample analysis of tissue distribution study in the rabbit eye 
Rapamycin was measured in ocular tissues post 1hour of topical 
administration of 0.2% rapamycin nanomicellar formulation. Rapamycin was 
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found to be at 2260 ± 500 ng/g tissues in the cornea, and 585 ± 80 ng/g tissues in 
the iris ciliary body. Rapamycin concentration found by mass spectrometry analysis 
in the cornea, lens, and iris ciliary muscle was normalized with the volume (500 
μL) used for homogenization and tissue (approx. 0.11 g) weight. In the lens and 
aqueous humor, rapamycin was found to be below the limit of quantitation (i.e. < 
2.3 ng/mg protein). The results of rapamycin distribution in the eye tissues and 
fluids are shown in Table 27. The distribution coefficient between hydrophilic and 
lipophilic phases is also important for estimation of drug distribution in the eye. 
Rapamycin is practically insoluble in water (2.6 μg/mL), and has a high molecular 
weight (MW 914 Da) because it’s more hydrophobic in nature. It contains no 
functional groups that are ionizable at pH range between 1 and 10 that easily 
penetrate the tissue (337).  
Discussion 
 
Rapamycin is a small molecule with poor aqueous solubility (2.6 µg/mL) 
(337). In the present study, we selected a blend of two FDA approved polymers 
(Vit. E TPGS and Oc-40) to entrap rapamycin into nanomicelles to improve its 
solubility. A weight percent ratio of 4.5:2.0 for Vit. E TPGS and Oc-40 was selected 
due to their low critical micellar concentration (CMC) value of 0.012 wt% relative 
to individual polymers (Vit. E TPGS (0.025%) and Oc-40 (0.107 wt%)) (278). Low 
CMC of this polymeric mixture allows to improve stability of NMF. We 
successfully prepared 0.1% and 0.2% rapamycin loaded NMFs with a blend of Vit. 
E TPGS/Oc-40 (4.5:2.0) in phosphate buffer. Although, rapamycin solubility was 
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Table 25. Ocular tissue homogenate stability results in anterior and posterior eye tissues 
Nominal concentration (ng/mL) Cornea Iris ciliary body Lens   
 LQC HQC LQC HQC LQC HQC   
 10 800 10 800 10 800   
Freeze storage for 6 weeks at (−80 °C)      
Mean calculated concentration 
(ng/mL) 10.3 768 9.4 756 8.9 843  
 
CV (%) 4.9 4 9.6 11.8 13.5 1.5   
Bias(%) 2.9 −4.2 −6.4 −5.8 −12.4 5.1   
Freeze thaw (−80 °C) stability (3 cycles)      
Mean calculated concentration 
(ng/mL) 9.2 876 9.1 698 8.9 856  
 
CV (%) 5.4 3.5 9.9 12.8 13.5 1.5   
Bias (%) −8.7 8.7 −9.9 −14.6 −12.4 6.5   
Autosampler in injector storage stability (2 days)     
Mean calculated concentration 
(ng/mL) 8.9 708 8.8 876 11.1 893  
 
CV (%) 5.6 4.3 10.2 10.2 10.8 1.4   
Bias (%) −12.4 −13.0 −13.6 8.7 9.9 10.4   
Post extracted samples storage stability (15 days) at (−80 °C)    
Mean calculated concentration 
(ng/mL) 8.5 850.9 9.1 688 8.4 890  
 
CV (%) 5.9 3.6 9.9 12.9 14.3 
1.4 
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Nominal concentration (ng/mL) Cornea Iris ciliary body Lens   
Bias (%) −17.6 6 −9.9 −16.3 −19.0 10.1   
Bench top stability (4 h) at 25 °C      
Mean calculated concentration 
(ng/mL) 8.6 879 8.9 765 9.9 901  
 
CV (%) 5.8 3.5 10.1 11.6 12.1 1.4   
Bias (%) −16.3 9 −12.4 −4.6 −1.0 11.2   
       
Posterior chamber eye tissues 
     
 
 Aqueous humor Sclera Vitreous humor Retina-Choroid 
 LQC HQC LQC HQC LQC HQC LQC HQC 
Nominal Concentration (ng/mL) 10 800 10 800 10 800 10 800 
Freeze storage for 6 weeks at 
(−80 °C)        
 
Mean calculated concentration 
(ng/mL) 9.7 867 9.1 679 9.3 847 11.2 
 
893 
CV (%) 4.9 2.7 9.4 11.8 13.5 1.5 16.5 2.9 
Bias (%) −3.1 7.7 −9.9 −17.8 −7.5 5.5 10.7 10.4 
Freeze thaw (−80 °C) stability (3 cycles)      
Mean calculated concentration 
(ng/mL) 8.9 908 9.1 809 10.2 870 11 
 
805 
CV (%) 5.6 2.3 9.9 11 11.8 1.4 15.5 2.8 
Bias (%) 12.4 11.9 −9.9 1.1 2 8 9.1 0.6 
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Autosampler in injector storage stability (2 days)    
 
 Aqueous humor Sclera Vitreous humor Retina-Choroid 
Mean calculated concentration 
(ng/mL) 10.9 890 9.4 879 9.6 871 11.4 
 
931 
CV (%) 4.6 2.3 9.6 10.1 12.5 1.4 14.9 2.4 
Bias (%) 8.3 10.1 −6.4 9 −4.2 8.2 12.3 14.1 
Post extracted samples storage stability (15 days) at (−80 °C)    
Mean calculated concentration 
(ng/mL) 9.5 765 9.1 688 8.4 890 12.0 
 
912 
CV (%) 3.3 7.2 2.4 7.2 1.2 4.3 3.3 7.2 
Bias (%) −5.3 −4.6 −9.9 −16.3 −19.0 10.1 16.7 12.3 
Bench top stability (4 h) at 25 °C      
Mean calculated concentration 
(ng/mL) 12 765 9.1 688 10.3 809 9.4 
 
912 
CV (%) 3.3 7.2 2.4 7.2 1.2 4.3 3.3 7.2 
Bias (%) 16.7 −4.6 −9.9 −16.3 2.9 1.1 -6.4 12.3 
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Table 26. Table Anterior eye tissue sample analysis, calibration curve, and quality control (QC) standard (STD) results.        
Name 
Nominal 
conc 
.(ng/mL) 
 
No. of 
replicate 
processed  
 
No. of 
replicate 
injected 
 
Retention time, 
min 
(mean , SD) 
Calculated 
conc.(ng/mL) 
(Mean, SD) 
(%) 
Accuracy 
(%) 
Precision 
CORNEA 
Cornea  STD-1  2.3 2 2 3.104, 0.016 1.9, 0.33 82.6 17.4 
Cornea  STD-2 10 2 2 3.017, 0.071 8.5, 1.37 85.0 16.1 
Cornea  STD-3  100 2 2 3.012, 0.019 91.5, 7.03 91.6 7.7 
Cornea STD-4 250 2 2 3.018, 0.028 211.0, 26.0 85.6 12.7 
Cornea  STD-5  500 2 2 3.054, 0.047 432.9, 62.03 86.6 14.4 
Cornea STD-6  750 2 2 3.030, 0.045 761.2, 123.0 101.5 16.2 
Cornea  STD-7 850 2 2 3.024, 0.036 801.0, 124.33 94.6 15.6 
Cornea STD-8 1000 2 2 3.006, 0.011 899.9, 134.0 89.9 14.9 
Cornea LLOQQC  2.3 4 8 3.024, 0.036 1.88, 0.24 81.6 12.8 
Cornea LQC  10 4 8 3.016, 0.037 8.9, 1.31 89.0 14.7 
Cornea MQC 480 4 8 3.022, 0.038 501.0, 71.33 104.3 14.2 
Cornea HQC 800 4 8 3.041, 0.03 721.9, 81.33 90.1 7.4 
Cornea  10 samples (mean± SD) = 2260.74 ± 507.11 ng/g of tissue , the value obtained by LC-MS/MS was normalized with the 
tissue volume(mL)  and weight(g) 
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Name 
Nominal 
conc 
.(ng/mL) 
 
No. of 
replicate 
processed  
 
No. of 
replicate 
injected 
 
Retention time, 
min 
(mean , SD) 
Calculated 
conc.(ng/mL) 
(Mean, SD) 
(%) 
Accuracy 
(%) 
Precision 
IRIS CILIARY MUSCLE 
Iris cilairy body STD-1  2.3 2 2 3.002, 0.017 2.7, 0.36 117.4 13.3 
Iris cilairy body  STD-2 10 2 2 3.000, 0.061 9.5, 0.90 95.0 9.5 
Iris cilairy body STD-3  100 2 2 3.102, 0.016 101.5, 5.6 101.5 5.5 
Iris cilairy body STD-4 250 2 2 2.995, 0.005 267.0, 30.0 106.8 11.2 
Iris cilairy body  STD-5  500 2 2 3.007, 0.083 567.9, 32.03 113.6 5.6 
Iris cilairy body STD-6  750 2 2 3.028, 0.043 679.2, 102.0 90.5 15.0 
Iris cilairy body  STD-7 850 2 2 3.012, 0.043 900.9, 125.0 105.6 13.9 
Iris cilairy body STD-8 1000 2 2 3.022, 0.018 1100.0, 124.0 110.0 12.2 
Iris cilairy body 
LLOQQC 
2.3 4 8 3.024, 0.036 2.5, 0.21 108.7 8.4 
Iris cilairy body LQC  10 4 8 2.989, 0.061 10.9, 1.31 110.0 11.9 
Iris cilairy body MQC 480 4 8 2.992, 0.034 550.0, 71.00 114.3 12.2 
Iris cilairy body HQC 1000   3.001, 0.01 908.0, 101.33 113.1 11.4 
Iris cilairy body  10 samples (mean± SD) = 585.48  ±80.06 ng/g of tissue , the value obtained by LC-MS/MS was normalized 
with the tissue volume(mL)  and weight(g) 
Correlation coefficient equation (y=mx+c);  coefficient of determination(r2) =;  Limit of quantitation (LOQ)= 2.3ng/mL ; Upper 
limit of quantitation (ULOQ)=  1000 ng/mL; LLOQQC= Lower LOQ quality control, LQC= Low QC, MQC= middle QC, 
HQC= high QC; STD= Standard 
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Name 
Nominal 
conc 
.(ng/mL) 
 
No. of 
replicate 
processed  
 
No. of 
replicate 
injected 
 
Retention time, 
min 
(mean , SD) 
Calculated 
conc.(ng/mL) 
(Mean, SD) 
(%) 
Accuracy 
(%) 
Precision 
AQUEOUS HUMOR 
Aqueous humor STD-1  2.3 2 2 32000,0.002 1.99, 0.22 86.5 11.1 
Aqueous humor  STD-2 10 2 2 3.042, 0.061 10.9, 0.80 109.0 7.3 
Aqueous humor  STD-3  100 2 2 3.012, 0.019 111.5, 10.60 111.5 9.5 
Aqueous humor STD-4 250 2 2 3.018, 0.028 245.0, 12.0 98.0 4.9 
Aqueous humor  STD-5  500 2 2 3.024, 0.047 570.0, 23.03 114.0 4.0 
Aqueous humor STD-6  750 2 2 3.031, 0.041 789.2, 102.0 105.5 12.9 
Aqueous humor  STD-7 850 2 2 3.024, 0.037 906.0, 111.00 106.6 12.3 
Aqueous humor  STD-8 1000 2 2 3.006, 0.011 1113.9, 104.0 111.3 12.1 
Aqueous humor  
LLOQQC 
2.3 4 8 3.004, 0.016 2.6, 0.32 89.0 10.1 
Aqueous humor  LQC  10 4 8 3.018, 0.039 8.9, 0.90 89.7 10.1 
Aqueous humor  MQC 480 4 8 3.032, 0.018 421.0, 2.60 87.3 0.6 
Aqueous humor  HQC 1000 4 8 3.045, 0.031 709.9, 65.00 88.6 9.2 
Aqueous 10 samples (mean± SD) = Below limit of quantitation(BLOQ), the value obtained by LC-MS/MS was below limit of 
quantitation  
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Name 
Nominal 
conc 
.(ng/mL) 
 
No. of 
replicate 
processed  
 
No. of 
replicate 
injected 
 
Retention time, 
min 
(mean , SD) 
Calculated 
conc.(ng/mL) 
(Mean, SD) 
(%) 
Accuracy 
(%) 
Precision 
LENS 
Lens  STD-1  2.3 2 2 2.958,0.042 2.6, 0.11 113.0 4.2 
Lens  STD-2 10 2 2 2.958,0.048 9.9, 0.89 99.0 9.0 
Lens  STD-3  100 2 2 2.959, 0.014 114.0, 8.90 114.0 7.8 
Lens  STD-4 250 2 2 2.952, 0.023 230.0, 11.0 92.0 4.7 
Lens  STD-5  500 2 2 2.956, 0.024 532.0, 20.03 106.2 3.8 
Lens STD-6  750 2 2 2.979, 0.016 700.2, 103.0 93.3 14.7 
Lens  STD-7 850 2 2 2.969, 0.055 768.9, 102.33 90.6 13.3 
Lens STD-8 1000 2 2 3.009, 0.058 1089.9, 112.0 108.9 10.3 
Lens LLOQQC 2.3 4 8 2.986, 0.065 2.03, 0.30 88.3 114.8 
Lens LQC  10 4 8 2.949, 0.036 9.9, 1.10 99.0 11.1 
Lens MQC 480 4 8 2.966, 0.019 521.0, 2.40 108.5 0.5 
Lens HQC 1000 4 8 2.984, 0.050 721.9, 81.33 113.6 7.8 
Lens 10 samples (mean± SD) = Below limit of quantitation(BLOQ), the value obtained by LC-MS/MS was below limit of 
quantitation 
Correlation coefficient equation (y=mx+c);  coefficient of determination(r2) =;  Limit of quantitation (LOQ)= 2.3ng/mL ; Upper 
limit of quantitation (ULOQ)=  1000 ng/mL; LLOQQC= Lower LOQ quality control, LQC= Low QC, MQC= middle QC, 
HQC= high QC; STD= Standard 
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improved with aqueous NMF, but topical drop instillation of aqueous drop may not 
retain the formulation in the pre-corneal pocket for longer period of time. A large 
portion (>90 %) of the topically applied formulations is lost due to tear drainage, 
induced lacrimation and tear dilution. Reflex blinking and loss of excess drop 
instillation may lead to spill over. Therefore, to improve NMF retention in the pre-
corneal pocket viscosity enhancer with bio-adhesive properties is advisable. In the 
current study, we selected povidone K 90 as a viscosity and bio-adhesive property 
enhancing agent.  
 
Dilution stability studies 
Upon topical drop instillation rapamycin loaded nanomicelles may be 
rapidly hydrated causing increase in particle size and release of drug. To study the 
effect of dilution on the NMF, samples were diluted from 0 to 100 times. The 
concentrations at these dilutions of the monomers are well above the CMC. In 
general, tears are produced at an average flow rate of 1.2 µL/min. Any excessive 
tear production upon NMF instillation should not have an impact on NMF size. 
Therefore, we examined the dilution effect on nanomicellar size up to 100 fold 
dilution (way above tear dilution that is expected in vivo).  The results of this 
dilution study are shown in Figure 64. Mean micelle increased with dilution 
without any significant impact. The reason may be attributed to decrease in 
concentration of monomers in the NMF with dilution. Our results are similar to the 
earlier studies. Xu, et al. hypothesized that the outer hydrophilic polyethylene oxide 
segment would form large and loose complex clusters in aqueous solution (288). 
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These new larger aggregates developed during dilution exhibit thermodynamically 
reversible association. Hydrophobic effect and hydrogen bonding may force the 
outer hydrophilic segment to cluster in aqueous solution. Clustering of outer 
hydrophilic segments may be the reason for increase in micelle size increase with 
dilution. The same reason is applicable to our studies. Upon dilution polymer 
concentration is lowered which leads to slight increase in micellar size (288). The 
prepared nanomicelles in this study sustained the dilution effect on their size and 
demonstrated negligible effect upon dilution indicating high stability upon dilution. 
 
Cytotoxicity studies 
After topical ophthalmic drop instillation into pre-corneal pocket, the 
formulations/solutions are rapidly cleared (within 5 to 10 minutes) (14, 355). 
Therefore, to determine the cytotoxic effect of NMF upon long time exposure to 
ocular tissues, LDH and cell proliferation assay were performed for one and two 
hour exposure. It was assumed that a 1h incubation period would be sufficient to 
evaluate any toxicity. Percent rPCEC viable cells for 0.2% rapamycin NMFs were 
comparable to that of positive control (culture medium) (Figure 65). Triton-X 100 
served as negative control which reduced the percent cell viability to ~30% and 
~6% for rPCEC and D407 cells. In another set of studies, cell plasma membrane 
damage tests (LDH assay) were studied with rPCEC cells. The amount of LDH 
released in the culture media directly correlates with membrane damage and 
cytotoxicity. Triton-X 100 caused significant toxicity/membrane damage. 
Percentage cytotoxicity to rPCEC cells post exposure to NMFs (blank and 0.2% 
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rapamycin) for 2 h appeared to be similar to negative control (Figure 66) indicating 
NMFs do not cause cell membrane damage.  Results from these assays clearly 
suggest that NMF's are not cytotoxicity. Therefore these formulations appeared to 
be safe for topical ocular application. 
 
In vivo ocular tissue rapamycin distribution studies 
Delivery of drug to back-of-the-eye tissues is a major challenge. Diseases 
affecting the posterior segment ocular tissues, retina-choroid, require long term 
drug delivery. To determine whether the developed NMF can deliver the 
hydrophobic rapamycin, to back-of-the-eye tissues, an in vivo ocular tissue 
distribution study was conducted following topical (0.2% rapamycin) instillation 
into the pre-corneal pocket of rabbits.   
Individual calibration curve were prepared for each ocular tissue and fluid. 
Multiple reactions monitoring (MRM) mode was utilized to detect the compound 
of interest. MRM transition for rapamycin m/z [M+Na]+: 936.4/409.3 and for IS 
(erythromycin) m/z [M+H]+: 734.4/576.5 were optimized. Specificity and 
selectivity of the method were tested by analyzing posterior ocular blank tissues 
and fluid. To assess blank interference with the peak of interest (rapamycin) we 
processed six replicates at lower limit of quantification (LLOQ). Peak areas of 
blanks co-eluting with the analyte was less than 20% of the mean peak area at 
LLOQ. Intra-day and inter-day precision and accuracy experiments were performed 
by analyzing extracted calibration curve and QC standards. Accuracy of the method 
was between 85% and 115% of the nominal value in all the standards, except at the 
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 Table 27. Rapamycin levels in individual ocular tissues 
Tissue 
0.2% formulation Average 
amount of rapamycin 
(ng/g of tissue) Mean ±S.E.M 
Retina-Choroid 362  ±56.17 
Iris Ciliary Body 585  ±80.06 
Cornea 2261  ±507.11 
Sclera 486  ±89.99 
Lens BLOQ 
Vitreous Humor N.D 
Aqueous Humor BLOQ 
S.E.M – Standard error of mean 
BLOQ – Below limit of quantification 
BLOQ for the first and the second set of experiment for all matrices except 
Retina-Choroid – 10.4 ng/mL 
BLOQ for first set Retina-Choroid = 10.4 ng/mL 
BLOQ for second set Retina-Choroid = 3.5 ng/mL 
N.D – Not detectable  
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lower limit of quantitation (LLOQ) level, which was 80–120%. Precision was 
calculated using the coefficient of variation multiplied by 100. Precision of the 
method was less than 15% of the nominal concentration except at the LLOQ, which 
was below 20%. The interday precision validation was conducted at 3.5 ng/mL, 10 
ng/mL, 480 ng/mL and 800 ng/mL. The LLOQ with inter-day coefficients of 
variation ranged between 2.3% and 16.7% for sclera, vitreous humor, and retina- 
choroid. The calibration curve was prepared from 3.5 ng/mL, 10.48 ng/mL, 29.5 
ng/mL, 187.2 ng/mL, 312.0 ng/mL, 480 ng/mL and 800 ng/mL rapamycin doped 
in respective tissue sample extracts. The lower limit of quantitation (LLOQ) was 
determined to be 10.48 ng/mL for sclera and vitreous humor. LLOQ for retina-
choroid was 3.5 ng/mL with a regression coefficient of 0.9984. 
Topical drop instillation of 0.2% rapamycin NMF demonstrated detectable 
and quantifiable rapamycin levels in the back-of-the-eye tissues (sclera and retina-
choroid). Rapamycin concentrations were quantified in anterior chamber eye 
tissues (cornea, iris-ciliary body) but not in lens and aqueous humor which was 
blow limit of quantitation (348). Rapamycin concentrations were also detected in 
back-of-the-eye tissues (sclera, retina-choroid) but not in fluid (vitreous humor) 
(Table 27). Results indicate that retina-choroid retained the drug at a concentration 
of 362.35 ± 56.7 ng/g tissue.   
Topically administered drugs may follow corneal and/or conjunctival-
scleral pathway to reach back-of-the-eye tissues (356). The current mode of drug 
delivery to posterior segment of the eye is primarily by invasive routes like 
subconjunctival, intravitreal injections or implants. These methods are also 
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associated with serious complications. Again, this method of drug delivery requires 
medical specialist to administer the drug, which makes treatment expensive. Also, 
these drugs are required to be administered for multiple times. Such invasive mode 
of delivery may provide treatment to back-of-the-eye disease but may cause serious 
ocular complications leading to vision loss. Therefore, to overcome such 
complications, patient compliant formulations like topical drops need to be 
developed. One of the major drawbacks with topically applied drug formulations is 
sub-therapeutic levels of drug reaching back-of-the-eye tissues. To address these 
problems and replace the current existing route of drug administration to retina-
choroid, we have developed patient compliant clear, aqueous NMF topical drops 
that could deliver the drug non-invasively to the back-of-the-eye tissues. Most of 
the potent drug molecules suffer from two major barriers (i) sub-optimal 
physicochemical properties such as low aqueous solubility and (ii) ocular static and 
dynamic barriers. Ocular static barriers include sclera, RPE and multi-drug 
resistance efflux pumps. The dynamic barriers include conjunctival and choroidal 
blood and lymph vessels that wash drug out of ocular tissues into systemic 
circulation. Moreover, due to high lipophilicity, rapamycin may not be able to 
translocate across cornea (337), which is in agreement with our previously reported 
results (348).  
 The non-corneal route may be explored as a predominant route for back-of-
the-eye delivery in comparison to corneal route. Aqueous solubility of the molecule 
is an important determinant for its transport across sclera but also for its ability to 
evade the conjunctival blood and lymph vessels mediated washout (357). Scleral 
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aqueous pore diameter varies between 20 and 80 nm (63), which facilitates the 
diffusion of small hydrophilic molecules. However, since rapamycin is highly 
hydrophobic, it undergoes partitioning to a larger extent into the lipophilic retinal 
tissue. In current formulation, rapamycin was sequestered into aqueous NMF with 
improved solubility (~800 times) relative to its aqueous solubility of 2.6 µg/mL 
(337). At the same time hydrophilic corona of the nanomicelles can be highly 
effective in utilizing scleral aqueous channels/pores (Figure 74). This alternative 
route may help permeation of nanomicelles to reach back-of-the-eye tissues (retina-
choroid). Moreover, highly polar hydrophilic nanomicellar corona may minimize 
wash out into the systemic circulation from the conjunctival and choroidal blood 
and lymph vessels thus overcoming dynamic barriers. The rapamycin NMF present 
in sclera may act as a depot and slowly release the drug to deeper ocular tissues 
(Figure 74). On the other hand, we hypothesize that if the nanomicelles release 
rapamycin in scleral tissue, a constant rapamycin release to retinal tissues may be 
achieved which is an added advantage with NMF.  NMF can follow the same route 
of drug transport (transscleral pathway) that was previously observed with sub-
conjunctival injection of rapamycin (358). 
 Nanomicelles in the posterior ocular tissues release rapamycin to highly 
lipophilic retinal tissues (Figure 74). However, rapamycin molecules do not 
appreciably partition into hydrophilic vitreous humor as evidenced by non-
detectable rapamycin in vitreous humor. Hence, rapamycin accumulates in the 
lipoidal retinal layers. This drug is a substrate for efflux pumps like P-gp (23, 41). 
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Figure 74. Hypothetical representation of rapamycin-loaded nanomicelles reaching the back-of-the-eye (retina-choroid) following 
conjunctival scleral pathway after topical drop administration. Vitamin E tocopherol polyethylene glycol succinate-1000 (Vit. E 
TPGS), P-glycoprotein (P-gp)  
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Vit. E TPGS is found to modulate P-gp efflux transport via P-gp ATPase inhibition 
(359). Upon disruption of micelles and release of rapamycin into back-of-the-eye 
lipid tissues, Vit. E TPGS monomers may help to inhibit P-gp (Figure 74). 
Thereby, higher rapamycin accumulation into the retina-choroid area may be 
achieved. Results from this study suggest that nanomicelles are novel carriers that 
can overcome both the static and dynamic ocular barriers and deliver therapeutic 
levels of rapamycin to back-of-the-eye tissue (retina-choroid). It is noted that much 
higher than presumably therapeutic levels of rapamycin (7 - 12 ng/mL) (337) were 
delivered to retina-choroid with a single topical drop instillation, indicating that the 
NMF should be safe and novel carriers for rapamycin.  
Conclusion 
 
A stable, clear aqueous 0.2% rapamycin loaded NMF has been prepared and 
characterized. Rapamycin loading in the NMF show excellent entrapment 
efficiency. Nanomicellar size was found to be ~10 nm with narrow polydispersity 
index. Surface potential studies demonstrated the formulations to carry slight 
negative charge. MNF were tested in vitro for their cytotoxicity on rPCEC cells and 
D407 cells following cell proliferation and LDH assays. Both cell assays 
demonstrated negligible cytotoxic effect with MNF relative to triton-x 100. Both 
studies demonstrated that placebo and 0.2% rapamycin loaded MNF are very safe 
and tolerable to eye. Bioanalytical, sensitive, robust LC-MS/MS method has been 
developed and validated. In vivo ocular tissue distribution studies with single 
topical drop instillation demonstrated rapamycin in anterior ocular tissues and to 
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reach retina-choroid. High levels of rapamycin were obtained in retina-choroid 
measured with sensitive LC-MS/MS. No rapamycin was present in vitreous body. 
These results indicate that MNF is able to deliver rapamycin to the retina-choroid 
tissues following topical drop administration to eye and rapamycin is sequestered 
into the lipid environment of RPE and Bruch’s membrane and does not partition 
back to the aqueous environment of vitreous humor.  
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Chapter 7 
SUMMARY AND RECOMMENDATIONS 
Summary 
 
Drugs like CsA, resolvin analog (RX-10045), dexamethasone and 
rapamycin are used to treat ocular conditions such as dry eye syndrome and uveitis. 
However, these drugs suffer from low oral and ocular bioavailability due to their 
lipophilicity and poor aqueous solubility. Moreover, topically administered dose to 
eye will be immediately diluted by excessive tear production, drained away into 
nasolacrimal duct and lost due to spillage over the cheeks. The small remainder 
amount of dose will be further prevented from ocular tissue penetration due to 
ocular static and dynamic barriers causing sub-therapeutic levels of drug in the 
tissue. Therefore, the broad long term objective of this dissertation is directed to 
improve solubility, drug stability, improve bioavailability and deliver therapeutic 
concentrations of drug to ocular tissues with topical drop. Chapter 3, the first part 
of the project (Chapter 3) is to develop and optimize aqueous solution of CsA, 
improve the ocular bioavailability with topical drop administration and 
minimize/avoid adverse effects that are observed with commercially available 
Restasis®. In this study, FDA approved amphiphilic polymers (hydrogenated 
castor oil-40 and Oc-40) for human use were used to encapsulate cyclosporine. 
Solvent evaporation rehydration method was used which generated 0.1% CsA 
aqueous solution. Further, blend of polymers (1.0:0.05 wt%) had lower critical 
micellar concentration (CMC)  relative to individual polymers. Several NMF 
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physicochemical characterization studies were conducted. Studies revealed that no 
free drug was present in the aqueous NMF, nanomicelles were ~20 nm, spherical, 
devoid of aggregation and nanomicelles retained stability upon dilution. 
Cytotoxicity evaluation on rPCEC and human retinal pigment epithelial (D407) 
cells demonstrated the CsA loaded NMF to be safe and well-tolerated. In vivo 
biocompatibility and toxicological studies in rabbits demonstrated NMF to be safe 
and results were comparable to that of negative control (BSS). In vivo 
pharmacokinetic studies with topical ocular drop administration of Restasis (0.05% 
CsA emulsion), 0.05% CsA NMF, and 0.1% CsA NMF 4 times daily at 2-hour 
intervals for 7 days, revealed that CsA exposures followed 0.1% CsA NMF > 
0.05% CsA NMF and Restasis® (0.05% CsA emulsion). Interestingly, negligible 
CsA concentrations were observed in vitreous and aqueous humor. The results 
suggest that NMF not only delivered therapeutic levels of CsA to anterior ocular 
tissues but also to back-of-the-eye tissues (retina-choroid). A corneal pathway may 
not be possible due to very low CsA concentrations in aqueous humor, lens and 
vitreous humor. Moreover the flow of aqueous humor is in opposite direction to 
that of molecular entry. Alternatively, ~12 nm nanomicelles efficiently permeate 
through 20 nm to 80 nm scleral pores and reach back-of-the-eye tissues (retina-
choroid) following conjunctival-scleral (transscleral) pathway. In the lipoidal 
posterior ocular tissues, these nanoconstruct may release the cargo into Bruch’s 
membrane/retina-choroid generating high drug levels.  Moreover, hydrophobic 
CsA may not appreciably partition into hydrophilic vitreous humor. Chapter 4, the 
next aim (Chapter 4) was to (a) screen resolvin analog for efflux transporters and 
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(b) develop and aqueous clear resolvin NMF by improving aqueous solubility, 
stability and ocular bioavailability of yellow oily resolvin analog (RX-10045). 
Madin-Darby canine kidney (MDCK) cells transfected with the human MDR1 gene 
(MDCKII-MDR1), human MRP2 gene (MDCKII-MRP2), and human BCRP gene 
(MDCKII-BCRP) were employed to screen resolvin analog. From these studies 
resolvin analog was identified as substrate/inhibitor for efflux transporters (MRP 
and BCRP). Also, resolvin analog appears to be a strong inhibitor/substrate of 
OCT-1. Moreover, encapsulation of resolvin analog in NMF improved its aqueous 
stability, well-tolerated and had higher bioavailability. Ocular drug concentrations 
followed similar pattern as observed in earlier studies with CsA.  
Next aim was to determine whether blend of Vitamin E TPGS and Oc-40 
can entrap drugs with low and high lipophilicity. We selected DEX and RAP to 
entrap inside nanomicellar core. Solvent evaporation rehydration technique was 
used to develop formulation. NMF was optimized with statistical design of 
experiment. Physicochemical properties of nanomicelles were studied and 
observed to possess similar properties to that of NMF prepared in Chapter 3. These 
new blend of drug loaded NMF were safe and well tolerated by ocular cell lines. 
Sensitive, robust, rugged bioanalytical LC-MS/MS method was developed and 
validated for DEX and RAP in ocular tissues. Moreover, in vivo studies in rabbits 
with topical eye drops demonstrated surprisingly similar results as observed with 
earlier formulations. Drug was found in cornea, iris-ciliary body, sclera and retina-
choroid. However, no drug was quantified in aqueous humor, lens and vitreous 
humor. Results repeatedly suggests that NMF utilize aqueous scleral pores (20 nm 
 322 
 
to 80 nm), follow conjunctival-scleral pathway to reach back-of-the-eye lipoidal 
tissues (retina-choroid). Moreover, lipophilic drug is being released in the lipoidal 
tissues and further permeation of drug into hydrophilic stroma is prevented. Chapter 
7, in summary, proper selection of surfactant/polymers, design and engineering 
techniques can produce nanomicelles which could be utilized to deliver drugs to 
both anterior and posterior ocular tissues i.e., retina-choroid, non-invasively in 
therapeutic levels. Such nanomicellar topical drop approach, in the near future, may 
replace the patient non-compliant routes of drug administration to posterior ocular 
tissues such as intravitreal and periocular injections into the globe.  
Recommendations 
The above studies were aimed at improving solubility, develop aqueous 
formulation of drug molecules and safely delivery to ocular tissues without any side 
effects. A few recommendations can be made to move further with this work based 
on the results obtained from the above studies. 
First, investigations for DEX and RAP in vivo ocular tolerability and 
pharmacokinetic studies with single and multiple drop administration of NMF 
should be undertaken. Such studies allow to identify the best possible dose to treat 
ocular diseases such as dry eye syndrome, uveitis and ocular neovascularization. 
Second, these drug molecules may be conjugated with targeting moieties 
and loaded into NMF. Such carriers may deliver the cargo non-invasively to back-
of-the-eye tissues. Moreover, targeted drugs (constructs) helps to improve drug 
permeability and overcome efflux transporters. Peptide transporter and folate 
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receptor are expressed on the choroidal side of RPE. Conjugation of peptide and/or 
folate molecule to drug and simultaneous loading into NMF should be undertaken 
in order to come up with the best possible formulation.   
Third, the concept of drug loaded NMF can be extended to delivery of other 
drug molecules such as ganciclovir and cidofovir to treat CMV retinitis, digoxin to 
treat choroidal/ retinal neovascularization and other back-of-the-eye diseases. 
Since, this novel nanomicellar design demonstrated higher drug concentrations in 
back-of-the-eye tissues, this approach may also result in higher permeability of 
macromolecules/peptides/protein therapeutics and other therapeutics such as genes, 
siRNA, antisense RNA and oligonucleotides. 
Finally, in this dissertation project, a resolvin analog was for the first time 
screened for efflux transporters. NMF of hydrophobic drugs was successfully 
prepared, characterized and optimized. Results from these projects appeared to be 
very promising and laid a platform for posterior ocular delivery with topical drop. 
Interestingly and repeatedly similar results were achieved with different blends of 
polymers. Moreover, targeted delivery of drugs may be achieved by covalently 
conjugating targeting ligands to drug molecule (constructs). Topical drops of 
nanomicelles may deliver constructs to the retina-choroid. Constructs may reach 
into target tissue and cleaved to regenerate parent drug. Therefore, nanomicelles 
loaded with drug constructs may result in enhanced drug delivery and cellular 
uptake into target cells. Such novel nanocarriers may be used for enhanced delivery 
of poorly water soluble drugs to various diseased sites via variety of mechanisms.  
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